PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
20627594-0	2010	Inhibition of prolyl oligopeptidase with a synthetic unnatural dipeptide.	Dipeptides	63-72	prolyl endopeptidase	Homo sapiens	14-35
20627594-1	2010	A new inhibitor, containing a linked proline-piperidine structure, for the enzyme prolyl oligopeptidase (POP) has been synthesised and demonstrated to bind covalently with the enzyme at the active site.	proline-piperidine	37-55	prolyl endopeptidase	Homo sapiens	82-103
20627594-1	2010	A new inhibitor, containing a linked proline-piperidine structure, for the enzyme prolyl oligopeptidase (POP) has been synthesised and demonstrated to bind covalently with the enzyme at the active site.	proline-piperidine	37-55	prolyl endopeptidase	Homo sapiens	105-108
20627594-2	2010	This provides evidence that covalent inhibitors of POP do not have to be limited to structures containing five-membered N-containing heterocyclic rings.	Nitrogen	120-121	prolyl endopeptidase	Homo sapiens	51-54
20567601-6	2010	Further studies demonstrated that PO is a negative regulator of inositol(1,4,5)trisphosphate (IP(3)) synthesis, a Li(+) sensitive intracellular signal.	Inositol	64-72	prolyl endopeptidase	Homo sapiens	34-36
20567601-6	2010	Further studies demonstrated that PO is a negative regulator of inositol(1,4,5)trisphosphate (IP(3)) synthesis, a Li(+) sensitive intracellular signal.	1,4,5)trisphosphate	73-92	prolyl endopeptidase	Homo sapiens	34-36
20567601-6	2010	Further studies demonstrated that PO is a negative regulator of inositol(1,4,5)trisphosphate (IP(3)) synthesis, a Li(+) sensitive intracellular signal.	Inositol 1,4,5-Trisphosphate	94-99	prolyl endopeptidase	Homo sapiens	34-36
19798721-0	2009	A cost-effective labeling strategy for the NMR study of large proteins: selective 15N-labeling of the tryptophan side chains of prolyl oligopeptidase.	15n	82-85	prolyl endopeptidase	Homo sapiens	128-149
20536450-1	2010	The natural tetrapeptide acetyl-ser-asp-lys-pro (AcSDKP) is formed in vivo by enzymatic cleavage of the N terminus of thymosin beta4 by prolyl oligopeptidase (POP).	Acetyl-Ser-Asp-Lys-Pro	25-47	prolyl endopeptidase	Homo sapiens	136-157
20536450-1	2010	The natural tetrapeptide acetyl-ser-asp-lys-pro (AcSDKP) is formed in vivo by enzymatic cleavage of the N terminus of thymosin beta4 by prolyl oligopeptidase (POP).	Acetyl-Ser-Asp-Lys-Pro	25-47	prolyl endopeptidase	Homo sapiens	159-162
19875179-1	2009	Prolyl endopeptidase (PE), a protease that cleaves after proline residues in oligopeptides, is highly active in brain and degrades neuropeptides in vitro.	Proline	57-64	prolyl endopeptidase	Homo sapiens	0-20
19875179-1	2009	Prolyl endopeptidase (PE), a protease that cleaves after proline residues in oligopeptides, is highly active in brain and degrades neuropeptides in vitro.	Proline	57-64	prolyl endopeptidase	Homo sapiens	22-24
19875179-2	2009	We have recently demonstrated that PE, in concert with MMP"s, can generate PGP (proline-glycine-proline), a novel, neutrophil chemoattractant, from collagen.	pgp	75-78	prolyl endopeptidase	Homo sapiens	35-37
19875179-2	2009	We have recently demonstrated that PE, in concert with MMP"s, can generate PGP (proline-glycine-proline), a novel, neutrophil chemoattractant, from collagen.	proline-glycine-proline	80-103	prolyl endopeptidase	Homo sapiens	35-37
19875179-3	2009	In this study, we demonstrate that human peripheral blood neutrophils contain PE, which is constitutively active, and can generate PGP de novo from collagen after activation with LPS.	pgp	131-134	prolyl endopeptidase	Homo sapiens	78-80
19798721-0	2009	A cost-effective labeling strategy for the NMR study of large proteins: selective 15N-labeling of the tryptophan side chains of prolyl oligopeptidase.	Tryptophan	102-112	prolyl endopeptidase	Homo sapiens	128-149
23940487-9	2009	CONCLUSION: MTAD and 17% EDTA were effective in debriding the apical third of curved molar root canals during endodontic treatment, whereas Glyde File Prep does not provide adequate debridement.	Glipizide	140-145	prolyl endopeptidase	Homo sapiens	151-155
19877690-16	2009	The poly(3,4-ethylenedioxythiophene) (PEDOT)-based DSSCs, which we obtain through photoelectrochemical polymerization (PEP) using 3-alkylthiophen-bearing ruthenium dye, HRS-1, and bis-EDOT, demonstrates the importance of nonbonding interface contact (e.g., pi-pi-stacking) for the successful inclusion of HTMs.	poly(3,4-ethylene dioxythiophene)	4-36	prolyl endopeptidase	Homo sapiens	119-122
19877690-16	2009	The poly(3,4-ethylenedioxythiophene) (PEDOT)-based DSSCs, which we obtain through photoelectrochemical polymerization (PEP) using 3-alkylthiophen-bearing ruthenium dye, HRS-1, and bis-EDOT, demonstrates the importance of nonbonding interface contact (e.g., pi-pi-stacking) for the successful inclusion of HTMs.	poly(3,4-ethylene dioxythiophene)	38-43	prolyl endopeptidase	Homo sapiens	119-122
19877690-16	2009	The poly(3,4-ethylenedioxythiophene) (PEDOT)-based DSSCs, which we obtain through photoelectrochemical polymerization (PEP) using 3-alkylthiophen-bearing ruthenium dye, HRS-1, and bis-EDOT, demonstrates the importance of nonbonding interface contact (e.g., pi-pi-stacking) for the successful inclusion of HTMs.	3-alkylthiophen	130-145	prolyl endopeptidase	Homo sapiens	119-122
19877690-16	2009	The poly(3,4-ethylenedioxythiophene) (PEDOT)-based DSSCs, which we obtain through photoelectrochemical polymerization (PEP) using 3-alkylthiophen-bearing ruthenium dye, HRS-1, and bis-EDOT, demonstrates the importance of nonbonding interface contact (e.g., pi-pi-stacking) for the successful inclusion of HTMs.	Ruthenium	154-163	prolyl endopeptidase	Homo sapiens	119-122
20024801-1	2009	We used the crystal structure of prolyl oligopeptidase (POP) with bound Z-pro-prolinal (ZPP) inhibitor (Protein Data Bank (PDB) structure 1QFS) to perform an intensive molecular dynamics study of the POP-ZPP complex.	N-benzyloxycarbonylprolylprolinal	72-86	prolyl endopeptidase	Homo sapiens	33-54
20024801-1	2009	We used the crystal structure of prolyl oligopeptidase (POP) with bound Z-pro-prolinal (ZPP) inhibitor (Protein Data Bank (PDB) structure 1QFS) to perform an intensive molecular dynamics study of the POP-ZPP complex.	N-benzyloxycarbonylprolylprolinal	72-86	prolyl endopeptidase	Homo sapiens	56-59
20024801-1	2009	We used the crystal structure of prolyl oligopeptidase (POP) with bound Z-pro-prolinal (ZPP) inhibitor (Protein Data Bank (PDB) structure 1QFS) to perform an intensive molecular dynamics study of the POP-ZPP complex.	N-benzyloxycarbonylprolylprolinal	72-86	prolyl endopeptidase	Homo sapiens	200-203
20024801-1	2009	We used the crystal structure of prolyl oligopeptidase (POP) with bound Z-pro-prolinal (ZPP) inhibitor (Protein Data Bank (PDB) structure 1QFS) to perform an intensive molecular dynamics study of the POP-ZPP complex.	N-benzyloxycarbonylprolylprolinal	88-91	prolyl endopeptidase	Homo sapiens	33-54
20024801-1	2009	We used the crystal structure of prolyl oligopeptidase (POP) with bound Z-pro-prolinal (ZPP) inhibitor (Protein Data Bank (PDB) structure 1QFS) to perform an intensive molecular dynamics study of the POP-ZPP complex.	N-benzyloxycarbonylprolylprolinal	88-91	prolyl endopeptidase	Homo sapiens	56-59
20024801-1	2009	We used the crystal structure of prolyl oligopeptidase (POP) with bound Z-pro-prolinal (ZPP) inhibitor (Protein Data Bank (PDB) structure 1QFS) to perform an intensive molecular dynamics study of the POP-ZPP complex.	N-benzyloxycarbonylprolylprolinal	204-207	prolyl endopeptidase	Homo sapiens	33-54
20024801-1	2009	We used the crystal structure of prolyl oligopeptidase (POP) with bound Z-pro-prolinal (ZPP) inhibitor (Protein Data Bank (PDB) structure 1QFS) to perform an intensive molecular dynamics study of the POP-ZPP complex.	N-benzyloxycarbonylprolylprolinal	204-207	prolyl endopeptidase	Homo sapiens	56-59
20024801-1	2009	We used the crystal structure of prolyl oligopeptidase (POP) with bound Z-pro-prolinal (ZPP) inhibitor (Protein Data Bank (PDB) structure 1QFS) to perform an intensive molecular dynamics study of the POP-ZPP complex.	N-benzyloxycarbonylprolylprolinal	204-207	prolyl endopeptidase	Homo sapiens	200-203
20024801-2	2009	We performed 100 ns of simulation with the hemiacetal bond, through which the ZPP is bound to the POP, removed in order to better investigate the binding cavity environment.	Hemiacetal	43-53	prolyl endopeptidase	Homo sapiens	98-101
20024801-2	2009	We performed 100 ns of simulation with the hemiacetal bond, through which the ZPP is bound to the POP, removed in order to better investigate the binding cavity environment.	N-benzyloxycarbonylprolylprolinal	78-81	prolyl endopeptidase	Homo sapiens	98-101
19688784-3	2009	Here, we have synthesized a dipeptidyl phosphonate activity-based probe that has proved to be highly selective for a specific postproline protease, prolyl oligopeptidase (POP).	dipeptidyl phosphonate	28-50	prolyl endopeptidase	Homo sapiens	148-169
19688784-3	2009	Here, we have synthesized a dipeptidyl phosphonate activity-based probe that has proved to be highly selective for a specific postproline protease, prolyl oligopeptidase (POP).	dipeptidyl phosphonate	28-50	prolyl endopeptidase	Homo sapiens	171-174
19687473-1	2009	Prolyl oligopeptidase (POP) is a serine endopeptidase that hydrolyses proline-containing peptides shorter than 30 amino acids.	Proline	70-77	prolyl endopeptidase	Homo sapiens	0-21
19687473-1	2009	Prolyl oligopeptidase (POP) is a serine endopeptidase that hydrolyses proline-containing peptides shorter than 30 amino acids.	Proline	70-77	prolyl endopeptidase	Homo sapiens	23-26
19687473-4	2009	Moreover, POP has also been proposed as a regulator of inositol 1,4,5-triphosphate signaling and several other functions such as cell proliferation and differentiation, as well as signal transduction in the central nervous system, and it is suspected to be involved in pathological conditions such as Parkinson"s and Alzheimer"s diseases and cancer.	Inositol 1,4,5-Trisphosphate	55-82	prolyl endopeptidase	Homo sapiens	10-13
20024801-6	2009	The two domains of the protein are bound by a set of approximately 12 hydrogen bonds, specific to the particular POP protein.	Hydrogen	70-78	prolyl endopeptidase	Homo sapiens	113-116
19593439-3	2009	Unexpectedly, the enzymatic evaluation of the substrates attached on solid-phase by means of the HMBA linker were cleaved through the ester bond, thereby suggesting an unknown esterase activity of POP, in addition to its known peptidase activity.	Esters	134-139	prolyl endopeptidase	Homo sapiens	197-200
19760926-2	2009	The preparation used in the Endoscopy Unit was adopted after testing it against the classic 4-liter polyethylene glicol (PEG) preparation (Klean-Prep).	klean	139-144	prolyl endopeptidase	Homo sapiens	145-149
19299743-6	2009	The enzymes responsible for generating PGP, matrix metalloproteases 8 and -9 and prolyl endopeptidase, are also elevated in these samples.	pgp	39-42	prolyl endopeptidase	Homo sapiens	81-101
19295284-9	2009	Then she received chemotherapy PEP(BEP), but after eight months of PEP (BEP), her serum hCG-CTP was again elevated to 14.5 mIU/mL.	hcg-ctp	88-95	prolyl endopeptidase	Homo sapiens	67-70
18718510-1	2008	Prolyl oligopeptidase (POP) is an endopeptidase which cleaves short proline-containing neuropeptides, and it is involved in memory and learning.	Proline	68-75	prolyl endopeptidase	Homo sapiens	0-21
19290936-1	2009	The proline-, glutamic acid-, serine- and threonine-rich (PEST) family of protein tyrosine phosphatases (PTPs) includes proline-enriched phosphatase (PEP)/lymphoid tyrosine phosphatase (LYP), PTP-PEST, and PTP-hematopoietic stem cell fraction (HSCF).	Proline	4-11	prolyl endopeptidase	Homo sapiens	120-148
19290936-1	2009	The proline-, glutamic acid-, serine- and threonine-rich (PEST) family of protein tyrosine phosphatases (PTPs) includes proline-enriched phosphatase (PEP)/lymphoid tyrosine phosphatase (LYP), PTP-PEST, and PTP-hematopoietic stem cell fraction (HSCF).	Proline	4-11	prolyl endopeptidase	Homo sapiens	150-153
19290936-1	2009	The proline-, glutamic acid-, serine- and threonine-rich (PEST) family of protein tyrosine phosphatases (PTPs) includes proline-enriched phosphatase (PEP)/lymphoid tyrosine phosphatase (LYP), PTP-PEST, and PTP-hematopoietic stem cell fraction (HSCF).	Glutamic Acid	14-27	prolyl endopeptidase	Homo sapiens	120-148
19290936-1	2009	The proline-, glutamic acid-, serine- and threonine-rich (PEST) family of protein tyrosine phosphatases (PTPs) includes proline-enriched phosphatase (PEP)/lymphoid tyrosine phosphatase (LYP), PTP-PEST, and PTP-hematopoietic stem cell fraction (HSCF).	Glutamic Acid	14-27	prolyl endopeptidase	Homo sapiens	150-153
19290936-1	2009	The proline-, glutamic acid-, serine- and threonine-rich (PEST) family of protein tyrosine phosphatases (PTPs) includes proline-enriched phosphatase (PEP)/lymphoid tyrosine phosphatase (LYP), PTP-PEST, and PTP-hematopoietic stem cell fraction (HSCF).	Serine	30-36	prolyl endopeptidase	Homo sapiens	120-148
19290936-1	2009	The proline-, glutamic acid-, serine- and threonine-rich (PEST) family of protein tyrosine phosphatases (PTPs) includes proline-enriched phosphatase (PEP)/lymphoid tyrosine phosphatase (LYP), PTP-PEST, and PTP-hematopoietic stem cell fraction (HSCF).	Serine	30-36	prolyl endopeptidase	Homo sapiens	150-153
19006380-0	2008	Prolyl oligopeptidase inhibition by N-acyl-pro-pyrrolidine-type molecules.	n-acyl-pro-pyrrolidine	36-58	prolyl endopeptidase	Homo sapiens	0-21
19006380-1	2008	Three novel, N-acyl-pro-pyrrolidine-type, inhibitors of prolyl oligopeptidase (POP) with nanomolar activities were synthesized and their binding analyzed to the host enzyme in the light of X-ray diffraction and molecular modeling studies.	n-acyl-pro-pyrrolidine	13-35	prolyl endopeptidase	Homo sapiens	56-77
19006380-1	2008	Three novel, N-acyl-pro-pyrrolidine-type, inhibitors of prolyl oligopeptidase (POP) with nanomolar activities were synthesized and their binding analyzed to the host enzyme in the light of X-ray diffraction and molecular modeling studies.	n-acyl-pro-pyrrolidine	13-35	prolyl endopeptidase	Homo sapiens	79-82
18927208-9	2009	The intracellular enzyme prolyl oligopeptidase probably degrades tasidotin to P5.	tasidotin	65-74	prolyl endopeptidase	Homo sapiens	25-46
18927208-10	2009	When CCRF-CEM human leukemia cells were treated with N-benzyloxycarbonylprolylprolinal (BCPP), an inhibitor of prolyl oligopeptidase, there was a 30-fold increase in the IC(50) of tasidotin and a marked increase in intracellular [(3)H]tasidotin.	N-benzyloxycarbonylprolylprolinal	53-86	prolyl endopeptidase	Homo sapiens	111-132
18927208-10	2009	When CCRF-CEM human leukemia cells were treated with N-benzyloxycarbonylprolylprolinal (BCPP), an inhibitor of prolyl oligopeptidase, there was a 30-fold increase in the IC(50) of tasidotin and a marked increase in intracellular [(3)H]tasidotin.	N-benzyloxycarbonylprolylprolinal	88-92	prolyl endopeptidase	Homo sapiens	111-132
18927208-10	2009	When CCRF-CEM human leukemia cells were treated with N-benzyloxycarbonylprolylprolinal (BCPP), an inhibitor of prolyl oligopeptidase, there was a 30-fold increase in the IC(50) of tasidotin and a marked increase in intracellular [(3)H]tasidotin.	tasidotin	180-189	prolyl endopeptidase	Homo sapiens	111-132
18718510-1	2008	Prolyl oligopeptidase (POP) is an endopeptidase which cleaves short proline-containing neuropeptides, and it is involved in memory and learning.	Proline	68-75	prolyl endopeptidase	Homo sapiens	23-26
18718510-2	2008	POP also has an intercellular function mediated through the inositol pathway, and has been involved in cell death.	Inositol	60-68	prolyl endopeptidase	Homo sapiens	0-3
18718510-7	2008	We used the tight-binding inhibitor JTP-4819 covalently coupled with fluorescein (FJTP) as a tool to study the changes on expression and localization of POP protein.	JTP 4819	36-44	prolyl endopeptidase	Homo sapiens	153-156
18718510-7	2008	We used the tight-binding inhibitor JTP-4819 covalently coupled with fluorescein (FJTP) as a tool to study the changes on expression and localization of POP protein.	Fluorescein	69-80	prolyl endopeptidase	Homo sapiens	153-156
18718510-7	2008	We used the tight-binding inhibitor JTP-4819 covalently coupled with fluorescein (FJTP) as a tool to study the changes on expression and localization of POP protein.	fjtp	82-86	prolyl endopeptidase	Homo sapiens	153-156
19035315-1	2008	BACKGROUND: The natural tetrapeptide acetyl-Ser-Asp-Lys-Pro (AcSDKP), generated from thymosin beta4 following its cleavage by prolyl oligopeptidase (POP), is a physiological stimulator of angiogenesis.	Acetyl-Ser-Asp-Lys-Pro	37-59	prolyl endopeptidase	Homo sapiens	126-147
18792035-1	2008	Prolyl oligopeptidase (POP) is a cytosolic serine peptidase that hydrolyzes proline-containing peptides at the carboxy terminus of proline residues.	Proline	76-83	prolyl endopeptidase	Homo sapiens	0-21
18792035-1	2008	Prolyl oligopeptidase (POP) is a cytosolic serine peptidase that hydrolyzes proline-containing peptides at the carboxy terminus of proline residues.	Proline	76-83	prolyl endopeptidase	Homo sapiens	23-26
18792035-1	2008	Prolyl oligopeptidase (POP) is a cytosolic serine peptidase that hydrolyzes proline-containing peptides at the carboxy terminus of proline residues.	Proline	131-138	prolyl endopeptidase	Homo sapiens	0-21
18792035-1	2008	Prolyl oligopeptidase (POP) is a cytosolic serine peptidase that hydrolyzes proline-containing peptides at the carboxy terminus of proline residues.	Proline	131-138	prolyl endopeptidase	Homo sapiens	23-26
18792035-6	2008	Our results show for the first time that benzimidazolium salts are new POP-inhibitory scaffolds with properties of solubility, specificity, and lipophilicity that may allow them to cross the BBB by passive diffusion.	benzimidazolium salts	41-62	prolyl endopeptidase	Homo sapiens	71-74
19035315-1	2008	BACKGROUND: The natural tetrapeptide acetyl-Ser-Asp-Lys-Pro (AcSDKP), generated from thymosin beta4 following its cleavage by prolyl oligopeptidase (POP), is a physiological stimulator of angiogenesis.	Acetyl-Ser-Asp-Lys-Pro	37-59	prolyl endopeptidase	Homo sapiens	149-152
18606544-0	2008	Pyrrolidinyl pyridone and pyrazinone analogues as potent inhibitors of prolyl oligopeptidase (POP).	pyrrolidinyl pyridone	0-21	prolyl endopeptidase	Homo sapiens	71-92
18657187-1	2008	Prolyl oligopeptidase (POP) is a serine protease that cleaves small peptides at the carboxyl side of an internal proline residue.	Proline	113-120	prolyl endopeptidase	Homo sapiens	0-21
18657187-1	2008	Prolyl oligopeptidase (POP) is a serine protease that cleaves small peptides at the carboxyl side of an internal proline residue.	Proline	113-120	prolyl endopeptidase	Homo sapiens	23-26
18792035-0	2008	Benzimidazolium salts as small, nonpeptidic and BBB-permeable human prolyl oligopeptidase inhibitors.	benzimidazolium salts	0-21	prolyl endopeptidase	Homo sapiens	68-89
18606544-0	2008	Pyrrolidinyl pyridone and pyrazinone analogues as potent inhibitors of prolyl oligopeptidase (POP).	pyrrolidinyl pyridone	0-21	prolyl endopeptidase	Homo sapiens	94-97
18650094-0	2008	Baicalin, a prodrug able to reach the CNS, is a prolyl oligopeptidase inhibitor.	baicalin	0-8	prolyl endopeptidase	Homo sapiens	48-69
18606544-0	2008	Pyrrolidinyl pyridone and pyrazinone analogues as potent inhibitors of prolyl oligopeptidase (POP).	2-Hydroxypyrazine	26-36	prolyl endopeptidase	Homo sapiens	71-92
18650094-1	2008	Prolyl oligopeptidase is a cytosolic serine peptidase that hydrolyzes proline-containing peptides at the carboxy terminus of proline residues.	Proline	70-77	prolyl endopeptidase	Homo sapiens	0-21
18650094-1	2008	Prolyl oligopeptidase is a cytosolic serine peptidase that hydrolyzes proline-containing peptides at the carboxy terminus of proline residues.	Proline	125-132	prolyl endopeptidase	Homo sapiens	0-21
18606544-0	2008	Pyrrolidinyl pyridone and pyrazinone analogues as potent inhibitors of prolyl oligopeptidase (POP).	2-Hydroxypyrazine	26-36	prolyl endopeptidase	Homo sapiens	94-97
18650094-4	2008	Here, the flavonoid baicalin was isolated as the active component of an extract of Scutellaria baicalensis roots having prolyl oligopeptidase inhibitory activity.	Flavonoids	10-19	prolyl endopeptidase	Homo sapiens	120-141
18606544-1	2008	We report the synthesis and in vitro activity of a series of novel pyrrolidinyl pyridones and pyrazinones as potent inhibitors of prolyl oligopeptidase (POP).	pyrrolidinyl pyridones	67-89	prolyl endopeptidase	Homo sapiens	130-151
18606544-1	2008	We report the synthesis and in vitro activity of a series of novel pyrrolidinyl pyridones and pyrazinones as potent inhibitors of prolyl oligopeptidase (POP).	pyrrolidinyl pyridones	67-89	prolyl endopeptidase	Homo sapiens	153-156
18606544-1	2008	We report the synthesis and in vitro activity of a series of novel pyrrolidinyl pyridones and pyrazinones as potent inhibitors of prolyl oligopeptidase (POP).	pyrazinones	94-105	prolyl endopeptidase	Homo sapiens	130-151
18606544-1	2008	We report the synthesis and in vitro activity of a series of novel pyrrolidinyl pyridones and pyrazinones as potent inhibitors of prolyl oligopeptidase (POP).	pyrazinones	94-105	prolyl endopeptidase	Homo sapiens	153-156
18336325-1	2008	A group of serine peptidases, the prolyl oligopeptidase family, cannot hydrolyze proteins and peptides containing more than 30 residues.	Serine	11-17	prolyl endopeptidase	Homo sapiens	34-55
24692807-2	2008	Although prophylactic use of gabexate mesylate (GM) for the reduction of pancreatic injury after ERCP has been evaluated, uncertainty remains regarding the effectiveness of GM treatment in post-ERCP pancreatitis (PEP).	Gabexate	173-175	prolyl endopeptidase	Homo sapiens	213-216
24692807-3	2008	OBJECTIVE: The aim of this study was to determine through systematic review and meta-analysis the effectiveness and tolerability of GM in the prophylaxis of PEP.	Gabexate	132-134	prolyl endopeptidase	Homo sapiens	157-160
24692807-5	2008	We used the method recommended by The Cochrane Collaboration to perform a systematic review and meta-analysis of randomized controlled trials (RCTs) of GM in the prevention of PEP.	Gabexate	152-154	prolyl endopeptidase	Homo sapiens	176-179
18538760-2	2008	Alogliptin potently inhibited human DPP-4 in vitro (mean IC(50), ~ 6.9 nM) and exhibited > 10,000-fold selectivity for DPP-4 over the closely related serine proteases DPP-2, DPP-8, DPP-9, fibroblast activation protein/seprase, prolyl endopeptidase, and tryptase (IC(50) > 100,000 nM).	alogliptin	0-10	prolyl endopeptidase	Homo sapiens	230-250
18293395-10	2008	We then evaluated two specific PEP inhibitors, Boc-Asn-Phe-Pro-aldehyde and Z-Pro-Pro-aldehyde-dimethyl acetal, for their potential to reduce toxicity of stimulated THP-1 cell and human microglia supernatants towards SH-SY5Y cells.	Boc-Asn-Phe-Pro-aldehyde	47-71	prolyl endopeptidase	Homo sapiens	31-34
18293395-10	2008	We then evaluated two specific PEP inhibitors, Boc-Asn-Phe-Pro-aldehyde and Z-Pro-Pro-aldehyde-dimethyl acetal, for their potential to reduce toxicity of stimulated THP-1 cell and human microglia supernatants towards SH-SY5Y cells.	Z-Pro-Pro-aldehyde-dimethyl acetal	76-110	prolyl endopeptidase	Homo sapiens	31-34
18390751-5	2008	We describe the specific multistep proteolytic pathway involved in PGP generation from collagen, involving matrix metalloproteases 8 and 9 and prolyl endopeptidase, a serine protease for which we identify a novel role in inflammation.	pgp	67-70	prolyl endopeptidase	Homo sapiens	107-163
18336325-6	2008	Many reports addressed experimentally the possible role of POP in cognitive and psychiatric processes, its involvement in the inositol phosphate signaling pathway, and its ability to metabolize bioactive peptides.	Inositol Phosphates	126-144	prolyl endopeptidase	Homo sapiens	59-62
17714777-0	2007	Sulfated chitooligosaccharides as prolyl endopeptidase inhibitor.	oligochitosan	9-30	prolyl endopeptidase	Homo sapiens	34-54
17714777-1	2007	Prolyl endopeptidase (PEP, EC 3.4.21.26) is a proline-specific endopeptidase with a serine-type mechanism, which digests small peptide-like hormones, neuroactive peptides, and various cellular factors.	Proline	46-53	prolyl endopeptidase	Homo sapiens	0-20
17714777-1	2007	Prolyl endopeptidase (PEP, EC 3.4.21.26) is a proline-specific endopeptidase with a serine-type mechanism, which digests small peptide-like hormones, neuroactive peptides, and various cellular factors.	Proline	46-53	prolyl endopeptidase	Homo sapiens	22-25
17714777-1	2007	Prolyl endopeptidase (PEP, EC 3.4.21.26) is a proline-specific endopeptidase with a serine-type mechanism, which digests small peptide-like hormones, neuroactive peptides, and various cellular factors.	Serine	84-90	prolyl endopeptidase	Homo sapiens	0-20
17714777-1	2007	Prolyl endopeptidase (PEP, EC 3.4.21.26) is a proline-specific endopeptidase with a serine-type mechanism, which digests small peptide-like hormones, neuroactive peptides, and various cellular factors.	Serine	84-90	prolyl endopeptidase	Homo sapiens	22-25
17714777-7	2007	It was concluded that the 50-SCOS II may be useful for PEP inhibitor and for developing a new type PEP inhibitor from carbohydrate based materials.	Carbohydrates	118-130	prolyl endopeptidase	Homo sapiens	99-102
17904692-1	2007	Prolyl oligopeptidase (POP, EC 3.4.21.26) is a member of a family of serine peptidases with post-proline cleaving activity towards peptides.	Proline	97-104	prolyl endopeptidase	Homo sapiens	0-21
16942854-0	2006	A prolyl oligopeptidase inhibitor, Z-Pro-Prolinal, inhibits glyceraldehyde-3-phosphate dehydrogenase translocation and production of reactive oxygen species in CV1-P cells exposed to 6-hydroxydopamine.	N-benzyloxycarbonylprolylprolinal	35-49	prolyl endopeptidase	Homo sapiens	2-23
17154628-5	2006	The difference is thought to reflect poor passivation to oxide formation in the latter Prep B procedure, which is supported by X-ray photoelectron spectroscopy results.	Oxides	57-62	prolyl endopeptidase	Homo sapiens	87-91
17401647-2	2007	POP may have a role in inositol 1,4,5-triphosphate (IP(3)) signaling and in the actions of antidepressants, and POP inhibitors have exhibited antiamnesic and neuroprotective properties.	Inositol 1,4,5-Trisphosphate	23-50	prolyl endopeptidase	Homo sapiens	0-3
17401647-2	2007	POP may have a role in inositol 1,4,5-triphosphate (IP(3)) signaling and in the actions of antidepressants, and POP inhibitors have exhibited antiamnesic and neuroprotective properties.	Inositol 1,4,5-Trisphosphate	52-57	prolyl endopeptidase	Homo sapiens	0-3
17703733-6	2007	No significant structure-activity relationship was found; however, at least, three pyrogallol groups seem to be a minimal requirement for stronger activity against PEP All 19 active compounds inhibited PEP in a non-competitive mode with a substrate in Dixon plots.	Pyrogallol	83-93	prolyl endopeptidase	Homo sapiens	164-167
17703733-6	2007	No significant structure-activity relationship was found; however, at least, three pyrogallol groups seem to be a minimal requirement for stronger activity against PEP All 19 active compounds inhibited PEP in a non-competitive mode with a substrate in Dixon plots.	Pyrogallol	83-93	prolyl endopeptidase	Homo sapiens	202-205
17878957-1	2007	Prolyl oligopeptidase (POP) is a ubiquitous post-proline cleaving enzyme that is highly expressed in brain.	Proline	49-56	prolyl endopeptidase	Homo sapiens	0-21
17878957-1	2007	Prolyl oligopeptidase (POP) is a ubiquitous post-proline cleaving enzyme that is highly expressed in brain.	Proline	49-56	prolyl endopeptidase	Homo sapiens	23-26
17174090-2	2007	Several N-acyl-Gly- and N-blocked-boroPro compounds showed low nanomolar inhibitory activity against fibroblast activation protein (FAP) and prolyl oligopeptidase (POP) and selectivity against dipeptidyl peptidase-4 (DPP4).	n-acyl-gly- and n-blocked-boropro compounds	8-51	prolyl endopeptidase	Homo sapiens	141-162
17174090-2	2007	Several N-acyl-Gly- and N-blocked-boroPro compounds showed low nanomolar inhibitory activity against fibroblast activation protein (FAP) and prolyl oligopeptidase (POP) and selectivity against dipeptidyl peptidase-4 (DPP4).	n-acyl-gly- and n-blocked-boropro compounds	8-51	prolyl endopeptidase	Homo sapiens	164-167
17295371-0	2007	The natural product berberine is a human prolyl oligopeptidase inhibitor.	Berberine	20-29	prolyl endopeptidase	Homo sapiens	41-62
17295371-1	2007	Prolyl oligopeptidase is a cytosolic serine peptidase that hydrolyzes proline-containing peptides at the carboxy terminus.	Proline	70-77	prolyl endopeptidase	Homo sapiens	0-21
17295371-6	2007	The alkaloid berberine was the prolyl oligopeptidase inhibitory molecule isolated from Rhizoma coptidis extract.	Alkaloids	4-12	prolyl endopeptidase	Homo sapiens	31-52
17295371-6	2007	The alkaloid berberine was the prolyl oligopeptidase inhibitory molecule isolated from Rhizoma coptidis extract.	Berberine	13-22	prolyl endopeptidase	Homo sapiens	31-52
17295371-7	2007	Berberine inhibited prolyl oligopeptidase in a dose-dependent manner.	Berberine	0-9	prolyl endopeptidase	Homo sapiens	20-41
17160352-2	2007	The most well studied PEP family has a two-domain structure whose unique seven-blade beta-propeller domain works with the catalytic domain to hydrolyze the peptide bond on the carboxyl side of internal proline residues of an oligopeptide substrate.	Proline	202-209	prolyl endopeptidase	Homo sapiens	22-25
16942854-0	2006	A prolyl oligopeptidase inhibitor, Z-Pro-Prolinal, inhibits glyceraldehyde-3-phosphate dehydrogenase translocation and production of reactive oxygen species in CV1-P cells exposed to 6-hydroxydopamine.	Reactive Oxygen Species	133-156	prolyl endopeptidase	Homo sapiens	2-23
16942854-0	2006	A prolyl oligopeptidase inhibitor, Z-Pro-Prolinal, inhibits glyceraldehyde-3-phosphate dehydrogenase translocation and production of reactive oxygen species in CV1-P cells exposed to 6-hydroxydopamine.	Oxidopamine	183-200	prolyl endopeptidase	Homo sapiens	2-23
16942854-1	2006	We studied the ability of prolyl oligopeptidase (POP) inhibitors, Z-Pro-Prolinal and JTP-4819, to prevent translocation of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and formation of reactive oxygen species (ROS), in 6-hydroxydopamine (6-OHDA) and cytosine arabinoside (Ara-C) treated monkey fibroblast (CV1-P) and human neuroblastoma (SH-SY5Y) cells.	Reactive Oxygen Species	189-212	prolyl endopeptidase	Homo sapiens	26-47
16942854-1	2006	We studied the ability of prolyl oligopeptidase (POP) inhibitors, Z-Pro-Prolinal and JTP-4819, to prevent translocation of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and formation of reactive oxygen species (ROS), in 6-hydroxydopamine (6-OHDA) and cytosine arabinoside (Ara-C) treated monkey fibroblast (CV1-P) and human neuroblastoma (SH-SY5Y) cells.	Reactive Oxygen Species	189-212	prolyl endopeptidase	Homo sapiens	49-52
16942854-1	2006	We studied the ability of prolyl oligopeptidase (POP) inhibitors, Z-Pro-Prolinal and JTP-4819, to prevent translocation of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and formation of reactive oxygen species (ROS), in 6-hydroxydopamine (6-OHDA) and cytosine arabinoside (Ara-C) treated monkey fibroblast (CV1-P) and human neuroblastoma (SH-SY5Y) cells.	Reactive Oxygen Species	214-217	prolyl endopeptidase	Homo sapiens	26-47
16942854-1	2006	We studied the ability of prolyl oligopeptidase (POP) inhibitors, Z-Pro-Prolinal and JTP-4819, to prevent translocation of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and formation of reactive oxygen species (ROS), in 6-hydroxydopamine (6-OHDA) and cytosine arabinoside (Ara-C) treated monkey fibroblast (CV1-P) and human neuroblastoma (SH-SY5Y) cells.	Reactive Oxygen Species	214-217	prolyl endopeptidase	Homo sapiens	49-52
16942854-1	2006	We studied the ability of prolyl oligopeptidase (POP) inhibitors, Z-Pro-Prolinal and JTP-4819, to prevent translocation of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and formation of reactive oxygen species (ROS), in 6-hydroxydopamine (6-OHDA) and cytosine arabinoside (Ara-C) treated monkey fibroblast (CV1-P) and human neuroblastoma (SH-SY5Y) cells.	Oxidopamine	223-240	prolyl endopeptidase	Homo sapiens	26-47
16942854-1	2006	We studied the ability of prolyl oligopeptidase (POP) inhibitors, Z-Pro-Prolinal and JTP-4819, to prevent translocation of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and formation of reactive oxygen species (ROS), in 6-hydroxydopamine (6-OHDA) and cytosine arabinoside (Ara-C) treated monkey fibroblast (CV1-P) and human neuroblastoma (SH-SY5Y) cells.	Oxidopamine	223-240	prolyl endopeptidase	Homo sapiens	49-52
16942854-1	2006	We studied the ability of prolyl oligopeptidase (POP) inhibitors, Z-Pro-Prolinal and JTP-4819, to prevent translocation of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and formation of reactive oxygen species (ROS), in 6-hydroxydopamine (6-OHDA) and cytosine arabinoside (Ara-C) treated monkey fibroblast (CV1-P) and human neuroblastoma (SH-SY5Y) cells.	-ohda	243-248	prolyl endopeptidase	Homo sapiens	26-47
16942854-1	2006	We studied the ability of prolyl oligopeptidase (POP) inhibitors, Z-Pro-Prolinal and JTP-4819, to prevent translocation of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and formation of reactive oxygen species (ROS), in 6-hydroxydopamine (6-OHDA) and cytosine arabinoside (Ara-C) treated monkey fibroblast (CV1-P) and human neuroblastoma (SH-SY5Y) cells.	-ohda	243-248	prolyl endopeptidase	Homo sapiens	49-52
16942854-1	2006	We studied the ability of prolyl oligopeptidase (POP) inhibitors, Z-Pro-Prolinal and JTP-4819, to prevent translocation of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and formation of reactive oxygen species (ROS), in 6-hydroxydopamine (6-OHDA) and cytosine arabinoside (Ara-C) treated monkey fibroblast (CV1-P) and human neuroblastoma (SH-SY5Y) cells.	Cytarabine	254-274	prolyl endopeptidase	Homo sapiens	26-47
16942854-1	2006	We studied the ability of prolyl oligopeptidase (POP) inhibitors, Z-Pro-Prolinal and JTP-4819, to prevent translocation of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and formation of reactive oxygen species (ROS), in 6-hydroxydopamine (6-OHDA) and cytosine arabinoside (Ara-C) treated monkey fibroblast (CV1-P) and human neuroblastoma (SH-SY5Y) cells.	Cytarabine	254-274	prolyl endopeptidase	Homo sapiens	49-52
16942854-1	2006	We studied the ability of prolyl oligopeptidase (POP) inhibitors, Z-Pro-Prolinal and JTP-4819, to prevent translocation of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and formation of reactive oxygen species (ROS), in 6-hydroxydopamine (6-OHDA) and cytosine arabinoside (Ara-C) treated monkey fibroblast (CV1-P) and human neuroblastoma (SH-SY5Y) cells.	Cytarabine	276-281	prolyl endopeptidase	Homo sapiens	26-47
16942854-1	2006	We studied the ability of prolyl oligopeptidase (POP) inhibitors, Z-Pro-Prolinal and JTP-4819, to prevent translocation of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and formation of reactive oxygen species (ROS), in 6-hydroxydopamine (6-OHDA) and cytosine arabinoside (Ara-C) treated monkey fibroblast (CV1-P) and human neuroblastoma (SH-SY5Y) cells.	Cytarabine	276-281	prolyl endopeptidase	Homo sapiens	49-52
16942854-9	2006	In conclusion, POP inhibitors are able to prevent certain cell stress related factors such as ROS production or GAPDH translocation.	Reactive Oxygen Species	94-97	prolyl endopeptidase	Homo sapiens	15-18
16849325-6	2006	We have cloned, overexpressed, and purified recombinant hPreP and its mutant with catalytic base Glu(78) in the inverted zinc-binding motif replaced by Gln.	Glutamic Acid	97-100	prolyl endopeptidase	Homo sapiens	56-61
16919454-0	2006	An introduction of a pyridine group into the structure of prolyl oligopeptidase inhibitors.	pyridine	21-29	prolyl endopeptidase	Homo sapiens	58-79
16919454-2	2006	The study was performed on previously developed prolyl oligopeptidase inhibitors with proline mimetics at the P2 position.	Proline	86-93	prolyl endopeptidase	Homo sapiens	48-69
16849325-6	2006	We have cloned, overexpressed, and purified recombinant hPreP and its mutant with catalytic base Glu(78) in the inverted zinc-binding motif replaced by Gln.	Glutamine	152-155	prolyl endopeptidase	Homo sapiens	56-61
16849325-9	2006	Molecular modeling of hPreP based on the crystal structure at 2.1 A resolution of AtPreP allowed us to identify Cys(90) and Cys(527) that form disulfide bridges under oxidized conditions and might be involved in redox regulation of the enzyme.	Cysteine	112-115	prolyl endopeptidase	Homo sapiens	22-27
16849325-9	2006	Molecular modeling of hPreP based on the crystal structure at 2.1 A resolution of AtPreP allowed us to identify Cys(90) and Cys(527) that form disulfide bridges under oxidized conditions and might be involved in redox regulation of the enzyme.	Cysteine	124-127	prolyl endopeptidase	Homo sapiens	22-27
16849325-9	2006	Molecular modeling of hPreP based on the crystal structure at 2.1 A resolution of AtPreP allowed us to identify Cys(90) and Cys(527) that form disulfide bridges under oxidized conditions and might be involved in redox regulation of the enzyme.	Disulfides	143-152	prolyl endopeptidase	Homo sapiens	22-27
16406204-4	2006	Incubation of ODN with PEP generated two products, i.e. ODN3-18 and ODN5-18 which resulted from cleavage of the Ala-Thr and Val-Gly peptide bonds.	Alanine	112-115	prolyl endopeptidase	Homo sapiens	23-26
16406204-10	2006	In addition, this study reveals for the first time that the endoproteolytic activity of PEP can specifically take place after a valine moiety.	Valine	128-134	prolyl endopeptidase	Homo sapiens	88-91
16406204-4	2006	Incubation of ODN with PEP generated two products, i.e. ODN3-18 and ODN5-18 which resulted from cleavage of the Ala-Thr and Val-Gly peptide bonds.	Threonine	116-119	prolyl endopeptidase	Homo sapiens	23-26
16406204-4	2006	Incubation of ODN with PEP generated two products, i.e. ODN3-18 and ODN5-18 which resulted from cleavage of the Ala-Thr and Val-Gly peptide bonds.	Valine	124-127	prolyl endopeptidase	Homo sapiens	23-26
16406204-4	2006	Incubation of ODN with PEP generated two products, i.e. ODN3-18 and ODN5-18 which resulted from cleavage of the Ala-Thr and Val-Gly peptide bonds.	Glycine	128-131	prolyl endopeptidase	Homo sapiens	23-26
16406204-7	2006	For all these peptides, cleavage of the Pro-Gly peptide bond by PEP was never observed, even after prolonged incubation times.	Glycine	44-47	prolyl endopeptidase	Homo sapiens	64-67
16406204-8	2006	In contrast, PEP hydrolyzed human urotensin II at the canonical post-proline site.	Proline	69-76	prolyl endopeptidase	Homo sapiens	13-16
16143118-4	2005	METHODS: In vitro degradation by PEP of 3H-labeled gliadin peptides 56-88 (33-mer) and 31-49, was analyzed by radio-reverse-phase high-performance liquid chromatography and mass spectrometry.	Tritium	40-42	prolyl endopeptidase	Homo sapiens	33-36
16628753-1	2006	Prolyl oligopeptidase is a cytosolic serine peptidase that hydrolyzes proline-containing peptides at the carboxy termini of the proline residues.	Proline	70-77	prolyl endopeptidase	Homo sapiens	0-21
16628753-1	2006	Prolyl oligopeptidase is a cytosolic serine peptidase that hydrolyzes proline-containing peptides at the carboxy termini of the proline residues.	Proline	128-135	prolyl endopeptidase	Homo sapiens	0-21
16478242-0	2006	Prolyl endopeptidase inhibitory activity of unsaturated fatty acids.	Fatty Acids, Unsaturated	44-67	prolyl endopeptidase	Homo sapiens	0-20
16478242-3	2006	In this study, mono- and polyunsaturated fatty acids were investigated to determine their role as PEP inhibitors.	mono- and polyunsaturated fatty acids	15-52	prolyl endopeptidase	Homo sapiens	98-101
16478242-4	2006	Oleic, linoleic, and arachidonic acids, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) showed PEP inhibitory activities (IC50 values of 23.6 +/- 0.4, 43.8 +/- 1.8, 53.4 +/- 1.2, 99.4 +/- 1.2, and 46.2 +/- 1.0 microM, respectively), indicating that they were effective PEP inhibitors, with inhibition constant (Ki) values of 26.7 +/- 0.3, 51.0 +/- 0.7, 91.3 +/- 3.1, 247.5 +/- 2.6, and 89.0 +/- 2.3 microM, respectively.	oleic	0-5	prolyl endopeptidase	Homo sapiens	107-110
16478242-4	2006	Oleic, linoleic, and arachidonic acids, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) showed PEP inhibitory activities (IC50 values of 23.6 +/- 0.4, 43.8 +/- 1.8, 53.4 +/- 1.2, 99.4 +/- 1.2, and 46.2 +/- 1.0 microM, respectively), indicating that they were effective PEP inhibitors, with inhibition constant (Ki) values of 26.7 +/- 0.3, 51.0 +/- 0.7, 91.3 +/- 3.1, 247.5 +/- 2.6, and 89.0 +/- 2.3 microM, respectively.	oleic	0-5	prolyl endopeptidase	Homo sapiens	281-284
16478242-4	2006	Oleic, linoleic, and arachidonic acids, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) showed PEP inhibitory activities (IC50 values of 23.6 +/- 0.4, 43.8 +/- 1.8, 53.4 +/- 1.2, 99.4 +/- 1.2, and 46.2 +/- 1.0 microM, respectively), indicating that they were effective PEP inhibitors, with inhibition constant (Ki) values of 26.7 +/- 0.3, 51.0 +/- 0.7, 91.3 +/- 3.1, 247.5 +/- 2.6, and 89.0 +/- 2.3 microM, respectively.	Linoleic Acid	7-15	prolyl endopeptidase	Homo sapiens	107-110
16478242-4	2006	Oleic, linoleic, and arachidonic acids, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) showed PEP inhibitory activities (IC50 values of 23.6 +/- 0.4, 43.8 +/- 1.8, 53.4 +/- 1.2, 99.4 +/- 1.2, and 46.2 +/- 1.0 microM, respectively), indicating that they were effective PEP inhibitors, with inhibition constant (Ki) values of 26.7 +/- 0.3, 51.0 +/- 0.7, 91.3 +/- 3.1, 247.5 +/- 2.6, and 89.0 +/- 2.3 microM, respectively.	Linoleic Acid	7-15	prolyl endopeptidase	Homo sapiens	281-284
16279765-0	2005	Synthesis and characterization of the novel fluorescent prolyl oligopeptidase inhibitor 4-fluoresceinthiocarbamoyl-6-aminocaproyl-L-prolyl-2(S)-(hydroxyacetyl)pyrrolidine.	4-fluoresceinthiocarbamoyl-6-aminocaproyl-prolyl-2-(hydroxyacetyl)pyrrolidine	88-170	prolyl endopeptidase	Homo sapiens	56-77
16279765-1	2005	The synthesis and characterization of the first fluorescent prolyl oligopeptidase inhibitor 4-fluoresceinthiocarbamoyl-6-aminocaproyl-L-prolyl-2(S)-(hydroxyacetyl)pyrrolidine is described.	4-fluoresceinthiocarbamoyl-6-aminocaproyl-prolyl-2-(hydroxyacetyl)pyrrolidine	92-174	prolyl endopeptidase	Homo sapiens	60-81
16478242-4	2006	Oleic, linoleic, and arachidonic acids, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) showed PEP inhibitory activities (IC50 values of 23.6 +/- 0.4, 43.8 +/- 1.8, 53.4 +/- 1.2, 99.4 +/- 1.2, and 46.2 +/- 1.0 microM, respectively), indicating that they were effective PEP inhibitors, with inhibition constant (Ki) values of 26.7 +/- 0.3, 51.0 +/- 0.7, 91.3 +/- 3.1, 247.5 +/- 2.6, and 89.0 +/- 2.3 microM, respectively.	Arachidonic Acids	21-38	prolyl endopeptidase	Homo sapiens	107-110
16478242-4	2006	Oleic, linoleic, and arachidonic acids, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) showed PEP inhibitory activities (IC50 values of 23.6 +/- 0.4, 43.8 +/- 1.8, 53.4 +/- 1.2, 99.4 +/- 1.2, and 46.2 +/- 1.0 microM, respectively), indicating that they were effective PEP inhibitors, with inhibition constant (Ki) values of 26.7 +/- 0.3, 51.0 +/- 0.7, 91.3 +/- 3.1, 247.5 +/- 2.6, and 89.0 +/- 2.3 microM, respectively.	Arachidonic Acids	21-38	prolyl endopeptidase	Homo sapiens	281-284
16478242-4	2006	Oleic, linoleic, and arachidonic acids, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) showed PEP inhibitory activities (IC50 values of 23.6 +/- 0.4, 43.8 +/- 1.8, 53.4 +/- 1.2, 99.4 +/- 1.2, and 46.2 +/- 1.0 microM, respectively), indicating that they were effective PEP inhibitors, with inhibition constant (Ki) values of 26.7 +/- 0.3, 51.0 +/- 0.7, 91.3 +/- 3.1, 247.5 +/- 2.6, and 89.0 +/- 2.3 microM, respectively.	Eicosapentaenoic Acid	40-61	prolyl endopeptidase	Homo sapiens	107-110
16478242-4	2006	Oleic, linoleic, and arachidonic acids, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) showed PEP inhibitory activities (IC50 values of 23.6 +/- 0.4, 43.8 +/- 1.8, 53.4 +/- 1.2, 99.4 +/- 1.2, and 46.2 +/- 1.0 microM, respectively), indicating that they were effective PEP inhibitors, with inhibition constant (Ki) values of 26.7 +/- 0.3, 51.0 +/- 0.7, 91.3 +/- 3.1, 247.5 +/- 2.6, and 89.0 +/- 2.3 microM, respectively.	Eicosapentaenoic Acid	40-61	prolyl endopeptidase	Homo sapiens	281-284
16478242-4	2006	Oleic, linoleic, and arachidonic acids, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) showed PEP inhibitory activities (IC50 values of 23.6 +/- 0.4, 43.8 +/- 1.8, 53.4 +/- 1.2, 99.4 +/- 1.2, and 46.2 +/- 1.0 microM, respectively), indicating that they were effective PEP inhibitors, with inhibition constant (Ki) values of 26.7 +/- 0.3, 51.0 +/- 0.7, 91.3 +/- 3.1, 247.5 +/- 2.6, and 89.0 +/- 2.3 microM, respectively.	Eicosapentaenoic Acid	63-66	prolyl endopeptidase	Homo sapiens	107-110
16478242-4	2006	Oleic, linoleic, and arachidonic acids, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) showed PEP inhibitory activities (IC50 values of 23.6 +/- 0.4, 43.8 +/- 1.8, 53.4 +/- 1.2, 99.4 +/- 1.2, and 46.2 +/- 1.0 microM, respectively), indicating that they were effective PEP inhibitors, with inhibition constant (Ki) values of 26.7 +/- 0.3, 51.0 +/- 0.7, 91.3 +/- 3.1, 247.5 +/- 2.6, and 89.0 +/- 2.3 microM, respectively.	Eicosapentaenoic Acid	63-66	prolyl endopeptidase	Homo sapiens	281-284
16478242-4	2006	Oleic, linoleic, and arachidonic acids, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) showed PEP inhibitory activities (IC50 values of 23.6 +/- 0.4, 43.8 +/- 1.8, 53.4 +/- 1.2, 99.4 +/- 1.2, and 46.2 +/- 1.0 microM, respectively), indicating that they were effective PEP inhibitors, with inhibition constant (Ki) values of 26.7 +/- 0.3, 51.0 +/- 0.7, 91.3 +/- 3.1, 247.5 +/- 2.6, and 89.0 +/- 2.3 microM, respectively.	Docosahexaenoic Acids	73-93	prolyl endopeptidase	Homo sapiens	107-110
16478242-4	2006	Oleic, linoleic, and arachidonic acids, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) showed PEP inhibitory activities (IC50 values of 23.6 +/- 0.4, 43.8 +/- 1.8, 53.4 +/- 1.2, 99.4 +/- 1.2, and 46.2 +/- 1.0 microM, respectively), indicating that they were effective PEP inhibitors, with inhibition constant (Ki) values of 26.7 +/- 0.3, 51.0 +/- 0.7, 91.3 +/- 3.1, 247.5 +/- 2.6, and 89.0 +/- 2.3 microM, respectively.	Docosahexaenoic Acids	73-93	prolyl endopeptidase	Homo sapiens	281-284
16478242-4	2006	Oleic, linoleic, and arachidonic acids, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) showed PEP inhibitory activities (IC50 values of 23.6 +/- 0.4, 43.8 +/- 1.8, 53.4 +/- 1.2, 99.4 +/- 1.2, and 46.2 +/- 1.0 microM, respectively), indicating that they were effective PEP inhibitors, with inhibition constant (Ki) values of 26.7 +/- 0.3, 51.0 +/- 0.7, 91.3 +/- 3.1, 247.5 +/- 2.6, and 89.0 +/- 2.3 microM, respectively.	Docosahexaenoic Acids	95-98	prolyl endopeptidase	Homo sapiens	107-110
16478242-4	2006	Oleic, linoleic, and arachidonic acids, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) showed PEP inhibitory activities (IC50 values of 23.6 +/- 0.4, 43.8 +/- 1.8, 53.4 +/- 1.2, 99.4 +/- 1.2, and 46.2 +/- 1.0 microM, respectively), indicating that they were effective PEP inhibitors, with inhibition constant (Ki) values of 26.7 +/- 0.3, 51.0 +/- 0.7, 91.3 +/- 3.1, 247.5 +/- 2.6, and 89.0 +/- 2.3 microM, respectively.	Docosahexaenoic Acids	95-98	prolyl endopeptidase	Homo sapiens	281-284
16478242-5	2006	Oleic acid showed the highest PEP inhibitory activity.	Oleic Acid	0-10	prolyl endopeptidase	Homo sapiens	30-33
16478242-6	2006	Dixon plots of PEP inhibition showed oleic, linoleic, and arachidonic acids, EPA, and DHA are noncompetitive inhibitors; despite higher IC50 values of these unsaturated fatty acids than strong natural inhibitors, they may have potential use in preventing memory loss.	oleic	37-42	prolyl endopeptidase	Homo sapiens	15-18
16478242-6	2006	Dixon plots of PEP inhibition showed oleic, linoleic, and arachidonic acids, EPA, and DHA are noncompetitive inhibitors; despite higher IC50 values of these unsaturated fatty acids than strong natural inhibitors, they may have potential use in preventing memory loss.	Linoleic Acid	44-52	prolyl endopeptidase	Homo sapiens	15-18
16478242-6	2006	Dixon plots of PEP inhibition showed oleic, linoleic, and arachidonic acids, EPA, and DHA are noncompetitive inhibitors; despite higher IC50 values of these unsaturated fatty acids than strong natural inhibitors, they may have potential use in preventing memory loss.	Arachidonic Acids	58-75	prolyl endopeptidase	Homo sapiens	15-18
16478242-6	2006	Dixon plots of PEP inhibition showed oleic, linoleic, and arachidonic acids, EPA, and DHA are noncompetitive inhibitors; despite higher IC50 values of these unsaturated fatty acids than strong natural inhibitors, they may have potential use in preventing memory loss.	Eicosapentaenoic Acid	77-80	prolyl endopeptidase	Homo sapiens	15-18
16478242-6	2006	Dixon plots of PEP inhibition showed oleic, linoleic, and arachidonic acids, EPA, and DHA are noncompetitive inhibitors; despite higher IC50 values of these unsaturated fatty acids than strong natural inhibitors, they may have potential use in preventing memory loss.	Docosahexaenoic Acids	86-89	prolyl endopeptidase	Homo sapiens	15-18
16478242-6	2006	Dixon plots of PEP inhibition showed oleic, linoleic, and arachidonic acids, EPA, and DHA are noncompetitive inhibitors; despite higher IC50 values of these unsaturated fatty acids than strong natural inhibitors, they may have potential use in preventing memory loss.	Fatty Acids, Unsaturated	157-180	prolyl endopeptidase	Homo sapiens	15-18
16390203-0	2006	Quantitative structure-activity relationship of prolyl oligopeptidase inhibitory peptides derived from beta-casein using simple amino acid descriptors.	simple amino acid	121-138	prolyl endopeptidase	Homo sapiens	48-69
16700513-0	2006	Prolyl endopeptidase cleaves the apoptosis rescue peptide humanin and exhibits an unknown post-cysteine cleavage specificity.	Cysteine	95-103	prolyl endopeptidase	Homo sapiens	0-20
16410071-6	2006	This study suggested that Glyde File Prep could negatively affect the bond strengths of MTA-dentin.	Glipizide	26-31	prolyl endopeptidase	Homo sapiens	37-41
16143118-4	2005	METHODS: In vitro degradation by PEP of 3H-labeled gliadin peptides 56-88 (33-mer) and 31-49, was analyzed by radio-reverse-phase high-performance liquid chromatography and mass spectrometry.	Peptides	59-67	prolyl endopeptidase	Homo sapiens	33-36
16206502-7	2005	In response to gluten not treated with PEP, an appreciable proportion of patients developed malabsorption of fat (7 of 17, 41%) or xylose (8 of 14, 57%).	Xylose	131-137	prolyl endopeptidase	Homo sapiens	39-42
16212427-10	2005	Prolyl endopeptidase treatment was shown to abolish the antigenicity of both the 33-mer and the 26-mer peptides, and was also predicted to have comparable effects on other proline-rich putatively immunotoxic peptides identified from other polypeptides within the gluten proteome.	Proline	172-179	prolyl endopeptidase	Homo sapiens	0-20
16092940-4	2005	Disassembly of the microtubules by nocodazole treatment disrupts both the fibrillar tubulin and PEP labelling.	Nocodazole	35-45	prolyl endopeptidase	Homo sapiens	96-99
16033257-0	2005	Dicarboxylic acid azacycle l-prolyl-pyrrolidine amides as prolyl oligopeptidase inhibitors and three-dimensional quantitative structure-activity relationship of the enzyme-inhibitor interactions.	dicarboxylic acid azacycle l-prolyl-pyrrolidine amides	0-54	prolyl endopeptidase	Homo sapiens	58-79
16033257-1	2005	A series of dicarboxylic acid azacycle l-prolyl-pyrrolidine amides was synthesized, and their inhibitory activity against prolyl oligopeptidase (POP) from porcine brain was tested.	dicarboxylic acid azacycle l-prolyl-pyrrolidine amides	12-66	prolyl endopeptidase	Homo sapiens	122-143
16033257-1	2005	A series of dicarboxylic acid azacycle l-prolyl-pyrrolidine amides was synthesized, and their inhibitory activity against prolyl oligopeptidase (POP) from porcine brain was tested.	dicarboxylic acid azacycle l-prolyl-pyrrolidine amides	12-66	prolyl endopeptidase	Homo sapiens	145-148
16206502-8	2005	When the gluten was pretreated with PEP, fat malabsorption was avoided in 5 of 7 and xylose malabsorption in 4 of 8 of these same patients.	Xylose	85-91	prolyl endopeptidase	Homo sapiens	36-39
16206502-10	2005	Pretreatment of gluten with PEP avoided the development of fat or carbohydrate malabsorption in the majority of those patients who developed fat or carbohydrate malabsorption after a 2-week gluten challenge.	Carbohydrates	66-78	prolyl endopeptidase	Homo sapiens	28-31
16206502-10	2005	Pretreatment of gluten with PEP avoided the development of fat or carbohydrate malabsorption in the majority of those patients who developed fat or carbohydrate malabsorption after a 2-week gluten challenge.	Carbohydrates	148-160	prolyl endopeptidase	Homo sapiens	28-31
15826309-7	2005	Of 60,263 cytidines in this test set, PREP-Mt correctly classified 58,994 as either an edited or unedited site (accuracy = 97.9%).	Cytidine	10-19	prolyl endopeptidase	Homo sapiens	38-42
15932649-1	2005	BACKGROUND: Prolyl Endopeptidase (PEP, EC 3.4.21.26), a cytosolic endopeptidase, hydrolyses peptide bonds on the carboxyl side of proline residue in proteins with a relatively small molecular weight.	Proline	130-137	prolyl endopeptidase	Homo sapiens	12-32
15932649-1	2005	BACKGROUND: Prolyl Endopeptidase (PEP, EC 3.4.21.26), a cytosolic endopeptidase, hydrolyses peptide bonds on the carboxyl side of proline residue in proteins with a relatively small molecular weight.	Proline	130-137	prolyl endopeptidase	Homo sapiens	34-37
15932649-6	2005	METHODS: Fluorometric assay was used to measure PEP activity in EDTA plasma in children with ASD (n = 18) aged 4-12 years (mean +/- SD: 7.9 +/- 2.5).	Edetic Acid	64-68	prolyl endopeptidase	Homo sapiens	48-51
15509157-0	2004	A cyclopent-2-enecarbonyl group mimics proline at the P2 position of prolyl oligopeptidase inhibitors.	cyclopent-2	2-13	prolyl endopeptidase	Homo sapiens	69-90
15713471-6	2005	Differential scanning calorimetry, kinetic denaturation with urea and equilibrium denaturation with guanidinium chloride have shown that the propeller is more stable than the parent prolyl oligopeptidase.	Urea	61-65	prolyl endopeptidase	Homo sapiens	182-203
15713471-6	2005	Differential scanning calorimetry, kinetic denaturation with urea and equilibrium denaturation with guanidinium chloride have shown that the propeller is more stable than the parent prolyl oligopeptidase.	Guanidine	100-120	prolyl endopeptidase	Homo sapiens	182-203
15612841-6	2004	Trajectories of positive behavior for NO and U-PREP partners showed significant declines compared with RO-PREP trajectories.	ro	103-105	prolyl endopeptidase	Homo sapiens	106-110
15509157-0	2004	A cyclopent-2-enecarbonyl group mimics proline at the P2 position of prolyl oligopeptidase inhibitors.	enecarbonyl	14-25	prolyl endopeptidase	Homo sapiens	69-90
15509157-0	2004	A cyclopent-2-enecarbonyl group mimics proline at the P2 position of prolyl oligopeptidase inhibitors.	Proline	39-46	prolyl endopeptidase	Homo sapiens	69-90
15509157-1	2004	With the aim to replace the natural amino acid proline by a proline mimetic structure, a cyclopent-2-enecarbonyl moiety was studied at the P2 position of prolyl oligopeptidase (POP) inhibitors.	Proline	60-67	prolyl endopeptidase	Homo sapiens	154-175
15509157-1	2004	With the aim to replace the natural amino acid proline by a proline mimetic structure, a cyclopent-2-enecarbonyl moiety was studied at the P2 position of prolyl oligopeptidase (POP) inhibitors.	cyclopent-2-enecarbonyl	89-112	prolyl endopeptidase	Homo sapiens	154-175
15509157-1	2004	With the aim to replace the natural amino acid proline by a proline mimetic structure, a cyclopent-2-enecarbonyl moiety was studied at the P2 position of prolyl oligopeptidase (POP) inhibitors.	cyclopent-2-enecarbonyl	89-112	prolyl endopeptidase	Homo sapiens	177-180
15509157-2	2004	The cyclopent-2-enecarbonyl moiety proved to be an excellent proline mimetic at the P2 position of POP inhibitors.	cyclopent-2-enecarbonyl	4-27	prolyl endopeptidase	Homo sapiens	99-102
15509157-2	2004	The cyclopent-2-enecarbonyl moiety proved to be an excellent proline mimetic at the P2 position of POP inhibitors.	Proline	61-68	prolyl endopeptidase	Homo sapiens	99-102
15005755-1	2004	BACKGROUND: Inhibition of prolyl oligopeptidase (PO) in primary neuronal cultures has been shown to reverse the effect of the common mood-stabilizers lithium, valproic acid and carbamazepine.	Lithium	150-157	prolyl endopeptidase	Homo sapiens	26-47
15217351-1	2004	POP (prolyl oligopeptidase) specifically hydrolyses a number of small proline-containing peptides at the carboxy end of the proline residue and POP inhibitors have been shown to have cognition-enhancing properties.	Proline	70-77	prolyl endopeptidase	Homo sapiens	0-3
15217351-1	2004	POP (prolyl oligopeptidase) specifically hydrolyses a number of small proline-containing peptides at the carboxy end of the proline residue and POP inhibitors have been shown to have cognition-enhancing properties.	Proline	70-77	prolyl endopeptidase	Homo sapiens	5-26
15217351-1	2004	POP (prolyl oligopeptidase) specifically hydrolyses a number of small proline-containing peptides at the carboxy end of the proline residue and POP inhibitors have been shown to have cognition-enhancing properties.	Proline	70-77	prolyl endopeptidase	Homo sapiens	144-147
15217351-1	2004	POP (prolyl oligopeptidase) specifically hydrolyses a number of small proline-containing peptides at the carboxy end of the proline residue and POP inhibitors have been shown to have cognition-enhancing properties.	Proline	124-131	prolyl endopeptidase	Homo sapiens	0-3
15217351-1	2004	POP (prolyl oligopeptidase) specifically hydrolyses a number of small proline-containing peptides at the carboxy end of the proline residue and POP inhibitors have been shown to have cognition-enhancing properties.	Proline	124-131	prolyl endopeptidase	Homo sapiens	5-26
15217351-4	2004	In the present study, we examined the effect of different functional groups at the P1 site of the parent inhibitor isophthalic acid bis-(L-prolylpyrrolidine) amide on the binding kinetics to POP.	isophthalic acid bis-(l-prolylpyrrolidine) amide	115-163	prolyl endopeptidase	Homo sapiens	191-194
15170343-4	2004	The pH dependence of k(cat)/K(M,PEP) demonstrates the importance of the same two acidic ionizations in the interaction of phosphoenolpyruvate with PEPCK and a single basic ionization with a pK(a) value of 8.1 that is assigned to Y220.	Phosphoenolpyruvate	122-141	prolyl endopeptidase	Homo sapiens	32-35
15147213-7	2004	(Benzyloxycarbonyl)glycylprolylmelphalan, but not the more sterically hindered doxorubicin prodrug, could be efficiently activated by prolyl endopeptidase [specific activity = 813.3 nmol min(-1) (mg of enzyme)(-1) at 25 degrees C].	(benzyloxycarbonyl)glycylprolylmelphalan	0-40	prolyl endopeptidase	Homo sapiens	134-154
15147213-8	2004	The melphalan prodrug was essentially nontoxic to CHO, F9 teratocarcinoma, MCF7 breast adenocarcinoma, and p3U1 mouse myeloma cells up to millimolar concentrations, while prodrug incubation with the engineered prolyl endopeptidase mutant led to a cell killing profile superimposable to the one of melphalan.	Melphalan	4-13	prolyl endopeptidase	Homo sapiens	210-230
15005755-1	2004	BACKGROUND: Inhibition of prolyl oligopeptidase (PO) in primary neuronal cultures has been shown to reverse the effect of the common mood-stabilizers lithium, valproic acid and carbamazepine.	Lithium	150-157	prolyl endopeptidase	Homo sapiens	49-51
15005755-1	2004	BACKGROUND: Inhibition of prolyl oligopeptidase (PO) in primary neuronal cultures has been shown to reverse the effect of the common mood-stabilizers lithium, valproic acid and carbamazepine.	Valproic Acid	159-172	prolyl endopeptidase	Homo sapiens	26-47
15005755-1	2004	BACKGROUND: Inhibition of prolyl oligopeptidase (PO) in primary neuronal cultures has been shown to reverse the effect of the common mood-stabilizers lithium, valproic acid and carbamazepine.	Valproic Acid	159-172	prolyl endopeptidase	Homo sapiens	49-51
15005755-1	2004	BACKGROUND: Inhibition of prolyl oligopeptidase (PO) in primary neuronal cultures has been shown to reverse the effect of the common mood-stabilizers lithium, valproic acid and carbamazepine.	Carbamazepine	177-190	prolyl endopeptidase	Homo sapiens	26-47
15005755-1	2004	BACKGROUND: Inhibition of prolyl oligopeptidase (PO) in primary neuronal cultures has been shown to reverse the effect of the common mood-stabilizers lithium, valproic acid and carbamazepine.	Carbamazepine	177-190	prolyl endopeptidase	Homo sapiens	49-51
14514675-1	2003	The positive electrostatic environment of the active site of prolyl oligopeptidase was investigated by using substrates with glutamic acid at positions P2, P3, P4, and P5, respectively.	Glutamic Acid	125-138	prolyl endopeptidase	Homo sapiens	61-82
14766370-3	2004	We chose to evaluate immunologic function in HIV negative patients who received Nelfinavir and Combivir (AZT and 3TC) as PEP.	lamivudine, zidovudine drug combination	95-103	prolyl endopeptidase	Homo sapiens	121-124
14766370-3	2004	We chose to evaluate immunologic function in HIV negative patients who received Nelfinavir and Combivir (AZT and 3TC) as PEP.	Lamivudine	113-116	prolyl endopeptidase	Homo sapiens	121-124
14723335-1	2003	A prolyl endopeptidase inhibitor was isolated from the ethyl acetate soluble fraction of Phyllanthus ussurensis.	ethyl acetate	55-68	prolyl endopeptidase	Homo sapiens	2-22
11437605-2	2001	The enzyme readily cleaves the prolyl oligopeptidase (PO) substrate Z-Gly-Pro-MCA, liberating the fluorophore MCA, thus allowing quantification of enzyme activity.	N-carbobenzoxyglycyl-prolyl-4-methylcoumarinyl amide	68-81	prolyl endopeptidase	Homo sapiens	31-52
12752647-9	2003	RESULTS: The canals treated with EDTA and Glyde File Prep were significantly cleaner than those treated with NaOCl alone.	Glipizide	42-47	prolyl endopeptidase	Homo sapiens	53-57
12752647-9	2003	RESULTS: The canals treated with EDTA and Glyde File Prep were significantly cleaner than those treated with NaOCl alone.	Sodium Hypochlorite	109-114	prolyl endopeptidase	Homo sapiens	53-57
12752647-11	2003	CONCLUSIONS: Used in conjunction with NaOCl irrigation, Glyde File Prep was effective in removing smear layer produced during root canal instrumentation.	Sodium Hypochlorite	38-43	prolyl endopeptidase	Homo sapiens	67-71
12752647-11	2003	CONCLUSIONS: Used in conjunction with NaOCl irrigation, Glyde File Prep was effective in removing smear layer produced during root canal instrumentation.	Glipizide	56-61	prolyl endopeptidase	Homo sapiens	67-71
14594319-4	2003	It was found that the PEP activity was about 10% higher in plasma (with EDTA and heparinate for anticoagulation) than in serum.	Edetic Acid	72-76	prolyl endopeptidase	Homo sapiens	22-25
14594319-7	2003	In conclusion, PEP activity should preferably be measured within one hour after sampling using EDTA- or heparinate plasma.	Edetic Acid	95-99	prolyl endopeptidase	Homo sapiens	15-18
12444969-0	2002	Modulation of inositol 1,4,5-triphosphate concentration by prolyl endopeptidase inhibition.	Inositol 1,4,5-Trisphosphate	14-41	prolyl endopeptidase	Homo sapiens	59-79
12444969-3	2002	Measuring different second-messenger concentrations revealed an inverse correlation between inositol 1,4,5-triphosphate [Ins(1,4,5)P3] concentration and PEP expression in the generated antisense cell lines.	Inositol 1,4,5-Trisphosphate	92-119	prolyl endopeptidase	Homo sapiens	153-156
12444969-3	2002	Measuring different second-messenger concentrations revealed an inverse correlation between inositol 1,4,5-triphosphate [Ins(1,4,5)P3] concentration and PEP expression in the generated antisense cell lines.	Inositol 1,4,5-Trisphosphate	121-133	prolyl endopeptidase	Homo sapiens	153-156
12444969-5	2002	In addition, complete suppression of PEP activity by the specific inhibitor, Fmoc-Ala-Pyrr-CN (5 micro m) induced in U343 and other cell lines an enhanced, but delayed, increase in Ins(1,4,5)P3 concentration.	Alanine	81-85	prolyl endopeptidase	Homo sapiens	37-40
12444969-5	2002	In addition, complete suppression of PEP activity by the specific inhibitor, Fmoc-Ala-Pyrr-CN (5 micro m) induced in U343 and other cell lines an enhanced, but delayed, increase in Ins(1,4,5)P3 concentration.	pyrr	86-90	prolyl endopeptidase	Homo sapiens	37-40
12444969-7	2002	Furthermore, the reduced PEP activity was found to amplify Substance P-mediated stimulation of Ins(1,4,5)P3.	Inositol 1,4,5-Trisphosphate	95-107	prolyl endopeptidase	Homo sapiens	25-28
12432165-1	2002	OBJECTIVE: To examine the acute effects of Advance, a potential reduced exposure product (PREP) for smokers marketed as a means to reduce exposure to toxic gases and tobacco specific nitrosamines.	Nitrosamines	183-195	prolyl endopeptidase	Homo sapiens	90-94
12204438-2	2002	The pyruvate kinase activation by low concentration of pyrophosphate and inhibition by high concentration of pyrophosphate was considered to be the result of reversible reactions of magnesium cation with pyrophosphate, ADP, ATP, and PEP.	diphosphoric acid	55-68	prolyl endopeptidase	Homo sapiens	233-236
12204438-2	2002	The pyruvate kinase activation by low concentration of pyrophosphate and inhibition by high concentration of pyrophosphate was considered to be the result of reversible reactions of magnesium cation with pyrophosphate, ADP, ATP, and PEP.	diphosphoric acid	109-122	prolyl endopeptidase	Homo sapiens	233-236
12204438-2	2002	The pyruvate kinase activation by low concentration of pyrophosphate and inhibition by high concentration of pyrophosphate was considered to be the result of reversible reactions of magnesium cation with pyrophosphate, ADP, ATP, and PEP.	Magnesium	182-191	prolyl endopeptidase	Homo sapiens	233-236
12204438-2	2002	The pyruvate kinase activation by low concentration of pyrophosphate and inhibition by high concentration of pyrophosphate was considered to be the result of reversible reactions of magnesium cation with pyrophosphate, ADP, ATP, and PEP.	diphosphoric acid	109-122	prolyl endopeptidase	Homo sapiens	233-236
11809072-0	2002	A prolyl endopeptidase-inhibiting benzofuran dimer from Polyozellus multiflex.	benzofuran	34-44	prolyl endopeptidase	Homo sapiens	2-22
11685249-1	2001	C-terminal Src kinase (Csk) takes part in a highly specific, high affinity interaction via its Src homology 3 (SH3) domain with the proline-enriched tyrosine phosphatase PEP in hematopoietic cells.	Proline	132-139	prolyl endopeptidase	Homo sapiens	170-173
11685249-2	2001	The solution structure of the Csk-SH3 domain in complex with a 25-residue peptide from the Pro/Glu/Ser/Thr-rich (PEST) domain of PEP reveals the basis for this specific peptide recognition motif involving an SH3 domain.	Peptides	74-81	prolyl endopeptidase	Homo sapiens	129-132
11685249-2	2001	The solution structure of the Csk-SH3 domain in complex with a 25-residue peptide from the Pro/Glu/Ser/Thr-rich (PEST) domain of PEP reveals the basis for this specific peptide recognition motif involving an SH3 domain.	Proline	91-94	prolyl endopeptidase	Homo sapiens	129-132
11685249-2	2001	The solution structure of the Csk-SH3 domain in complex with a 25-residue peptide from the Pro/Glu/Ser/Thr-rich (PEST) domain of PEP reveals the basis for this specific peptide recognition motif involving an SH3 domain.	Glutamic Acid	95-98	prolyl endopeptidase	Homo sapiens	129-132
11685249-2	2001	The solution structure of the Csk-SH3 domain in complex with a 25-residue peptide from the Pro/Glu/Ser/Thr-rich (PEST) domain of PEP reveals the basis for this specific peptide recognition motif involving an SH3 domain.	Serine	99-102	prolyl endopeptidase	Homo sapiens	129-132
11685249-2	2001	The solution structure of the Csk-SH3 domain in complex with a 25-residue peptide from the Pro/Glu/Ser/Thr-rich (PEST) domain of PEP reveals the basis for this specific peptide recognition motif involving an SH3 domain.	Threonine	103-106	prolyl endopeptidase	Homo sapiens	129-132
11685249-3	2001	Three residues, Ala 40, Thr 42 and Lys 43, in the SH3 domain of Csk specifically recognize two hydrophobic residues, Ile 625 and Val 626, in the proline-rich sequence of the PEST domain of PEP.	Alanine	16-19	prolyl endopeptidase	Homo sapiens	189-192
11685249-3	2001	Three residues, Ala 40, Thr 42 and Lys 43, in the SH3 domain of Csk specifically recognize two hydrophobic residues, Ile 625 and Val 626, in the proline-rich sequence of the PEST domain of PEP.	Threonine	0-3	prolyl endopeptidase	Homo sapiens	189-192
11685249-3	2001	Three residues, Ala 40, Thr 42 and Lys 43, in the SH3 domain of Csk specifically recognize two hydrophobic residues, Ile 625 and Val 626, in the proline-rich sequence of the PEST domain of PEP.	Lysine	35-38	prolyl endopeptidase	Homo sapiens	189-192
11685249-3	2001	Three residues, Ala 40, Thr 42 and Lys 43, in the SH3 domain of Csk specifically recognize two hydrophobic residues, Ile 625 and Val 626, in the proline-rich sequence of the PEST domain of PEP.	Isoleucine	117-120	prolyl endopeptidase	Homo sapiens	189-192
11685249-3	2001	Three residues, Ala 40, Thr 42 and Lys 43, in the SH3 domain of Csk specifically recognize two hydrophobic residues, Ile 625 and Val 626, in the proline-rich sequence of the PEST domain of PEP.	Valine	129-132	prolyl endopeptidase	Homo sapiens	189-192
11685249-3	2001	Three residues, Ala 40, Thr 42 and Lys 43, in the SH3 domain of Csk specifically recognize two hydrophobic residues, Ile 625 and Val 626, in the proline-rich sequence of the PEST domain of PEP.	Proline	145-152	prolyl endopeptidase	Homo sapiens	189-192
11685249-4	2001	These two residues are C-terminal to the conventional proline-rich SH3 domain recognition sequence of PEP.	Proline	54-61	prolyl endopeptidase	Homo sapiens	102-105
11534759-1	2001	Three prolyl endopeptidase (PEP) inhibitors were isolated from the methanolic extract of green tea leaves.	methanolic	67-77	prolyl endopeptidase	Homo sapiens	6-26
11534759-1	2001	Three prolyl endopeptidase (PEP) inhibitors were isolated from the methanolic extract of green tea leaves.	methanolic	67-77	prolyl endopeptidase	Homo sapiens	28-31
12941425-3	2003	More distant members include prolyl oligopeptidase (POP; post proline cleaving enzyme) and acylaminoacylpeptidase (AAP; acylpeptide hydrolase).	Proline	62-69	prolyl endopeptidase	Homo sapiens	29-50
12941425-3	2003	More distant members include prolyl oligopeptidase (POP; post proline cleaving enzyme) and acylaminoacylpeptidase (AAP; acylpeptide hydrolase).	Proline	62-69	prolyl endopeptidase	Homo sapiens	52-55
12943000-11	2003	All three mood stabilizers suppress inositol signaling, results further supported by studies on the enzyme prolyl oligopeptidase (PO) and the sodium myo-inositol transporter (SMIT).	Inositol	36-44	prolyl endopeptidase	Homo sapiens	107-128
12943000-11	2003	All three mood stabilizers suppress inositol signaling, results further supported by studies on the enzyme prolyl oligopeptidase (PO) and the sodium myo-inositol transporter (SMIT).	Inositol	36-44	prolyl endopeptidase	Homo sapiens	130-132
12388810-6	2002	P(rep) repression is mediated by binding of the Rep protein to the two inner hexamers, H1 and H2, located in the origin of PCV1, whereas binding of Rep to hexamers H3 and H4 was not necessary.	N,N-DIETHYLBENZAMIDE	48-51	prolyl endopeptidase	Homo sapiens	0-6
12015604-8	2002	Moreover, the development of Dictyostelium is sensitive to lithium and to valproic acid, but resistance to both is conferred by deletion of the gene that codes for prolyl oligopeptidase, which also regulates inositol metabolism.	Inositol	208-216	prolyl endopeptidase	Homo sapiens	164-185
12070525-3	2002	Therefore, based on the activity in rodents, S 17092 (2S,3aS,7aS)-1][(R,R)-2-phenylcyclopropyl]carbonyl]-2-[(thiazolidin-3-yl)carbonyl]octahydro-1H-indole) has been selected as a potent inhibitor of cerebral prolyl-endopeptidase (PEP).	[(r,r)-2-phenylcyclopropyl]carbonyl]-2-[(thiazolidin-3-yl)carbonyl]octahydro-1h-indole	68-154	prolyl endopeptidase	Homo sapiens	208-228
12070525-3	2002	Therefore, based on the activity in rodents, S 17092 (2S,3aS,7aS)-1][(R,R)-2-phenylcyclopropyl]carbonyl]-2-[(thiazolidin-3-yl)carbonyl]octahydro-1H-indole) has been selected as a potent inhibitor of cerebral prolyl-endopeptidase (PEP).	[(r,r)-2-phenylcyclopropyl]carbonyl]-2-[(thiazolidin-3-yl)carbonyl]octahydro-1h-indole	68-154	prolyl endopeptidase	Homo sapiens	230-233
12043868-0	2002	Evaluation of Glyde File Prep in combination with sodium hypochlorite as a root canal irrigant.	Glipizide	14-19	prolyl endopeptidase	Homo sapiens	25-29
12043868-2	2002	A modified technique for the use of Glyde File Prep is proposed.	Glipizide	36-41	prolyl endopeptidase	Homo sapiens	47-51
11771583-2	2001	The objective of this study was to evaluate the effect of 5% NaOCl and RC-Prep treatment on the bond strength of a resin cement, C&B Metabond.	c&amp	129-134	prolyl endopeptidase	Homo sapiens	74-78
11771583-6	2001	The results demonstrated that both 5% NaOCl and RC-Prep produced significantly (p < 0.05) large reductions in resin-dentin bond strengths, and the reductions could be completely reversed by the application of either 10% ascorbic acid or 10% sodium ascorbate.	Ascorbic Acid	223-236	prolyl endopeptidase	Homo sapiens	51-55
11771583-6	2001	The results demonstrated that both 5% NaOCl and RC-Prep produced significantly (p < 0.05) large reductions in resin-dentin bond strengths, and the reductions could be completely reversed by the application of either 10% ascorbic acid or 10% sodium ascorbate.	Ascorbic Acid	244-260	prolyl endopeptidase	Homo sapiens	51-55
11605121-4	2001	Using an oscillating PEP-system in the expiratory outlet of a nebulizer does not only increase the bronchodilatory effect of ipratropiumbromide but also shortens by combining inhalation and physiotherapy the time necessary for therapy in those patients.	Ipratropium	125-143	prolyl endopeptidase	Homo sapiens	21-24
11437605-2	2001	The enzyme readily cleaves the prolyl oligopeptidase (PO) substrate Z-Gly-Pro-MCA, liberating the fluorophore MCA, thus allowing quantification of enzyme activity.	N-carbobenzoxyglycyl-prolyl-4-methylcoumarinyl amide	68-81	prolyl endopeptidase	Homo sapiens	54-56
11437605-3	2001	Unlike PO, however, this peptidase is completely insensitive to the PO-specific inhibitor Z-Pro-prolinal and has been designated Z-Pro-prolinal-insensitive Z-Gly-Pro-MCA-hydrolyzing peptidase (ZIP).	N-benzyloxycarbonylprolylprolinal	90-104	prolyl endopeptidase	Homo sapiens	7-9
11437605-3	2001	Unlike PO, however, this peptidase is completely insensitive to the PO-specific inhibitor Z-Pro-prolinal and has been designated Z-Pro-prolinal-insensitive Z-Gly-Pro-MCA-hydrolyzing peptidase (ZIP).	N-benzyloxycarbonylprolylprolinal	129-143	prolyl endopeptidase	Homo sapiens	7-9
11543693-8	2001	Lowered serum activity of prolyl endopeptidase (PEP), a cytosolic endopeptidase that cleaves peptide bonds on the carboxyl side of proline in proteins of relatively small molecular mass, may play a role in the biophysiology of fibromyalgia through diminished inactivation of algesic and depression-related peptides, e.g. substance P.	Proline	131-138	prolyl endopeptidase	Homo sapiens	26-46
11404383-6	2001	Degradation was completely inhibited by proline-specific serine protease (prolyl endopeptidase) inhibitors but not by proteasome, calpain, and metalloprotease inhibitors.	Proline	40-47	prolyl endopeptidase	Homo sapiens	74-94
11543693-8	2001	Lowered serum activity of prolyl endopeptidase (PEP), a cytosolic endopeptidase that cleaves peptide bonds on the carboxyl side of proline in proteins of relatively small molecular mass, may play a role in the biophysiology of fibromyalgia through diminished inactivation of algesic and depression-related peptides, e.g. substance P.	Proline	131-138	prolyl endopeptidase	Homo sapiens	48-51
10522802-1	1999	OBJECTIVE AND DESIGN: The role of a tetrapeptide derivative PEP 1261 {Boc-Lys(Boc)-Arg-Asp-Ser(tBu)-OtBu}, corresponding to residues 39-42 of human lactoferrin, has been tested in vitro in the modulation of neutrophil function.	BOC-LYS(BOC)-OH	70-82	prolyl endopeptidase	Homo sapiens	60-63
11004527-1	2000	Aminopeptidase P (APP), dipeptidyl peptidase II (DP II), dipeptidyl peptidase IV (DP IV) and prolyl oligopeptidase (POP) are proline specific peptidases.	Proline	125-132	prolyl endopeptidase	Homo sapiens	93-114
11004527-1	2000	Aminopeptidase P (APP), dipeptidyl peptidase II (DP II), dipeptidyl peptidase IV (DP IV) and prolyl oligopeptidase (POP) are proline specific peptidases.	Proline	125-132	prolyl endopeptidase	Homo sapiens	116-119
11004527-3	2000	Amino acid pyrrolidides (Pyrr) and thiazolidides (Thia) are well-known product analogue inhibitors of DP IV and POP.	amino acid pyrrolidides	0-23	prolyl endopeptidase	Homo sapiens	112-115
10747969-4	2000	This assumption was tested with the Cys-255 --> Thr, Cys-255 --> Ala, and Cys-255 --> Ser variants of prolyl oligopeptidase.	Cysteine	36-39	prolyl endopeptidase	Homo sapiens	111-132
10747969-4	2000	This assumption was tested with the Cys-255 --> Thr, Cys-255 --> Ala, and Cys-255 --> Ser variants of prolyl oligopeptidase.	Serine	95-98	prolyl endopeptidase	Homo sapiens	111-132
10919078-1	2000	Selective prolyl endopeptidase inhibitors were elaborated by modification of the structure of SUAM-1221, by using a CoMFA study and protein crystallography.	N-(N-(phenyl)butyryl-L-prolyl)pyrrolidine	94-103	prolyl endopeptidase	Homo sapiens	10-30
10615015-6	1999	Other enzymes present in urine as the serine endopeptidase H1, prolyl endopeptidase and neutral endopeptidase-like were not able to hydrolyze the related substrate Abz-FRQ-EDDnp.	abz-frq-eddnp	164-177	prolyl endopeptidase	Homo sapiens	38-83
11070331-1	2001	The aim of this study was to examine whether anorexia and bulimia nervosa are accompanied by lower serum activity of prolyl endopeptidase (PEP;EC 3.4.21.26; post-proline cleaving enzyme), a cytosolic endopeptidase which cleaves peptide bonds on the carboxyl side of proline in proteins of relatively small molecular mass.	Proline	162-169	prolyl endopeptidase	Homo sapiens	117-137
11070331-1	2001	The aim of this study was to examine whether anorexia and bulimia nervosa are accompanied by lower serum activity of prolyl endopeptidase (PEP;EC 3.4.21.26; post-proline cleaving enzyme), a cytosolic endopeptidase which cleaves peptide bonds on the carboxyl side of proline in proteins of relatively small molecular mass.	Proline	266-273	prolyl endopeptidase	Homo sapiens	117-137
11137456-1	2000	A prolyl endopeptidase (PE) was purified 83 times from human urine by DEAE-cellulose and Sepharose Mercurial chromatographies.	DEAE-Cellulose	70-84	prolyl endopeptidase	Homo sapiens	2-22
11137456-1	2000	A prolyl endopeptidase (PE) was purified 83 times from human urine by DEAE-cellulose and Sepharose Mercurial chromatographies.	DEAE-Cellulose	70-84	prolyl endopeptidase	Homo sapiens	24-26
11137456-1	2000	A prolyl endopeptidase (PE) was purified 83 times from human urine by DEAE-cellulose and Sepharose Mercurial chromatographies.	Sepharose	89-98	prolyl endopeptidase	Homo sapiens	2-22
11137456-1	2000	A prolyl endopeptidase (PE) was purified 83 times from human urine by DEAE-cellulose and Sepharose Mercurial chromatographies.	Sepharose	89-98	prolyl endopeptidase	Homo sapiens	24-26
11137456-3	2000	Further characterization of the enzyme was carried out using BK and it"s analogue, Abz-RPPGFSPFRQ-EDDnp and Abz-FPQ-EDDnp, for measure of enzymatic activity of prolyl endopeptidase (Abz=ortho-aminobenzoic acid; EDDnp=N-[2, 4-dinitrophenyl]ethylenediamine).	abz-rppgfspfrq-eddnp	83-103	prolyl endopeptidase	Homo sapiens	160-180
11137456-3	2000	Further characterization of the enzyme was carried out using BK and it"s analogue, Abz-RPPGFSPFRQ-EDDnp and Abz-FPQ-EDDnp, for measure of enzymatic activity of prolyl endopeptidase (Abz=ortho-aminobenzoic acid; EDDnp=N-[2, 4-dinitrophenyl]ethylenediamine).	abz-fpq-eddnp	108-121	prolyl endopeptidase	Homo sapiens	160-180
11137456-3	2000	Further characterization of the enzyme was carried out using BK and it"s analogue, Abz-RPPGFSPFRQ-EDDnp and Abz-FPQ-EDDnp, for measure of enzymatic activity of prolyl endopeptidase (Abz=ortho-aminobenzoic acid; EDDnp=N-[2, 4-dinitrophenyl]ethylenediamine).	ortho-Aminobenzoates	186-209	prolyl endopeptidase	Homo sapiens	160-180
11137456-3	2000	Further characterization of the enzyme was carried out using BK and it"s analogue, Abz-RPPGFSPFRQ-EDDnp and Abz-FPQ-EDDnp, for measure of enzymatic activity of prolyl endopeptidase (Abz=ortho-aminobenzoic acid; EDDnp=N-[2, 4-dinitrophenyl]ethylenediamine).	N-(2,4-dinitrophenyl)ethylenediamine	217-254	prolyl endopeptidase	Homo sapiens	160-180
11137456-4	2000	The substrate Abz-FPQ-EDDnp was considered as specific for PE.	abz-fpq-eddnp	14-27	prolyl endopeptidase	Homo sapiens	59-61
11137456-5	2000	The endopeptidase PE, with a molecular weight of 45 kDa, was inhibited 100% by EDTA and pOHMB and resistant to PMSF, thyorphan, E64 and phosphoramidon, when we used the mentioned substrates.	Edetic Acid	79-83	prolyl endopeptidase	Homo sapiens	18-20
11137456-5	2000	The endopeptidase PE, with a molecular weight of 45 kDa, was inhibited 100% by EDTA and pOHMB and resistant to PMSF, thyorphan, E64 and phosphoramidon, when we used the mentioned substrates.	pohmb	88-93	prolyl endopeptidase	Homo sapiens	18-20
11137456-5	2000	The endopeptidase PE, with a molecular weight of 45 kDa, was inhibited 100% by EDTA and pOHMB and resistant to PMSF, thyorphan, E64 and phosphoramidon, when we used the mentioned substrates.	Phenylmethylsulfonyl Fluoride	111-115	prolyl endopeptidase	Homo sapiens	18-20
11137456-5	2000	The endopeptidase PE, with a molecular weight of 45 kDa, was inhibited 100% by EDTA and pOHMB and resistant to PMSF, thyorphan, E64 and phosphoramidon, when we used the mentioned substrates.	thyorphan	117-126	prolyl endopeptidase	Homo sapiens	18-20
11137456-5	2000	The endopeptidase PE, with a molecular weight of 45 kDa, was inhibited 100% by EDTA and pOHMB and resistant to PMSF, thyorphan, E64 and phosphoramidon, when we used the mentioned substrates.	phosphoramidon	136-150	prolyl endopeptidase	Homo sapiens	18-20
11137456-6	2000	These results suggest that PE is a metallo endopeptidase that contains a thiol group important for it"s activity.	Sulfhydryl Compounds	73-78	prolyl endopeptidase	Homo sapiens	27-29
11137456-8	2000	In the substrate Abz-FPQ-EDDnp PE hydrolyzes the P-Q peptide bound.	abz-fpq-eddnp	17-30	prolyl endopeptidase	Homo sapiens	31-33
11137456-11	2000	The optimum pH for the PE activity, using the substrate Abz-RPPGFSPFRQ-EDDnp was approximately 9.0, but using the specific substrate Abz-FPQ-EDDnp was 6.5 and 8.0.	abz-rppgfspfrq-eddnp	56-76	prolyl endopeptidase	Homo sapiens	23-25
11137456-11	2000	The optimum pH for the PE activity, using the substrate Abz-RPPGFSPFRQ-EDDnp was approximately 9.0, but using the specific substrate Abz-FPQ-EDDnp was 6.5 and 8.0.	abz-fpq-eddnp	133-146	prolyl endopeptidase	Homo sapiens	23-25
11004527-3	2000	Amino acid pyrrolidides (Pyrr) and thiazolidides (Thia) are well-known product analogue inhibitors of DP IV and POP.	pyrr	25-29	prolyl endopeptidase	Homo sapiens	112-115
11004527-3	2000	Amino acid pyrrolidides (Pyrr) and thiazolidides (Thia) are well-known product analogue inhibitors of DP IV and POP.	thiazolidides	35-48	prolyl endopeptidase	Homo sapiens	112-115
11004527-3	2000	Amino acid pyrrolidides (Pyrr) and thiazolidides (Thia) are well-known product analogue inhibitors of DP IV and POP.	thia	50-54	prolyl endopeptidase	Homo sapiens	112-115
10522802-1	1999	OBJECTIVE AND DESIGN: The role of a tetrapeptide derivative PEP 1261 {Boc-Lys(Boc)-Arg-Asp-Ser(tBu)-OtBu}, corresponding to residues 39-42 of human lactoferrin, has been tested in vitro in the modulation of neutrophil function.	Arginine	83-86	prolyl endopeptidase	Homo sapiens	60-63
10522802-1	1999	OBJECTIVE AND DESIGN: The role of a tetrapeptide derivative PEP 1261 {Boc-Lys(Boc)-Arg-Asp-Ser(tBu)-OtBu}, corresponding to residues 39-42 of human lactoferrin, has been tested in vitro in the modulation of neutrophil function.	Aspartic Acid	87-90	prolyl endopeptidase	Homo sapiens	60-63
10522802-1	1999	OBJECTIVE AND DESIGN: The role of a tetrapeptide derivative PEP 1261 {Boc-Lys(Boc)-Arg-Asp-Ser(tBu)-OtBu}, corresponding to residues 39-42 of human lactoferrin, has been tested in vitro in the modulation of neutrophil function.	Serine	91-94	prolyl endopeptidase	Homo sapiens	60-63
10522802-1	1999	OBJECTIVE AND DESIGN: The role of a tetrapeptide derivative PEP 1261 {Boc-Lys(Boc)-Arg-Asp-Ser(tBu)-OtBu}, corresponding to residues 39-42 of human lactoferrin, has been tested in vitro in the modulation of neutrophil function.	tert-Butyl Alcohol	95-98	prolyl endopeptidase	Homo sapiens	60-63
10522802-1	1999	OBJECTIVE AND DESIGN: The role of a tetrapeptide derivative PEP 1261 {Boc-Lys(Boc)-Arg-Asp-Ser(tBu)-OtBu}, corresponding to residues 39-42 of human lactoferrin, has been tested in vitro in the modulation of neutrophil function.	Fmoc-beta-HoSer(tBu)-OH	100-104	prolyl endopeptidase	Homo sapiens	60-63
10522802-5	1999	RESULTS: Addition of PEP 1261 effectively blocked the H2O2 and O2*- release, decreased the levels of MPO levels (p< 0.01) and lysosomal enzymes (p < 0.05) as compared to PMA stimulated human neutrophils.	Hydrogen Peroxide	54-58	prolyl endopeptidase	Homo sapiens	21-24
10522802-5	1999	RESULTS: Addition of PEP 1261 effectively blocked the H2O2 and O2*- release, decreased the levels of MPO levels (p< 0.01) and lysosomal enzymes (p < 0.05) as compared to PMA stimulated human neutrophils.	Oxygen	56-58	prolyl endopeptidase	Homo sapiens	21-24
10522802-6	1999	PEP 1261 was also observed to inhibit the levels of H2O2, O2*-, MPO and lysosomal enzymes (p < 0.05) as compared to PMA stimulated control rat neutrophils and neutrophils from arthritic rats.	Hydrogen Peroxide	52-56	prolyl endopeptidase	Homo sapiens	0-3
10522802-6	1999	PEP 1261 was also observed to inhibit the levels of H2O2, O2*-, MPO and lysosomal enzymes (p < 0.05) as compared to PMA stimulated control rat neutrophils and neutrophils from arthritic rats.	Tetradecanoylphorbol Acetate	119-122	prolyl endopeptidase	Homo sapiens	0-3
10234593-0	1999	Pharmacokinetics and safety of Z-321, a novel specific orally active prolyl endopeptidase inhibitor, in healthy male volunteers.	1-(3-(2-indanylacetyl)-L-thioprolyl)pyrrolidine	31-36	prolyl endopeptidase	Homo sapiens	69-89
10329620-0	1999	Loss of a prolyl oligopeptidase confers resistance to lithium by elevation of inositol (1,4,5) trisphosphate.	Lithium	54-61	prolyl endopeptidase	Homo sapiens	10-31
10329620-0	1999	Loss of a prolyl oligopeptidase confers resistance to lithium by elevation of inositol (1,4,5) trisphosphate.	Inositol 1,4,5-Trisphosphate	78-108	prolyl endopeptidase	Homo sapiens	10-31
10329620-7	1999	The same increase in IP3 is induced in wild-type cells by a prolyl oligopeptidase (POase) inhibitor.	Inositol 1,4,5-Trisphosphate	21-24	prolyl endopeptidase	Homo sapiens	60-81
10329620-7	1999	The same increase in IP3 is induced in wild-type cells by a prolyl oligopeptidase (POase) inhibitor.	Inositol 1,4,5-Trisphosphate	21-24	prolyl endopeptidase	Homo sapiens	83-88
10329620-11	1999	Our results offer a novel mechanism that links POase activity to IP3 signalling and provides further clues for the action of Li+ in the treatment of depression.	Inositol 1,4,5-Trisphosphate	65-68	prolyl endopeptidase	Homo sapiens	47-52
10234593-1	1999	This study investigates the pharmacokinetics and safety profile of Z-321, (4R)-3-(indan-2-ylacetyl)-4-(1-pyrrolidinyl-carbonyl)-1,3-thiazoli dine, a novel specific orally active prolyl endopeptidase (PEP) inhibitor.	1-(3-(2-indanylacetyl)-L-thioprolyl)pyrrolidine	67-72	prolyl endopeptidase	Homo sapiens	178-198
10234593-1	1999	This study investigates the pharmacokinetics and safety profile of Z-321, (4R)-3-(indan-2-ylacetyl)-4-(1-pyrrolidinyl-carbonyl)-1,3-thiazoli dine, a novel specific orally active prolyl endopeptidase (PEP) inhibitor.	1-(3-(2-indanylacetyl)-L-thioprolyl)pyrrolidine	67-72	prolyl endopeptidase	Homo sapiens	200-203
10234593-1	1999	This study investigates the pharmacokinetics and safety profile of Z-321, (4R)-3-(indan-2-ylacetyl)-4-(1-pyrrolidinyl-carbonyl)-1,3-thiazoli dine, a novel specific orally active prolyl endopeptidase (PEP) inhibitor.	(4r)-3-(indan-2-ylacetyl)-4-(1-pyrrolidinyl-carbonyl)-1,3-thiazoli dine	74-145	prolyl endopeptidase	Homo sapiens	200-203
10363664-1	1999	BACKGROUND: It is reported that psychiatric disorders, such as depression and schizophrenia, are associated with changes in serum activity of prolyl endopeptidase (EC 3.4.21.26), a cytosolic endopeptidase, which cleaves peptide bonds on the carboxylside of proline in proteins of relatively small molecular mass.	carboxylside	241-253	prolyl endopeptidase	Homo sapiens	142-162
10363664-1	1999	BACKGROUND: It is reported that psychiatric disorders, such as depression and schizophrenia, are associated with changes in serum activity of prolyl endopeptidase (EC 3.4.21.26), a cytosolic endopeptidase, which cleaves peptide bonds on the carboxylside of proline in proteins of relatively small molecular mass.	Proline	257-264	prolyl endopeptidase	Homo sapiens	142-162
9723150-1	1998	BACKGROUND: The aims of the present study were to examine serum activities of peptidases, i.e. prolyl endopeptidase (PEP) and dipeptidyl peptidase IV (DPP IV), in patients with fibromyalgia and to examine the effects of subchronic treatment with sertraline on these variables.	Sertraline	246-256	prolyl endopeptidase	Homo sapiens	117-120
9895030-2	1999	Alcohol-dependent patients had significantly lower serum PEP and DPP IV activity than normal controls.	Alcohols	0-7	prolyl endopeptidase	Homo sapiens	57-60
9895030-3	1999	We found that 58.3% and 50.0% of the alcohol-dependent patients, respectively, had PEP and DPP IV activities, which were lower than the mean control values minus 2 SD.	Alcohols	37-44	prolyl endopeptidase	Homo sapiens	83-86
9839007-1	1998	The S1"-S3" subsite specificity of prolyl endopeptidase from Flavobacterium meningoseptum was studied by acyl transfer to libraries of amino acid amides and peptides.	amino acid amides	135-152	prolyl endopeptidase	Homo sapiens	35-55
9587343-13	1998	Half-dose Klean Prep is an acceptable preparation to patients.	klean	10-15	prolyl endopeptidase	Homo sapiens	16-20
9741927-4	1998	The metabolic cleavage of thyrotropin-releasing hormone (TRH) to the free acid by cytosolic prolyl-endopeptidase was also detected in human nasal cell monolayers, suggesting that ca.	streptolydigin	69-78	prolyl endopeptidase	Homo sapiens	92-112
9254594-1	1997	Pepleomycin (PEP)1 is a metalloglycopeptide antitumor antibiotic that has improved pharmacological properties than does bleomycin (BLM).	Peplomycin	0-11	prolyl endopeptidase	Homo sapiens	13-16
9597757-1	1998	Prolyl endopeptidase (PE) belongs to a group of enzymes that specifically recognise the imino acid proline.	imino acid proline	88-106	prolyl endopeptidase	Homo sapiens	0-20
9597757-1	1998	Prolyl endopeptidase (PE) belongs to a group of enzymes that specifically recognise the imino acid proline.	imino acid proline	88-106	prolyl endopeptidase	Homo sapiens	22-24
9597757-6	1998	PE was optimally active at pH 8.0-8.5, demonstrated a preference for phosphate buffer and remained stable over a pH range of 5.0-9.0.	Phosphates	69-78	prolyl endopeptidase	Homo sapiens	0-2
9597757-11	1998	Specific inhibitor studies, using a range of compounds previously untested against a single PE source, indicated that alpha-ketobenzothiazole was the most effective PE inhibitor, with an IC50 value of 41 pM.	alpha-ketobenzothiazole	118-141	prolyl endopeptidase	Homo sapiens	92-94
9597757-11	1998	Specific inhibitor studies, using a range of compounds previously untested against a single PE source, indicated that alpha-ketobenzothiazole was the most effective PE inhibitor, with an IC50 value of 41 pM.	alpha-ketobenzothiazole	118-141	prolyl endopeptidase	Homo sapiens	165-167
9432007-0	1997	Development and evaluation of peptide-based prolyl oligopeptidase inhibitors--introduction of N-benzyloxycarbonyl-prolyl-3-fluoropyrrolidine as a lead in inhibitor design.	N-benzyloxycarbonyl-prolyl-3-fluoropyrrolidine	94-140	prolyl endopeptidase	Homo sapiens	44-65
9362123-1	1997	Four prolyl endopeptidase inhibitors isolated from actinomycetes, named propeptin, SNA-8073-B, staurosporine, and enduracidin were classified into 3 groups on the basis of their inhibition potency against prolyl endopeptidase from a bacterium (Flavobacterium) and a mammal (human placenta).	propeptin	72-81	prolyl endopeptidase	Homo sapiens	5-25
9362123-1	1997	Four prolyl endopeptidase inhibitors isolated from actinomycetes, named propeptin, SNA-8073-B, staurosporine, and enduracidin were classified into 3 groups on the basis of their inhibition potency against prolyl endopeptidase from a bacterium (Flavobacterium) and a mammal (human placenta).	fujianmycin B	83-93	prolyl endopeptidase	Homo sapiens	5-25
9355038-5	1997	However, a statistically significant decline in PEP activity (18%, P = 0.02) was observed in the ME of OVX ewes in which a surge was induced by estrogen when compared to oil-treated OVX controls, suggesting a possible negative regulation of PEP activity by this steroid.	Oils	170-173	prolyl endopeptidase	Homo sapiens	48-51
9355038-5	1997	However, a statistically significant decline in PEP activity (18%, P = 0.02) was observed in the ME of OVX ewes in which a surge was induced by estrogen when compared to oil-treated OVX controls, suggesting a possible negative regulation of PEP activity by this steroid.	Steroids	262-269	prolyl endopeptidase	Homo sapiens	48-51
9254594-1	1997	Pepleomycin (PEP)1 is a metalloglycopeptide antitumor antibiotic that has improved pharmacological properties than does bleomycin (BLM).	Bleomycin	120-129	prolyl endopeptidase	Homo sapiens	13-16
9254594-1	1997	Pepleomycin (PEP)1 is a metalloglycopeptide antitumor antibiotic that has improved pharmacological properties than does bleomycin (BLM).	Bleomycin	131-134	prolyl endopeptidase	Homo sapiens	13-16
9205821-0	1997	Pharmacokinetics and safety of JTP-4819, a novel specific orally active prolyl endopeptidase inhibitor, in healthy male volunteers.	JTP 4819	31-39	prolyl endopeptidase	Homo sapiens	72-92
9205821-1	1997	AIMS: To investigate the pharmacokinetics and safety profile of JTP-4819, (-)-(2S)-1-benzylaminocarbonyl-[(2S)-2-glycoloylpyrrolidinyl ]-2-pyrrolidinecarboxamide, a novel specific orally active prolyl endopeptidase (PEP) inhibitor.	JTP 4819	64-72	prolyl endopeptidase	Homo sapiens	216-219
9205821-1	1997	AIMS: To investigate the pharmacokinetics and safety profile of JTP-4819, (-)-(2S)-1-benzylaminocarbonyl-[(2S)-2-glycoloylpyrrolidinyl ]-2-pyrrolidinecarboxamide, a novel specific orally active prolyl endopeptidase (PEP) inhibitor.	JTP 4819	64-72	prolyl endopeptidase	Homo sapiens	194-214
9148758-0	1997	Benzyloxycarbonylprolylprolinal, a transition-state analogue for prolyl oligopeptidase, forms a tetrahedral adduct with catalytic serine, not a reactive cysteine.	Serine	130-136	prolyl endopeptidase	Homo sapiens	65-86
9205821-1	1997	AIMS: To investigate the pharmacokinetics and safety profile of JTP-4819, (-)-(2S)-1-benzylaminocarbonyl-[(2S)-2-glycoloylpyrrolidinyl ]-2-pyrrolidinecarboxamide, a novel specific orally active prolyl endopeptidase (PEP) inhibitor.	(-)-(2s)-1-benzylaminocarbonyl-[(2s)-2-glycoloylpyrrolidinyl ]-2-pyrrolidinecarboxamide	74-161	prolyl endopeptidase	Homo sapiens	194-214
9205821-1	1997	AIMS: To investigate the pharmacokinetics and safety profile of JTP-4819, (-)-(2S)-1-benzylaminocarbonyl-[(2S)-2-glycoloylpyrrolidinyl ]-2-pyrrolidinecarboxamide, a novel specific orally active prolyl endopeptidase (PEP) inhibitor.	(-)-(2s)-1-benzylaminocarbonyl-[(2s)-2-glycoloylpyrrolidinyl ]-2-pyrrolidinecarboxamide	74-161	prolyl endopeptidase	Homo sapiens	216-219
9148758-2	1997	While the 13C NMR chemical shift of the aldehyde carbon is 202 p.p.m., that of the aldehyde hydrate is between 91.6 and 91.8 p.p.m., that of the dithiothreitol adduct is between 74.8 and 75.0 p. p.m., and that in the presence of the serine protease prolyl oligopeptidase is at 92.3 p.p.m..	Dithiothreitol	145-159	prolyl endopeptidase	Homo sapiens	249-270
9148758-7	1997	It is concluded that Z-Pro-prolinal, a putative transition-state analogue for prolyl oligopeptidase, forms a tetrahedral complex with the enzyme at its catalytic serine, rather than at a neighbouring cysteine that was found to be highly reactive according to chemical modification studies.	N-benzyloxycarbonylprolylprolinal	21-35	prolyl endopeptidase	Homo sapiens	78-99
9148758-7	1997	It is concluded that Z-Pro-prolinal, a putative transition-state analogue for prolyl oligopeptidase, forms a tetrahedral complex with the enzyme at its catalytic serine, rather than at a neighbouring cysteine that was found to be highly reactive according to chemical modification studies.	Serine	162-168	prolyl endopeptidase	Homo sapiens	78-99
9148758-7	1997	It is concluded that Z-Pro-prolinal, a putative transition-state analogue for prolyl oligopeptidase, forms a tetrahedral complex with the enzyme at its catalytic serine, rather than at a neighbouring cysteine that was found to be highly reactive according to chemical modification studies.	Cysteine	200-208	prolyl endopeptidase	Homo sapiens	78-99
9054083-3	1997	Colonoscopy was performed in 104 patients over a two month period, 56 patients being allocated to the conventional preparation and 48 to Klean-Prep.	klean	137-142	prolyl endopeptidase	Homo sapiens	143-147
9128099-5	1997	The S2 binding subsite of POP can accommodate amino acid residues with a bulky side group, while it prefers a positively charged group (free Lys) instead of a negatively charged one (free Glu).	Lysine	141-144	prolyl endopeptidase	Homo sapiens	26-29
9128099-1	1997	The secondary specificity of prolyl oligopeptidase (POP) has been studied by using a series of fluorogenic substrates containing the highly fluorescent 7-amino-4-methyl-2-quinolinone (AMeq) marker.	7-amino-4-methyl-2-quinolinone	152-182	prolyl endopeptidase	Homo sapiens	29-50
9128099-5	1997	The S2 binding subsite of POP can accommodate amino acid residues with a bulky side group, while it prefers a positively charged group (free Lys) instead of a negatively charged one (free Glu).	Glutamic Acid	188-191	prolyl endopeptidase	Homo sapiens	26-29
9128099-1	1997	The secondary specificity of prolyl oligopeptidase (POP) has been studied by using a series of fluorogenic substrates containing the highly fluorescent 7-amino-4-methyl-2-quinolinone (AMeq) marker.	7-amino-4-methyl-2-quinolinone	152-182	prolyl endopeptidase	Homo sapiens	52-55
9128099-1	1997	The secondary specificity of prolyl oligopeptidase (POP) has been studied by using a series of fluorogenic substrates containing the highly fluorescent 7-amino-4-methyl-2-quinolinone (AMeq) marker.	7-amino-4-methyl-2-quinolinone	184-188	prolyl endopeptidase	Homo sapiens	29-50
8826725-0	1996	Barium enema preparation: a study of low-residue diet, "Picolax" and "Kleen-Prep".	Barium	0-6	prolyl endopeptidase	Homo sapiens	76-80
9128099-1	1997	The secondary specificity of prolyl oligopeptidase (POP) has been studied by using a series of fluorogenic substrates containing the highly fluorescent 7-amino-4-methyl-2-quinolinone (AMeq) marker.	7-amino-4-methyl-2-quinolinone	184-188	prolyl endopeptidase	Homo sapiens	52-55
8968396-0	1996	Poststatin, a new inhibitor of prolyl endopeptidase.	poststatin	0-10	prolyl endopeptidase	Homo sapiens	31-51
8968396-7	1996	These results indicate that these compounds are more selective inhibitors against prolyl endopeptidase than is natural poststatin.	poststatin	119-129	prolyl endopeptidase	Homo sapiens	82-102
8931723-0	1996	Poststatin, a new inhibitor of prolyl endopeptidase.	poststatin	0-10	prolyl endopeptidase	Homo sapiens	31-51
8931723-6	1996	Benzyloxycarbonyl-L-homophenylalanyl-(RS)- 3-amino-2-oxovaleryl-D-leucyl-L-valine was about 6 times more active to prolyl endopeptidase than natural poststatin.	benzyloxycarbonyl-l-homophenylalanyl-(rs)- 3-amino-2-oxovaleryl-d-leucyl-l-valine	0-81	prolyl endopeptidase	Homo sapiens	115-135
8931723-6	1996	Benzyloxycarbonyl-L-homophenylalanyl-(RS)- 3-amino-2-oxovaleryl-D-leucyl-L-valine was about 6 times more active to prolyl endopeptidase than natural poststatin.	poststatin	149-159	prolyl endopeptidase	Homo sapiens	115-135
8931724-0	1996	Poststatin, a new inhibitor of prolyl endopeptidase.	poststatin	0-10	prolyl endopeptidase	Homo sapiens	31-51
8931724-3	1996	Several pyrrolidine-containing analogues of poststatin were synthesized and examined for their inhibitory activity against prolyl endopeptidase and cathepsin B in vitro.	pyrrolidine	8-19	prolyl endopeptidase	Homo sapiens	123-143
8931724-3	1996	Several pyrrolidine-containing analogues of poststatin were synthesized and examined for their inhibitory activity against prolyl endopeptidase and cathepsin B in vitro.	poststatin	44-54	prolyl endopeptidase	Homo sapiens	123-143
8931724-4	1996	Replacement of the postine residue with 2-oxo-2-(2-pyrrolidinyl)acetic acid increased the selectivity and inhibitory activity against prolyl endopeptidase.	postine	19-26	prolyl endopeptidase	Homo sapiens	134-154
8931724-4	1996	Replacement of the postine residue with 2-oxo-2-(2-pyrrolidinyl)acetic acid increased the selectivity and inhibitory activity against prolyl endopeptidase.	2-oxo-2-(2-pyrrolidinyl)acetic acid	40-75	prolyl endopeptidase	Homo sapiens	134-154
8931725-0	1996	Poststatin, a new inhibitor of prolyl endopeptidase.	poststatin	0-10	prolyl endopeptidase	Homo sapiens	31-51
8931725-3	1996	Poststatin analogues containing (S)-2-oxo-2-(2-pyrrolidinyl)acetyl moiety in P1 were synthesized and examined for their inhibitory activity against prolyl endopeptidase and cathepsin B in vitro.	poststatin	0-10	prolyl endopeptidase	Homo sapiens	148-168
8931725-4	1996	Introduction of non-peptidyl cycloalkylamine component in P1, was effective and P3-acyl groups must be widely modifiable for prolyl endopeptidase inhibition.	peptidyl cycloalkylamine	20-44	prolyl endopeptidase	Homo sapiens	125-145
8931725-5	1996	Acyl-L-phenylalanyl-(S)-2-oxo-2-(2-pyrrolidinyl)acetyl-cycloalkylamid e type compounds showed IC50 value of nano to subnano g/ml as prolyl endopeptidase inhibitor and were shown no significant inhibitory activities against cathepsin B, a cysteine protease.	acyl-l-phenylalanyl-(s)-2-oxo-2-(2-pyrrolidinyl)acetyl	0-54	prolyl endopeptidase	Homo sapiens	132-152
7492323-2	1995	In contrast with these proteases, prolyl oligopeptidase is remarkably sensitive to ionic strength, being more active in the presence of high concentrations of salt.	Salts	159-163	prolyl endopeptidase	Homo sapiens	34-55
8652620-5	1996	In contrast, the reactivity of dipeptidyl peptidase IV and prolyl endopeptidase decreases more than two orders of magnitude towards the phosphorylated di- and tripeptide substrates compared to the hydrolysis of unmodified substrates.	di- and tripeptide	151-169	prolyl endopeptidase	Homo sapiens	59-79
8626245-0	1996	Poststatin, a new inhibitor of prolyl endopeptidase.	poststatin	0-10	prolyl endopeptidase	Homo sapiens	31-51
8626246-0	1996	Poststatin, a new inhibitor of prolyl endopeptidase.	poststatin	0-10	prolyl endopeptidase	Homo sapiens	31-51
7588785-11	1995	Its inability to cleave corticotropin-releasing factor, ubiquitin, albumin and aprotinin, together with the hydrolysis of bradykinin between Pro7-Arg8 confirms the affinity of prolyl oligopeptidase for small peptides.	pro7-arg8	141-150	prolyl endopeptidase	Homo sapiens	176-197
7932578-1	1994	The preparation and in vitro prolyl endopeptidase (PEP) inhibitory activity of a series of alpha-keto heterocyclic compounds is described.	alpha-keto heterocyclic compounds	91-124	prolyl endopeptidase	Homo sapiens	29-49
8570777-5	1995	In depressed subjects, plasma PEP activity was significantly increased during treatment with antidepressant drugs, such as fluoxetine.	Fluoxetine	123-133	prolyl endopeptidase	Homo sapiens	30-33
8570777-7	1995	In manic subjects, short-term treatment with valproate had a significant suppressive effect on PEP activity.	Valproic Acid	45-54	prolyl endopeptidase	Homo sapiens	95-98
7891026-3	1995	The enzyme responsible had a pH optimum of approximately 7.0, was inhibited by serine (di-isopropyl flurophosphate) and thiol (N-ethylmaleimide) protease inhibitors, bacitracin and concentrations of Zn2+ naturally present in seminal plasma: these functional reagents are all known to be potent inhibitors of prolyl endopeptidase.	Serine	79-85	prolyl endopeptidase	Homo sapiens	308-328
7891026-3	1995	The enzyme responsible had a pH optimum of approximately 7.0, was inhibited by serine (di-isopropyl flurophosphate) and thiol (N-ethylmaleimide) protease inhibitors, bacitracin and concentrations of Zn2+ naturally present in seminal plasma: these functional reagents are all known to be potent inhibitors of prolyl endopeptidase.	di-isopropyl flurophosphate	87-114	prolyl endopeptidase	Homo sapiens	308-328
7891026-3	1995	The enzyme responsible had a pH optimum of approximately 7.0, was inhibited by serine (di-isopropyl flurophosphate) and thiol (N-ethylmaleimide) protease inhibitors, bacitracin and concentrations of Zn2+ naturally present in seminal plasma: these functional reagents are all known to be potent inhibitors of prolyl endopeptidase.	Sulfhydryl Compounds	120-125	prolyl endopeptidase	Homo sapiens	308-328
7891026-3	1995	The enzyme responsible had a pH optimum of approximately 7.0, was inhibited by serine (di-isopropyl flurophosphate) and thiol (N-ethylmaleimide) protease inhibitors, bacitracin and concentrations of Zn2+ naturally present in seminal plasma: these functional reagents are all known to be potent inhibitors of prolyl endopeptidase.	Ethylmaleimide	127-143	prolyl endopeptidase	Homo sapiens	308-328
7891026-3	1995	The enzyme responsible had a pH optimum of approximately 7.0, was inhibited by serine (di-isopropyl flurophosphate) and thiol (N-ethylmaleimide) protease inhibitors, bacitracin and concentrations of Zn2+ naturally present in seminal plasma: these functional reagents are all known to be potent inhibitors of prolyl endopeptidase.	Bacitracin	166-176	prolyl endopeptidase	Homo sapiens	308-328
7891026-3	1995	The enzyme responsible had a pH optimum of approximately 7.0, was inhibited by serine (di-isopropyl flurophosphate) and thiol (N-ethylmaleimide) protease inhibitors, bacitracin and concentrations of Zn2+ naturally present in seminal plasma: these functional reagents are all known to be potent inhibitors of prolyl endopeptidase.	Zinc	199-203	prolyl endopeptidase	Homo sapiens	308-328
7891026-4	1995	The major product after incubation of [3H]TRH in seminal plasma for 100 min was acid TRH (deamidated TRH) which is also the product after incubation of TRH with prolyl endopeptidase.	Tritium	39-41	prolyl endopeptidase	Homo sapiens	161-181
7959018-1	1994	The human cDNA encoding prolyl endopeptidase, a cytoplasmic endoprotease which hydrolyses the peptide bond at the C-terminal side of proline, was sequenced.	Proline	133-140	prolyl endopeptidase	Homo sapiens	24-44
7534149-0	1994	A sensitive detection method for peptide using 4-fluoro-7-nitrobenzo-2-oxa-1,3-diazole and its application to measure prolyl endopeptidase activity.	Peptides	33-40	prolyl endopeptidase	Homo sapiens	118-138
7534149-0	1994	A sensitive detection method for peptide using 4-fluoro-7-nitrobenzo-2-oxa-1,3-diazole and its application to measure prolyl endopeptidase activity.	7-fluoro-4-nitrobenzo-2-oxa-1,3-diazole	47-86	prolyl endopeptidase	Homo sapiens	118-138
7534149-2	1994	The investigation of three different derivatization reagents, which had been developed for an amino acid analysis, demonstrated that 4-fluoro-7-nitrobenzo-2-oxa-1,3-diazole (NBDF) was the most suitable for the detection of Arg-Gly-NH2, which was released from Arg-vasopressin by PEP.	7-fluoro-4-nitrobenzo-2-oxa-1,3-diazole	133-172	prolyl endopeptidase	Homo sapiens	279-282
7534149-2	1994	The investigation of three different derivatization reagents, which had been developed for an amino acid analysis, demonstrated that 4-fluoro-7-nitrobenzo-2-oxa-1,3-diazole (NBDF) was the most suitable for the detection of Arg-Gly-NH2, which was released from Arg-vasopressin by PEP.	nbdf	174-178	prolyl endopeptidase	Homo sapiens	279-282
7932578-1	1994	The preparation and in vitro prolyl endopeptidase (PEP) inhibitory activity of a series of alpha-keto heterocyclic compounds is described.	alpha-keto heterocyclic compounds	91-124	prolyl endopeptidase	Homo sapiens	51-54
7932578-3	1994	Many of the compounds including those substituted with thiazole, benzothiazole, benzoxazole, imidazole, and pyridine groups exhibit IC50 potencies of PEP inhibition at nanomolar levels.	Thiazoles	55-63	prolyl endopeptidase	Homo sapiens	150-153
7932578-3	1994	Many of the compounds including those substituted with thiazole, benzothiazole, benzoxazole, imidazole, and pyridine groups exhibit IC50 potencies of PEP inhibition at nanomolar levels.	benzothiazole	65-78	prolyl endopeptidase	Homo sapiens	150-153
7932578-3	1994	Many of the compounds including those substituted with thiazole, benzothiazole, benzoxazole, imidazole, and pyridine groups exhibit IC50 potencies of PEP inhibition at nanomolar levels.	Benzoxazoles	80-91	prolyl endopeptidase	Homo sapiens	150-153
7932578-3	1994	Many of the compounds including those substituted with thiazole, benzothiazole, benzoxazole, imidazole, and pyridine groups exhibit IC50 potencies of PEP inhibition at nanomolar levels.	imidazole	93-102	prolyl endopeptidase	Homo sapiens	150-153
7932578-3	1994	Many of the compounds including those substituted with thiazole, benzothiazole, benzoxazole, imidazole, and pyridine groups exhibit IC50 potencies of PEP inhibition at nanomolar levels.	pyridine	108-116	prolyl endopeptidase	Homo sapiens	150-153
7932578-5	1994	This heterocyclic nitrogen atom would provide a critical hydrogen-bond interaction with the histidine residue of the catalytic triad in PEP.	Nitrogen	18-26	prolyl endopeptidase	Homo sapiens	136-139
7932578-5	1994	This heterocyclic nitrogen atom would provide a critical hydrogen-bond interaction with the histidine residue of the catalytic triad in PEP.	Hydrogen	57-65	prolyl endopeptidase	Homo sapiens	136-139
7932578-5	1994	This heterocyclic nitrogen atom would provide a critical hydrogen-bond interaction with the histidine residue of the catalytic triad in PEP.	Histidine	92-101	prolyl endopeptidase	Homo sapiens	136-139
7517035-5	1994	These data demonstrate that the primary enzyme in human lumbar CSF that acts on synthetic SP is a post-proline cleaving enzyme (PPCE).	TFF2 protein, human	90-92	prolyl endopeptidase	Homo sapiens	98-126
8089089-5	1994	This fused protein exhibited PEP activity, which was inhibited by Z-Pro-prolinal, a specific inhibitor of PEP.	N-benzyloxycarbonylprolylprolinal	66-80	prolyl endopeptidase	Homo sapiens	29-32
8089089-5	1994	This fused protein exhibited PEP activity, which was inhibited by Z-Pro-prolinal, a specific inhibitor of PEP.	N-benzyloxycarbonylprolylprolinal	66-80	prolyl endopeptidase	Homo sapiens	106-109
7517035-5	1994	These data demonstrate that the primary enzyme in human lumbar CSF that acts on synthetic SP is a post-proline cleaving enzyme (PPCE).	TFF2 protein, human	90-92	prolyl endopeptidase	Homo sapiens	128-132
8096464-5	1993	Additionally, alpha-N-BOC-(omega-N-hydroxy acetyl) glutaminyl pyrrolidide modifies human placenta prolyl endopeptidase in a time-dependent reaction.	alpha-n-boc-(omega-n-hydroxy acetyl) glutaminyl pyrrolidide	14-73	prolyl endopeptidase	Homo sapiens	98-118
8486154-3	1993	Our kinetic study using the thiono substrate, benzyloxycarbonyl-Gly-Pro[CS-NH]-2-naphthylamide suggests that the putative oxyanion binding site is important in prolyl oligopeptidase catalysis, although to a lesser extent than in the chymotrypsin- and subtilisin-catalyzed reactions.	thiono	28-34	prolyl endopeptidase	Homo sapiens	160-181
8486154-3	1993	Our kinetic study using the thiono substrate, benzyloxycarbonyl-Gly-Pro[CS-NH]-2-naphthylamide suggests that the putative oxyanion binding site is important in prolyl oligopeptidase catalysis, although to a lesser extent than in the chymotrypsin- and subtilisin-catalyzed reactions.	benzyloxycarbonyl-gly-pro[cs-nh]-2-naphthylamide	46-94	prolyl endopeptidase	Homo sapiens	160-181
8392718-2	1993	Bestatin and puromycin were used to inhibit aminopeptidase activity, lisinopril for angiotensin-converting enzyme, phosphoramidon for neutral endopeptidase 24.11, and Z-Pro-prolinal for prolyl endopeptidase.	N-benzyloxycarbonylprolylprolinal	167-181	prolyl endopeptidase	Homo sapiens	186-206
8318538-1	1993	Prolylendopeptidase is a cytoplasmic serine proteinase which hydrolyses peptide bonds at the C-terminal side of prolines.	Proline	112-120	prolyl endopeptidase	Homo sapiens	0-19
1525255-3	1992	The mean value of prolyl endopeptidase catalytic activity concentration in serum for 120 healthy volunteers was 0.455 (SD = 0.092) mumol of 7-amino-4-methylcoumarin released per litre of serum per minute.	7-amino-4-methylcoumarin	140-164	prolyl endopeptidase	Homo sapiens	18-38
8392718-2	1993	Bestatin and puromycin were used to inhibit aminopeptidase activity, lisinopril for angiotensin-converting enzyme, phosphoramidon for neutral endopeptidase 24.11, and Z-Pro-prolinal for prolyl endopeptidase.	ubenimex	0-8	prolyl endopeptidase	Homo sapiens	186-206
8392718-2	1993	Bestatin and puromycin were used to inhibit aminopeptidase activity, lisinopril for angiotensin-converting enzyme, phosphoramidon for neutral endopeptidase 24.11, and Z-Pro-prolinal for prolyl endopeptidase.	Puromycin	13-22	prolyl endopeptidase	Homo sapiens	186-206
7509871-1	1993	Prolyl endopeptidase (PEP) and dipeptidyl peptidase IV (DP IV) are serine enzymes cleaving highly specific prolyl peptide bonds.	Serine	67-73	prolyl endopeptidase	Homo sapiens	0-20
7509871-1	1993	Prolyl endopeptidase (PEP) and dipeptidyl peptidase IV (DP IV) are serine enzymes cleaving highly specific prolyl peptide bonds.	Serine	67-73	prolyl endopeptidase	Homo sapiens	22-25
7509871-3	1993	The most potent inhibitor of PEP is Z-Pro-Pro-CH2N+C5H5 exhibiting a Ki* value of 1.8 nM with a first-order rate constant of Kon 0.0022 s-1 for the formation of the tight enzyme-inhibitor complex.	z-pro-pro-ch2n	36-50	prolyl endopeptidase	Homo sapiens	29-32
7509871-3	1993	The most potent inhibitor of PEP is Z-Pro-Pro-CH2N+C5H5 exhibiting a Ki* value of 1.8 nM with a first-order rate constant of Kon 0.0022 s-1 for the formation of the tight enzyme-inhibitor complex.	c5h5	51-55	prolyl endopeptidase	Homo sapiens	29-32
1590752-6	1992	In contrast, for the acylation of prolyl endopeptidase similar rate constants were obtained with nitrophenyl ester and several amide substrates.	nitrophenyl ester	97-114	prolyl endopeptidase	Homo sapiens	34-54
1590752-6	1992	In contrast, for the acylation of prolyl endopeptidase similar rate constants were obtained with nitrophenyl ester and several amide substrates.	Amides	127-132	prolyl endopeptidase	Homo sapiens	34-54
8433499-3	1993	Enflurane 0.6 and 1.2MAC prolonged PEP, and shortened 1/PEP2 and Pd/ICT significantly.	Enflurane	0-9	prolyl endopeptidase	Homo sapiens	35-38
8433499-5	1993	Halothane 0.6MAC prolonged PEP, and shortened 1/PEP2 and Pd/ICT.	Halothane	0-9	prolyl endopeptidase	Homo sapiens	27-30
8433499-7	1993	Addition of nitrous oxide prolonged PEP and PEP/LVET, and shortened Pd/ICT.	Nitrous Oxide	12-25	prolyl endopeptidase	Homo sapiens	36-39
8433499-7	1993	Addition of nitrous oxide prolonged PEP and PEP/LVET, and shortened Pd/ICT.	Nitrous Oxide	12-25	prolyl endopeptidase	Homo sapiens	44-47
1397329-1	1992	In prolyl oligopeptidase and its homologues, which constitute a new serine protease family, the order of the catalytic Ser and His residues in the amino acid sequence is the reverse of what is found in the trypsin and subtilisin families.	Serine	119-122	prolyl endopeptidase	Homo sapiens	3-24
1397329-3	1992	Recent determination of the three-dimensional structures of pancreatic and microbial lipases has shown that the order of their catalytic residues is Ser, Asp, His, and this fits the order Ser, His of prolyl oligopeptidase.	Serine	149-152	prolyl endopeptidase	Homo sapiens	200-221
1397329-3	1992	Recent determination of the three-dimensional structures of pancreatic and microbial lipases has shown that the order of their catalytic residues is Ser, Asp, His, and this fits the order Ser, His of prolyl oligopeptidase.	Aspartic Acid	154-157	prolyl endopeptidase	Homo sapiens	200-221
1397329-3	1992	Recent determination of the three-dimensional structures of pancreatic and microbial lipases has shown that the order of their catalytic residues is Ser, Asp, His, and this fits the order Ser, His of prolyl oligopeptidase.	Serine	188-191	prolyl endopeptidase	Homo sapiens	200-221
1397329-3	1992	Recent determination of the three-dimensional structures of pancreatic and microbial lipases has shown that the order of their catalytic residues is Ser, Asp, His, and this fits the order Ser, His of prolyl oligopeptidase.	Histidine	193-196	prolyl endopeptidase	Homo sapiens	200-221
1397329-5	1992	This comparison identifies the catalytic Asp residue in the prolyl oligopeptidase family.	Aspartic Acid	41-44	prolyl endopeptidase	Homo sapiens	60-81
1355343-1	1992	Prolyl endopeptidase and dipeptidyl peptidase IV are serine proteases which cleave the peptide bonds at the carboxy group of proline residues.	Proline	125-132	prolyl endopeptidase	Homo sapiens	0-20
1723259-1	1991	We determined in vitro the antitumor activity of a conjugate prepared by binding a monoclonal antibody (B4G7), which recognizes the human epidermal growth factor (EGF) receptor, with peplomycin (PEP), which is an antitumor agent effective against squamous cell carcinoma.	Peplomycin	183-193	prolyl endopeptidase	Homo sapiens	195-198
1723259-2	1991	This B4G7-PEP conjugate was prepared by coupling of B4G7 and carboxymethylpeplomycin active ester.	carboxymethylpeplomycin active ester	61-97	prolyl endopeptidase	Homo sapiens	10-13
34481952-13	2022	CONCLUSIONS: Rectal indomethacin was the cost-effective strategy for preventing PEP in both average-risk and high-risk patients undergoing ERCP.	Indomethacin	20-32	prolyl endopeptidase	Homo sapiens	80-83
1590775-2	1992	Peptidyldiazomethanes with proline in the P1 position were found to be competitive slow-binding inhibitors of prolyl endopeptidase.	peptidyldiazomethanes	0-21	prolyl endopeptidase	Homo sapiens	110-130
1590775-2	1992	Peptidyldiazomethanes with proline in the P1 position were found to be competitive slow-binding inhibitors of prolyl endopeptidase.	Proline	27-34	prolyl endopeptidase	Homo sapiens	110-130
1590775-7	1992	Incorporation of [3H]Ac-Ala-Ala-Pro-diazomethane into prolyl endopeptidase was observed after denaturation of the inhibited complex.	[3h]ac-ala-ala-pro-diazomethane	17-48	prolyl endopeptidase	Homo sapiens	54-74
1645530-1	1991	Prolyl endopeptidase (EC 3.4.21.26) was purified from human brain by a series of column-chromatographic steps using DEAE-cellulose DE-52, hydroxyapatite, phenyl-Sepharose, Sephacryl S-200 and f.p.l.c.	DEAE-Cellulose	116-130	prolyl endopeptidase	Homo sapiens	0-20
1645530-1	1991	Prolyl endopeptidase (EC 3.4.21.26) was purified from human brain by a series of column-chromatographic steps using DEAE-cellulose DE-52, hydroxyapatite, phenyl-Sepharose, Sephacryl S-200 and f.p.l.c.	Durapatite	138-152	prolyl endopeptidase	Homo sapiens	0-20
1645530-1	1991	Prolyl endopeptidase (EC 3.4.21.26) was purified from human brain by a series of column-chromatographic steps using DEAE-cellulose DE-52, hydroxyapatite, phenyl-Sepharose, Sephacryl S-200 and f.p.l.c.	phenyl-sepharose	154-170	prolyl endopeptidase	Homo sapiens	0-20
1645530-1	1991	Prolyl endopeptidase (EC 3.4.21.26) was purified from human brain by a series of column-chromatographic steps using DEAE-cellulose DE-52, hydroxyapatite, phenyl-Sepharose, Sephacryl S-200 and f.p.l.c.	sephacryl S 200	172-187	prolyl endopeptidase	Homo sapiens	0-20
1900195-5	1991	[3H]Diisopropyl fluorophosphate was used to identify the active-site serine of prolyl endopeptidase.	[3h]diisopropyl fluorophosphate	0-31	prolyl endopeptidase	Homo sapiens	79-99
1900195-5	1991	[3H]Diisopropyl fluorophosphate was used to identify the active-site serine of prolyl endopeptidase.	Serine	69-75	prolyl endopeptidase	Homo sapiens	79-99
2175370-4	1990	Angiotensin I, instead of being activated, could be inactivated by the cleavage of its C-terminal tripeptide either by neutral endopeptidase 24.11 or by prolyl endopeptidase.	tripeptide K-26	98-108	prolyl endopeptidase	Homo sapiens	153-173
2179327-3	1990	The decreased output of PEP in the presence of F, in turn, results in the inhibition of sugar transport via the PEP phosphotransferase system (PTS).	Sugars	88-93	prolyl endopeptidase	Homo sapiens	24-27
2179327-3	1990	The decreased output of PEP in the presence of F, in turn, results in the inhibition of sugar transport via the PEP phosphotransferase system (PTS).	Sugars	88-93	prolyl endopeptidase	Homo sapiens	112-115
33822092-0	2021	Dual azithromycin/ceftriaxone therapy for gonorrhoea in PrEP cohorts results in levels of macrolide consumption that exceed resistance thresholds by up to 7-fold.	Azithromycin	5-17	prolyl endopeptidase	Homo sapiens	56-60
33822092-0	2021	Dual azithromycin/ceftriaxone therapy for gonorrhoea in PrEP cohorts results in levels of macrolide consumption that exceed resistance thresholds by up to 7-fold.	Ceftriaxone	18-29	prolyl endopeptidase	Homo sapiens	56-60
33822092-0	2021	Dual azithromycin/ceftriaxone therapy for gonorrhoea in PrEP cohorts results in levels of macrolide consumption that exceed resistance thresholds by up to 7-fold.	Macrolides	90-99	prolyl endopeptidase	Homo sapiens	56-60
27372977-1	2016	Raltegravir, maraviroc show promise as PrEP drugs in studies.	Raltegravir Potassium	0-11	prolyl endopeptidase	Homo sapiens	39-43
23562579-1	2013	Prolyl oligopeptidase (EC 3.4.21.26, PREP) is a serine protease that hydrolyzes proline-containing peptides shorter than 30-mer but it has also nonhydrolytic functions.	Serine	48-54	prolyl endopeptidase	Homo sapiens	0-21
23562579-1	2013	Prolyl oligopeptidase (EC 3.4.21.26, PREP) is a serine protease that hydrolyzes proline-containing peptides shorter than 30-mer but it has also nonhydrolytic functions.	Serine	48-54	prolyl endopeptidase	Homo sapiens	37-41
23562579-1	2013	Prolyl oligopeptidase (EC 3.4.21.26, PREP) is a serine protease that hydrolyzes proline-containing peptides shorter than 30-mer but it has also nonhydrolytic functions.	Proline	80-87	prolyl endopeptidase	Homo sapiens	0-21
23562579-1	2013	Prolyl oligopeptidase (EC 3.4.21.26, PREP) is a serine protease that hydrolyzes proline-containing peptides shorter than 30-mer but it has also nonhydrolytic functions.	Proline	80-87	prolyl endopeptidase	Homo sapiens	37-41
2064618-0	1991	Inactivation of prolyl endopeptidase by a peptidylchloromethane.	peptidylchloromethane	42-63	prolyl endopeptidase	Homo sapiens	16-36
2064618-2	1991	The kinetics of inactivation of prolyl endopeptidase by acetyl-Ala-Ala-Pro-CH2Cl were studied by progress-curve methods in the presence of substrate.	acetyl-ala-ala-pro-ch2cl	56-80	prolyl endopeptidase	Homo sapiens	32-52
2064618-7	1991	This residue (His-680) probably represents the active-site histidine of prolyl endopeptidase.	Histidine	14-17	prolyl endopeptidase	Homo sapiens	72-92
2064618-7	1991	This residue (His-680) probably represents the active-site histidine of prolyl endopeptidase.	Histidine	59-68	prolyl endopeptidase	Homo sapiens	72-92
1995635-11	1991	These data suggest that phosphorylation of a serine residue in the P1" position of at least a few substrates of prolyl endopeptidase will increase the rate of their cleavage.	Serine	45-51	prolyl endopeptidase	Homo sapiens	112-132
1368673-1	1991	Structural requirements of N-blocked L-proline derivatives as specific inhibitors for prolyl endopeptidase were investigated using a series of substrate analogs.	Nitrogen	27-28	prolyl endopeptidase	Homo sapiens	86-106
1368673-1	1991	Structural requirements of N-blocked L-proline derivatives as specific inhibitors for prolyl endopeptidase were investigated using a series of substrate analogs.	blocked l-proline	29-46	prolyl endopeptidase	Homo sapiens	86-106
2241932-0	1990	Slow tight-binding inhibition of prolyl endopeptidase by benzyloxycarbonyl-prolyl-prolinal.	benzyloxycarbonyl-prolyl-prolinal	57-90	prolyl endopeptidase	Homo sapiens	33-53
2241932-4	1990	We show that Z-prolyl-prolinal is a slow-binding inhibitor of mouse brain prolyl endopeptidase with Ki 0.35 +/- 0.05 nM.	N-benzyloxycarbonylprolylprolinal	13-30	prolyl endopeptidase	Homo sapiens	74-94
2241932-8	1990	Prolyl endopeptidase from human brain is also inhibited by Z-prolyl-prolinal with kinetics similar to those of the mouse brain enzyme.	N-benzyloxycarbonylprolylprolinal	59-76	prolyl endopeptidase	Homo sapiens	0-20
34891119-4	2022	We showed that PREP inhibitor exposure induced autophagy in the RPE cells, shown by increased LC3-II levels and decreased p62 levels.	lc3-ii	94-100	prolyl endopeptidase	Homo sapiens	15-19
34565255-1	2022	Doxycycline post-exposure prophylaxis (PEP) holds the potential to mitigate increasing rates of syphilis among sexual minority men (SMM) in the US yet has received limited attention.	Doxycycline	0-11	prolyl endopeptidase	Homo sapiens	39-42
34565255-9	2022	At year 10, under the same uptake and adherence level, 22% of infections would be prevented due to doxycycline PEP in the instances where condoms were not used or failed.	Doxycycline	99-110	prolyl endopeptidase	Homo sapiens	111-114
34565255-10	2022	Findings suggest that doxycycline PEP will have a modest impact on syphilis incidence when assuming a reasonable level of uptake and adherence.	Doxycycline	22-33	prolyl endopeptidase	Homo sapiens	34-37
34565255-11	2022	Doxycycline PEP may be most appropriate as a secondary prevention measure to condoms and enhanced syphilis screening for reducing infections among SMM.	Doxycycline	0-11	prolyl endopeptidase	Homo sapiens	12-15
34562427-1	2021	Post-exposure prophylaxis (PEP) with single-dose rifampicin (SDR) reduces the risk of developing leprosy among contacts of leprosy patients.	Rifampin	49-59	prolyl endopeptidase	Homo sapiens	27-30
34562427-1	2021	Post-exposure prophylaxis (PEP) with single-dose rifampicin (SDR) reduces the risk of developing leprosy among contacts of leprosy patients.	SDR	61-64	prolyl endopeptidase	Homo sapiens	27-30
34492601-1	2021	Casein hydrolysate (Pep) is a dispersant for poorly water-soluble drugs and nutraceutical ingredients.	Water	52-57	prolyl endopeptidase	Homo sapiens	20-23
34492601-2	2021	However, two types of complexes may be between Pep and poorly water-soluble molecules: those that are (1) dispersed as hydrocolloids in aqueous media with a particle size of 100-500 nm; and (2) not hydrocolloids, as indicated by permeability of the complex through an ultrafiltration (UF) membrane and the fact that the particle size is ambiguous by dynamic light scattering.	Water	62-67	prolyl endopeptidase	Homo sapiens	47-50
34492601-4	2021	We classified the dissolution state of the complexes between poorly water-soluble ingredients and Pep by the permeability using a UF membrane.	Water	68-73	prolyl endopeptidase	Homo sapiens	98-101
34492601-7	2021	Furthermore, we determined the stoichiometry and association constant for the complex between a major peptide in Pep and poorly water-soluble resveratrol (Res) based on fluorescence quenching.	Water	128-133	prolyl endopeptidase	Homo sapiens	113-116
34492601-7	2021	Furthermore, we determined the stoichiometry and association constant for the complex between a major peptide in Pep and poorly water-soluble resveratrol (Res) based on fluorescence quenching.	Resveratrol	142-153	prolyl endopeptidase	Homo sapiens	113-116
34492601-7	2021	Furthermore, we determined the stoichiometry and association constant for the complex between a major peptide in Pep and poorly water-soluble resveratrol (Res) based on fluorescence quenching.	Resveratrol	155-158	prolyl endopeptidase	Homo sapiens	113-116
34778734-2	2021	Lopinavir/ritonavir (LPV/r) was repurposed as a potential PEP agent against COVID-19.	lopinavir-ritonavir drug combination	0-19	prolyl endopeptidase	Homo sapiens	58-61
34778734-2	2021	Lopinavir/ritonavir (LPV/r) was repurposed as a potential PEP agent against COVID-19.	lopinavir-ritonavir drug combination	21-26	prolyl endopeptidase	Homo sapiens	58-61
34829125-8	2021	Glycation increased the antioxidant activities of the hydrolysates; however, their prolyl-endopeptidase-inhibiting activity was lost.	glycation	0-9	prolyl endopeptidase	Homo sapiens	83-103
34791583-2	2021	Novel HIV prevention research strategies to increase PrEP uptake and adherence among the high incidence populations, such as LMSM who misuse drugs, include social network analyses.	lmsm	125-129	prolyl endopeptidase	Homo sapiens	53-57
34791583-6	2021	Friendship relationships in which both friends used cocaine or marijuana were more likely to report PrEP-related conversations in the past six months.	Cocaine	52-59	prolyl endopeptidase	Homo sapiens	100-104
34358965-0	2021	Prolyl oligopeptidase participates in the cytosine arabinoside-induced nuclear translocation of glyceraldehyde 3-phosphate dehydrogenase in a human neuroblastoma cell line.	Cytarabine	42-62	prolyl endopeptidase	Homo sapiens	0-21
34791583-7	2021	The likelihood of talking about PrEP in the next six months was higher among dyads with cocaine use homophily and ecstasy use homophily, while lower among dyads with marijuana use homophily.	Cocaine	88-95	prolyl endopeptidase	Homo sapiens	32-36
34791583-7	2021	The likelihood of talking about PrEP in the next six months was higher among dyads with cocaine use homophily and ecstasy use homophily, while lower among dyads with marijuana use homophily.	N-Methyl-3,4-methylenedioxyamphetamine	114-121	prolyl endopeptidase	Homo sapiens	32-36
34196102-0	2021	Deletion or inhibition of prolyl oligopeptidase blocks lithium-induced phosphorylation of GSK3b and Akt by activation of protein phosphatase 2A.	Lithium	55-62	prolyl endopeptidase	Homo sapiens	26-47
34196102-1	2021	Alterations in prolyl oligopeptidase (PREP) activity have been connected e.g. with bipolar and major depressive disorder, and several studies have reported that lack or inhibition of PREP blocks the effects of lithium on inositol 1,4,5-triphosphate (IP3 ) levels.	Lithium	210-217	prolyl endopeptidase	Homo sapiens	15-36
34196102-1	2021	Alterations in prolyl oligopeptidase (PREP) activity have been connected e.g. with bipolar and major depressive disorder, and several studies have reported that lack or inhibition of PREP blocks the effects of lithium on inositol 1,4,5-triphosphate (IP3 ) levels.	Inositol 1,4,5-Trisphosphate	221-248	prolyl endopeptidase	Homo sapiens	15-36
34196102-1	2021	Alterations in prolyl oligopeptidase (PREP) activity have been connected e.g. with bipolar and major depressive disorder, and several studies have reported that lack or inhibition of PREP blocks the effects of lithium on inositol 1,4,5-triphosphate (IP3 ) levels.	Inositol 1,4,5-Trisphosphate	221-248	prolyl endopeptidase	Homo sapiens	183-187
34196102-1	2021	Alterations in prolyl oligopeptidase (PREP) activity have been connected e.g. with bipolar and major depressive disorder, and several studies have reported that lack or inhibition of PREP blocks the effects of lithium on inositol 1,4,5-triphosphate (IP3 ) levels.	Inositol 1,4,5-Trisphosphate	250-253	prolyl endopeptidase	Homo sapiens	15-36
34196102-1	2021	Alterations in prolyl oligopeptidase (PREP) activity have been connected e.g. with bipolar and major depressive disorder, and several studies have reported that lack or inhibition of PREP blocks the effects of lithium on inositol 1,4,5-triphosphate (IP3 ) levels.	Inositol 1,4,5-Trisphosphate	250-253	prolyl endopeptidase	Homo sapiens	183-187
34196102-2	2021	However, the impact of PREP modulation on other intracellular targets of lithium, such as glycogen synthase kinase 3 beta (GSK3b) or protein kinase B (Akt), has not been studied.	Lithium	73-80	prolyl endopeptidase	Homo sapiens	23-27
34196102-3	2021	We recently found that PREP regulates protein phosphatase 2A (PP2A), and since GSK3b and Akt are PP2A substrates, we studied if PREP-related lithium insensitivity is dependent on PP2A.	Lithium	141-148	prolyl endopeptidase	Homo sapiens	128-132
34358965-4	2021	These results indicate that the anticancer effects of Ara-C not only include the commonly known antimetabolic effects, but also the induction of cell death by nuclear transfer of GAPDH through interaction with POP.	Cytarabine	54-59	prolyl endopeptidase	Homo sapiens	210-213
34757603-4	2021	MSM taking PrEP were more likely to report condomless anal sex with drug use (AOR: 1.21; 95%CI: 1.07-1.37) and alcohol use (AOR: 1.29; 95%CI: 1.14-1.46) compared with MSM not taking PrEP.	Alcohols	111-118	prolyl endopeptidase	Homo sapiens	11-15
34358965-1	2021	Previously, we reported that glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is a binding partner of prolyl oligopeptidase (POP) in neuroblastoma NB-1 cells and that the POP inhibitor, SUAM-14746, inhibits cytosine arabinoside (Ara-C)-induced nuclear translocation of GAPDH and protects against Ara-C cytotoxicity.	3-((4-(2-styrylphenoxy)butanoyl)-4-hydroxyprolyl)thiazolidine	186-196	prolyl endopeptidase	Homo sapiens	102-123
34358965-1	2021	Previously, we reported that glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is a binding partner of prolyl oligopeptidase (POP) in neuroblastoma NB-1 cells and that the POP inhibitor, SUAM-14746, inhibits cytosine arabinoside (Ara-C)-induced nuclear translocation of GAPDH and protects against Ara-C cytotoxicity.	3-((4-(2-styrylphenoxy)butanoyl)-4-hydroxyprolyl)thiazolidine	186-196	prolyl endopeptidase	Homo sapiens	171-174
34358965-1	2021	Previously, we reported that glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is a binding partner of prolyl oligopeptidase (POP) in neuroblastoma NB-1 cells and that the POP inhibitor, SUAM-14746, inhibits cytosine arabinoside (Ara-C)-induced nuclear translocation of GAPDH and protects against Ara-C cytotoxicity.	Cytarabine	207-227	prolyl endopeptidase	Homo sapiens	102-123
34358965-1	2021	Previously, we reported that glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is a binding partner of prolyl oligopeptidase (POP) in neuroblastoma NB-1 cells and that the POP inhibitor, SUAM-14746, inhibits cytosine arabinoside (Ara-C)-induced nuclear translocation of GAPDH and protects against Ara-C cytotoxicity.	Cytarabine	207-227	prolyl endopeptidase	Homo sapiens	171-174
34358965-1	2021	Previously, we reported that glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is a binding partner of prolyl oligopeptidase (POP) in neuroblastoma NB-1 cells and that the POP inhibitor, SUAM-14746, inhibits cytosine arabinoside (Ara-C)-induced nuclear translocation of GAPDH and protects against Ara-C cytotoxicity.	Cytarabine	229-234	prolyl endopeptidase	Homo sapiens	102-123
34358965-1	2021	Previously, we reported that glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is a binding partner of prolyl oligopeptidase (POP) in neuroblastoma NB-1 cells and that the POP inhibitor, SUAM-14746, inhibits cytosine arabinoside (Ara-C)-induced nuclear translocation of GAPDH and protects against Ara-C cytotoxicity.	Cytarabine	229-234	prolyl endopeptidase	Homo sapiens	125-128
34358965-1	2021	Previously, we reported that glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is a binding partner of prolyl oligopeptidase (POP) in neuroblastoma NB-1 cells and that the POP inhibitor, SUAM-14746, inhibits cytosine arabinoside (Ara-C)-induced nuclear translocation of GAPDH and protects against Ara-C cytotoxicity.	Cytarabine	229-234	prolyl endopeptidase	Homo sapiens	171-174
34671446-0	2021	2-Imidazole as a Substitute for the Electrophilic Group Gives Highly Potent Prolyl Oligopeptidase Inhibitors.	2-imidazole	0-11	prolyl endopeptidase	Homo sapiens	76-97
34321424-2	2021	Because of difficulty in accurately dosing indomethacin suppositories in pediatric patients, our center has used IV ketorolac for PEP prevention and present data on its safety and associated PEP rates.	Ketorolac	116-125	prolyl endopeptidase	Homo sapiens	130-133
34321424-5	2021	Routine use of ketorolac for PEP prevention began in 2014.	Ketorolac	15-24	prolyl endopeptidase	Homo sapiens	29-32
34321424-10	2021	However, for high-risk pediatric patients with injection of contrast into and/or cannulation of the PD, the rates of PEP were significantly lower for patients who received ketorolac (11% vs 25% p = 0.035).	Ketorolac	172-181	prolyl endopeptidase	Homo sapiens	117-120
34321424-11	2021	CONCLUSIONS: Pediatric patients undergoing ERCP with manipulation of the PD are high risk for PEP, and ketorolac was associated with a lower rate of PEP in these patients.	Ketorolac	103-112	prolyl endopeptidase	Homo sapiens	149-152
34353727-4	2021	AIM: We aimed to assess the efficacy of a combination of indomethacin and hydration - type and amount - for PEP prevention via a network meta-analysis.	Indomethacin	57-69	prolyl endopeptidase	Homo sapiens	108-111
34671446-1	2021	Different five-membered nitrogen-containing heteroaromatics in the position of the typical electrophilic group in prolyl oligopeptidase (PREP) inhibitors were investigated and compared to tetrazole.	Nitrogen	24-32	prolyl endopeptidase	Homo sapiens	114-135
34671446-6	2021	Among the highly potent PREP inhibiting 2-imidazoles, only one was also a potent modulator of PREP-catalyzed alpha-synuclein dimerization, indicating that the linker length on the opposite side of the molecule from the five-membered heteroaromatic is critical for the disconnected structure-activity relationships.	2-imidazoles	40-52	prolyl endopeptidase	Homo sapiens	24-28
34487093-9	2021	The incidence of ERCP-induced pancreatitis (PEP) was 3.1% (1/32) in the indomethacin group and 21.4% (6/28) in the control group.	Indomethacin	72-84	prolyl endopeptidase	Homo sapiens	44-47
34478015-3	2022	We estimated the relative prevalence of high adherence (intracellular tenofovir-diphosphate concentration >= 700 fmol/punch) 3- and 6-months after PrEP initiation among those who disclosed vs. did not disclose their PrEP use, both overall and by age.	tenofovir diphosphate	70-91	prolyl endopeptidase	Homo sapiens	147-151
34478015-3	2022	We estimated the relative prevalence of high adherence (intracellular tenofovir-diphosphate concentration >= 700 fmol/punch) 3- and 6-months after PrEP initiation among those who disclosed vs. did not disclose their PrEP use, both overall and by age.	tenofovir diphosphate	70-91	prolyl endopeptidase	Homo sapiens	216-220
34487093-11	2021	The incidence of PEP was significantly lower in the indomethacin group than in the control group (p = 0.043).	Indomethacin	52-64	prolyl endopeptidase	Homo sapiens	17-20
34487093-13	2021	CONCLUSION: According to the results of our study, rectal indomethacin administration decreased the frequency of PEP in high-risk patients.	Indomethacin	58-70	prolyl endopeptidase	Homo sapiens	113-116
34714289-8	2021	Female sex, age younger than 50 years, a benign indication of ERCP, and low bilirubin levels have higher chances of PEP.	Bilirubin	76-85	prolyl endopeptidase	Homo sapiens	116-119
34081665-1	2021	An analysis of Be-PrEP-ared, the Belgian PrEP demonstration study .	Beryllium	15-17	prolyl endopeptidase	Homo sapiens	18-22
34461842-1	2021	BACKGROUND: In a previous retrospective observational study, a 3-day regimen of oseltamivir as post-exposure prophylaxis (PEP) for preventing transmission of influenza in wards was shown to be comparable to 7- to 10-day regimens provided index cases were immediately separated from close contacts.	Oseltamivir	80-91	prolyl endopeptidase	Homo sapiens	122-125
34116970-4	2021	AIMS AND METHODS: We evaluated the thiopurine use in PEP.	2-mercaptopyrazine	35-45	prolyl endopeptidase	Homo sapiens	53-56
34322026-0	2021	Cyclotides Isolated From Violet Plants of Cameroon Are Inhibitors of Human Prolyl Oligopeptidase.	Cyclotides	0-10	prolyl endopeptidase	Homo sapiens	75-96
34196102-5	2021	As expected, PREP deletion and inhibition blocked the lithium-induced phosphorylation on GSK3b and Akt in both cell lines.	Lithium	54-61	prolyl endopeptidase	Homo sapiens	13-17
34196102-7	2021	Therefore, we conclude that PREP deletion or inhibition blocks the intracellular effects of lithium on GSK3b and Akt via PP2A activation.	Lithium	92-99	prolyl endopeptidase	Homo sapiens	28-32
34446483-3	2021	Post-exposure prophylaxis with single-dose rifampicin (SDR-PEP) reduces the risk of developing leprosy when administered to screened contacts of patients.	Rifampin	43-53	prolyl endopeptidase	Homo sapiens	59-62
34298658-0	2021	KYP-2047, an Inhibitor of Prolyl-Oligopeptidase, Reduces GlioBlastoma Proliferation through Angiogenesis and Apoptosis Modulation.	4-phenylbutanoyl-prolylcyanopyrrolidine	0-8	prolyl endopeptidase	Homo sapiens	26-47
34298658-5	2021	This study aimed to investigate the potential effect of KYP-2047, an inhibitor of the prolyl-oligopeptidase (POP), known to modulate angiogenesis, in an in vivo U87-xenograft model and in an in vitro study on human GB cells.	4-phenylbutanoyl-prolylcyanopyrrolidine	56-64	prolyl endopeptidase	Homo sapiens	86-107
34298658-5	2021	This study aimed to investigate the potential effect of KYP-2047, an inhibitor of the prolyl-oligopeptidase (POP), known to modulate angiogenesis, in an in vivo U87-xenograft model and in an in vitro study on human GB cells.	4-phenylbutanoyl-prolylcyanopyrrolidine	56-64	prolyl endopeptidase	Homo sapiens	109-112
34222616-2	2021	Rectal indomethacin administered before or immediately after an ERCP and prophylactic pancreatic duct stent placement (PPS) are associated with a reduction in the incidence of PEP.	Indomethacin	7-19	prolyl endopeptidase	Homo sapiens	176-179
34461842-7	2021	DISCUSSION: A 3-day regimen of oseltamivir as PEP has advantages over 7- to 10-day regimens in terms of costs, medication adherence and adverse effects.	Oseltamivir	31-42	prolyl endopeptidase	Homo sapiens	46-49
33710023-1	2021	ABSTRACT: We previously reported a higher incidence of non-albumin proteinuria and a small but significant decline in estimated glomerular filtration rate among HIV-negative adults randomized to emtricitabine/ tenofovir disoproxil fumarate pre-exposure prophylaxis (FTC/TDF PrEP) versus placebo.	Emtricitabine	195-208	prolyl endopeptidase	Homo sapiens	274-278
35583574-1	2022	Approval of the first injectable PrEP product (cabotegravir) provides an exciting addition to oral PrEP that could encourage those not currently on PrEP to use it.	cabotegravir	47-59	prolyl endopeptidase	Homo sapiens	33-37
34150284-7	2021	After optimizing the PEP/nZVI process, the proposed optimal conditions was pH = 3.4, persulfate concentration equal to 0.49 mg/l, in 1 A direct current, nZVI dose equal to 0.1 mg/l, in 50.05 mg/l herbicide concentration as an initial concentration, in 80 min reaction time.	Peroxydisulfate	85-95	prolyl endopeptidase	Homo sapiens	21-24
34078819-10	2021	Of the 47 healthcare workers who responded to the item regarding reasons for non-adherence, 36 (76.6%) reported forgetting to take oseltamivir or discontinuing it due to a misguided self-decision that continuation of PEP was unnecessary, and 5 (10.6%) reported discontinuing treatment due to adverse effects.	Oseltamivir	131-142	prolyl endopeptidase	Homo sapiens	217-220
34078819-11	2021	In conclusion, healthcare workers, particularly physicians, had low PEP adherence owing to forgetting or stopping to take oseltamivir due to a misguided self-decision.	Oseltamivir	122-133	prolyl endopeptidase	Homo sapiens	68-71
34109014-8	2021	While some participants had not heard of PrEP, the majority described mentions or conversations about PrEP on GSN-apps.	GSN	110-113	prolyl endopeptidase	Homo sapiens	102-106
35182281-10	2022	These findings indicate that using the principals of PAPA to unpick influencers of PrEP use, could help tailor adherence support in PrEP programmes.	PAPA	53-57	prolyl endopeptidase	Homo sapiens	83-87
34991141-4	2022	METHODS: Individuals accessing PEP were enrolled in an open label study of co-formulated BIC/FTC/TAF, taken as one pill daily for 28 days.	bic/ftc	89-96	prolyl endopeptidase	Homo sapiens	31-34
35464773-5	2022	Tertbutyl hydroperoxide can inhibit the expression of PREP by activating the PI3K/AKT signaling pathway at low concentrations in NP cells.	tert-Butylhydroperoxide	0-23	prolyl endopeptidase	Homo sapiens	54-58
35298162-3	2022	PEP-FOLD originality is threefold: (i) it uses a predetermined structural alphabet, (ii) it uses a sequential algorithm to reconstruct the tridimensional structures of these peptides in a discrete space using a fragment library, and (iii) it assesses the energy of these structures using a coarse-grained representation in which all of the backbone atoms but the alpha-hydrogen are present, and the side chain corresponds to a unique bead.	alpha-hydrogen	363-377	prolyl endopeptidase	Homo sapiens	0-3
35499175-3	2022	Tenofovir alafenamide fumarate has become the "backbone" of multiple combination products for the treatment of HIV, combined with emtricitabine for PreP and as a monotherapy for the treatment or HBV.	Tenofovir Alafenamide fumarate	0-30	prolyl endopeptidase	Homo sapiens	148-152
35499175-3	2022	Tenofovir alafenamide fumarate has become the "backbone" of multiple combination products for the treatment of HIV, combined with emtricitabine for PreP and as a monotherapy for the treatment or HBV.	Emtricitabine	130-143	prolyl endopeptidase	Homo sapiens	148-152
35499503-11	2022	PrEP discontinuation was associated with non-Hispanic Black race/ethnicity (hazard ratio (HR) 1.34, 95% confidence interval (CI) 1.02-1.76), age <20 years (HR 2.17, 95% CI 1.26-3.75), age 20-29 (HR 1.55, 95% CI 1.06-2.28), and methamphetamine use (HR 1.98, 95% CI 1.57-2.49).	Methamphetamine	227-242	prolyl endopeptidase	Homo sapiens	0-4
35448257-1	2022	A new preparation route for high-luminescent blue-emission pepsin copper nanoclusters (Pep-CuNCs) is introduced in this work.	Copper	66-72	prolyl endopeptidase	Homo sapiens	87-90
35448257-8	2022	Thus, great selectivity of Pep-CuNCs towards Pb(II) ions was observed, allowing sensitive determination of this metal ion at lab-scale and in the environment.	pb(ii)	45-51	prolyl endopeptidase	Homo sapiens	27-30
35448257-8	2022	Thus, great selectivity of Pep-CuNCs towards Pb(II) ions was observed, allowing sensitive determination of this metal ion at lab-scale and in the environment.	Metals	112-117	prolyl endopeptidase	Homo sapiens	27-30
35448257-10	2022	The resulting Pep-CuNCs were utilized significantly to detect Pb(II) ions in environmental samples.	pb(ii)	62-68	prolyl endopeptidase	Homo sapiens	14-17
35239448-6	2022	PrEP adherence was measured at week 48 using intracellular tenofovir-diphosphate drug concentrations.	tenofovir diphosphate	59-80	prolyl endopeptidase	Homo sapiens	0-4
35133388-4	2022	By immobilizing both terminals of an IAPP-recognizing CDR loop (PEP) on the surface of AuNPs, the active conformation of PEP can simply recur on the gold-based antibody mimic, significantly enhancing the binding affinity between PEP and IAPP.	cdr	54-57	prolyl endopeptidase	Homo sapiens	64-67
35133388-4	2022	By immobilizing both terminals of an IAPP-recognizing CDR loop (PEP) on the surface of AuNPs, the active conformation of PEP can simply recur on the gold-based antibody mimic, significantly enhancing the binding affinity between PEP and IAPP.	cdr	54-57	prolyl endopeptidase	Homo sapiens	121-124
35133388-4	2022	By immobilizing both terminals of an IAPP-recognizing CDR loop (PEP) on the surface of AuNPs, the active conformation of PEP can simply recur on the gold-based antibody mimic, significantly enhancing the binding affinity between PEP and IAPP.	cdr	54-57	prolyl endopeptidase	Homo sapiens	229-232
35127846-9	2021	Combining the predictability of the LVEF to the determinant role of SBP/PEP on the Ees variations, we obtained: (SBP*LVEF)/PEP mm Hg/ms, with an improved R 2 value (R 2 = 0.848; P < 0.001).	ees	83-86	prolyl endopeptidase	Homo sapiens	72-75
35127846-9	2021	Combining the predictability of the LVEF to the determinant role of SBP/PEP on the Ees variations, we obtained: (SBP*LVEF)/PEP mm Hg/ms, with an improved R 2 value (R 2 = 0.848; P < 0.001).	ees	83-86	prolyl endopeptidase	Homo sapiens	123-126
2553370-0	1989	[The effect of amidinomercaptic acids on prolyl endopeptidase and carboxycathepsin activity (angiotensin converting enzyme)].	amidinomercaptic acids	15-37	prolyl endopeptidase	Homo sapiens	41-61
35055534-2	2022	Post-exposure prophylaxis (PEP) is an effective strategy for individuals who are exposed to HIV, but there is limited research about PEP use among young SMM and its relationship with methamphetamine use.	Methamphetamine	183-198	prolyl endopeptidase	Homo sapiens	27-30
35055534-2	2022	Post-exposure prophylaxis (PEP) is an effective strategy for individuals who are exposed to HIV, but there is limited research about PEP use among young SMM and its relationship with methamphetamine use.	Methamphetamine	183-198	prolyl endopeptidase	Homo sapiens	133-136
35055534-4	2022	Multivariable logistic regression models were used to assess the association between methamphetamine use and ever PEP use.	Methamphetamine	85-100	prolyl endopeptidase	Homo sapiens	114-117
35055534-5	2022	Compared with those who had not used methamphetamine in the last 6 months, young SMM who did use methamphetamine were significantly more likely to have ever used PEP (AOR = 6.07, 95% CI: 2.10-16.86).	Methamphetamine	97-112	prolyl endopeptidase	Homo sapiens	162-165
3048412-0	1988	Porcine muscle prolyl endopeptidase: limited proteolysis of tryptic peptides from hemoglobin beta-chains at prolyl and alanyl bonds.	Peptides	68-76	prolyl endopeptidase	Homo sapiens	15-35
2904815-2	1988	When [18O]-PEP specifically labeled in the enolic oxygen is a substrate for KDO8P synthase, the 18O is recovered in Pi.	Oxygen	50-56	prolyl endopeptidase	Homo sapiens	11-14
2904815-3	1988	This indicates that the KDO8P synthase reaction proceeds with C-O bond cleavage of PEP similar to that observed in the 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase catalyzed condensation of PEP and erythrose-4-phosphate (1).	3-deoxy-d-arabino-heptulosonate	119-150	prolyl endopeptidase	Homo sapiens	83-86
2904815-3	1988	This indicates that the KDO8P synthase reaction proceeds with C-O bond cleavage of PEP similar to that observed in the 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase catalyzed condensation of PEP and erythrose-4-phosphate (1).	3-deoxy-d-arabino-heptulosonate	119-150	prolyl endopeptidase	Homo sapiens	198-201
2904815-3	1988	This indicates that the KDO8P synthase reaction proceeds with C-O bond cleavage of PEP similar to that observed in the 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase catalyzed condensation of PEP and erythrose-4-phosphate (1).	erythrose 4-phosphate	206-227	prolyl endopeptidase	Homo sapiens	83-86
2904815-7	1988	It is likely that bromopyruvate reacts with a functional group at the PEP binding site since PEP, but not arabinose-5-phosphate, protects against inactivation.	bromopyruvate	18-31	prolyl endopeptidase	Homo sapiens	70-73
2904815-7	1988	It is likely that bromopyruvate reacts with a functional group at the PEP binding site since PEP, but not arabinose-5-phosphate, protects against inactivation.	bromopyruvate	18-31	prolyl endopeptidase	Homo sapiens	93-96
2904815-7	1988	It is likely that bromopyruvate reacts with a functional group at the PEP binding site since PEP, but not arabinose-5-phosphate, protects against inactivation.	arabinose 5-phosphate	106-127	prolyl endopeptidase	Homo sapiens	70-73
3048412-1	1988	Tryptic peptides from hemoglobin (Hb) beta-chains were used as model substrates for limited proteolysis by prolyl endopeptidase (EC 3.4.21.26) from porcine muscle.	Peptides	8-16	prolyl endopeptidase	Homo sapiens	107-127
3541940-9	1987	The IC50 values for bradykinin, diisopropylfluorophosphate (DFP), and N-benzyloxycarbonyl-Pro-Prolinal (Z-Pro-Prolinal) to inhibit Z-Gly-Pro-MCA hydrolysis by PPCE were 5.9 +/- 1.4 X 10(-7) M, 8.8 +/- 3.1 X 10(-7) and 7.9 +/- 0.3 X 10(-9) M respectively.	-benzyloxycarbonyl-pro-prolinal	71-102	prolyl endopeptidase	Homo sapiens	159-163
3071442-6	1988	The change of PEP/LVET ratio correlated significantly with the changes of blood glucose and glycosylated haemoglobin Alc levels, but the correlation between these metabolic variables and the change of left ventricular ejection fraction during exercise did not reach statistical significance.	Glucose	80-87	prolyl endopeptidase	Homo sapiens	14-17
3539636-1	1986	A series of tetrapeptides, Cbz(Bz)-Gly-X-Leu-Gly, were synthesized and the kinetic parameters, kcat and kcat/Km, determined for their hydrolyses by prolyl endopeptidase from Flavobacterium.	cbz(bz)-gly-x-leu-gly	27-48	prolyl endopeptidase	Homo sapiens	148-168
6433837-6	1984	PEP was associated with increased myocardial noradrenaline secretion (-3.1 +/- 31.5 ng/min under basal conditions to 30.2 +/- 42.8 ng/min, p less than 0.05).	Norepinephrine	45-58	prolyl endopeptidase	Homo sapiens	0-3
2429467-6	1986	At a dose of 4 X 10 mg/d NPAB the increase of the quotient pre-ejection period to ejection time PEP/LVET became significant, increasing continuously from 0.35 to 0.48.	npab	25-29	prolyl endopeptidase	Homo sapiens	96-99
2871517-4	1986	We have also used an inhibitor of PPCE: Z-Gly-ProCHN2.	N-benzyloxycarbonylglycyl-proline diazomethyl ketone	40-53	prolyl endopeptidase	Homo sapiens	34-38
3544718-2	1986	However, post proline cleaving enzyme (PPCE; EC 3.4.21.26), a proline specific endopeptidase which specifically hydrolyzes internal peptide bonds on the carboxyl side of proline residues, has been shown to inactivate numerous vasoactive peptides including angiotensins, kinins, substance P, vasopressin and oxytocin.	Proline	14-21	prolyl endopeptidase	Homo sapiens	39-43
3544718-2	1986	However, post proline cleaving enzyme (PPCE; EC 3.4.21.26), a proline specific endopeptidase which specifically hydrolyzes internal peptide bonds on the carboxyl side of proline residues, has been shown to inactivate numerous vasoactive peptides including angiotensins, kinins, substance P, vasopressin and oxytocin.	Proline	62-69	prolyl endopeptidase	Homo sapiens	9-37
3544718-2	1986	However, post proline cleaving enzyme (PPCE; EC 3.4.21.26), a proline specific endopeptidase which specifically hydrolyzes internal peptide bonds on the carboxyl side of proline residues, has been shown to inactivate numerous vasoactive peptides including angiotensins, kinins, substance P, vasopressin and oxytocin.	Proline	62-69	prolyl endopeptidase	Homo sapiens	39-43
3544718-4	1986	PPCE was assayed fluorometrically at pH 7.0 using the specific PPCE substrate CBZ-Gly-Pro-4-methyl-coumarinylamide.	cbz-gly-pro-4-methyl-coumarinylamide	78-114	prolyl endopeptidase	Homo sapiens	0-4
3544718-4	1986	PPCE was assayed fluorometrically at pH 7.0 using the specific PPCE substrate CBZ-Gly-Pro-4-methyl-coumarinylamide.	cbz-gly-pro-4-methyl-coumarinylamide	78-114	prolyl endopeptidase	Homo sapiens	63-67
3544718-7	1986	Similar to PPCE characterized from other sites, vascular PPCE was stabilized and activated by dithiothreitol and EDTA, and inhibited by DFP, p-chloromercuriphenyl sulfonic acid, L-1-tosylamido-2-phenylethylchloromethyl ketone, Cu++, Ca++, and Zn++.	Dithiothreitol	94-108	prolyl endopeptidase	Homo sapiens	11-15
3544718-7	1986	Similar to PPCE characterized from other sites, vascular PPCE was stabilized and activated by dithiothreitol and EDTA, and inhibited by DFP, p-chloromercuriphenyl sulfonic acid, L-1-tosylamido-2-phenylethylchloromethyl ketone, Cu++, Ca++, and Zn++.	Dithiothreitol	94-108	prolyl endopeptidase	Homo sapiens	57-61
3544718-7	1986	Similar to PPCE characterized from other sites, vascular PPCE was stabilized and activated by dithiothreitol and EDTA, and inhibited by DFP, p-chloromercuriphenyl sulfonic acid, L-1-tosylamido-2-phenylethylchloromethyl ketone, Cu++, Ca++, and Zn++.	Edetic Acid	113-117	prolyl endopeptidase	Homo sapiens	57-61
3544718-7	1986	Similar to PPCE characterized from other sites, vascular PPCE was stabilized and activated by dithiothreitol and EDTA, and inhibited by DFP, p-chloromercuriphenyl sulfonic acid, L-1-tosylamido-2-phenylethylchloromethyl ketone, Cu++, Ca++, and Zn++.	Isoflurophate	136-139	prolyl endopeptidase	Homo sapiens	11-15
3544718-7	1986	Similar to PPCE characterized from other sites, vascular PPCE was stabilized and activated by dithiothreitol and EDTA, and inhibited by DFP, p-chloromercuriphenyl sulfonic acid, L-1-tosylamido-2-phenylethylchloromethyl ketone, Cu++, Ca++, and Zn++.	Isoflurophate	136-139	prolyl endopeptidase	Homo sapiens	57-61
3544718-7	1986	Similar to PPCE characterized from other sites, vascular PPCE was stabilized and activated by dithiothreitol and EDTA, and inhibited by DFP, p-chloromercuriphenyl sulfonic acid, L-1-tosylamido-2-phenylethylchloromethyl ketone, Cu++, Ca++, and Zn++.	p-chloromercuriphenyl sulfonic acid	141-176	prolyl endopeptidase	Homo sapiens	57-61
3544718-7	1986	Similar to PPCE characterized from other sites, vascular PPCE was stabilized and activated by dithiothreitol and EDTA, and inhibited by DFP, p-chloromercuriphenyl sulfonic acid, L-1-tosylamido-2-phenylethylchloromethyl ketone, Cu++, Ca++, and Zn++.	Tosylphenylalanyl Chloromethyl Ketone	178-225	prolyl endopeptidase	Homo sapiens	11-15
3544718-7	1986	Similar to PPCE characterized from other sites, vascular PPCE was stabilized and activated by dithiothreitol and EDTA, and inhibited by DFP, p-chloromercuriphenyl sulfonic acid, L-1-tosylamido-2-phenylethylchloromethyl ketone, Cu++, Ca++, and Zn++.	Tosylphenylalanyl Chloromethyl Ketone	178-225	prolyl endopeptidase	Homo sapiens	57-61
3544718-7	1986	Similar to PPCE characterized from other sites, vascular PPCE was stabilized and activated by dithiothreitol and EDTA, and inhibited by DFP, p-chloromercuriphenyl sulfonic acid, L-1-tosylamido-2-phenylethylchloromethyl ketone, Cu++, Ca++, and Zn++.	Copper	227-231	prolyl endopeptidase	Homo sapiens	11-15
3544718-7	1986	Similar to PPCE characterized from other sites, vascular PPCE was stabilized and activated by dithiothreitol and EDTA, and inhibited by DFP, p-chloromercuriphenyl sulfonic acid, L-1-tosylamido-2-phenylethylchloromethyl ketone, Cu++, Ca++, and Zn++.	Copper	227-231	prolyl endopeptidase	Homo sapiens	57-61
3544718-7	1986	Similar to PPCE characterized from other sites, vascular PPCE was stabilized and activated by dithiothreitol and EDTA, and inhibited by DFP, p-chloromercuriphenyl sulfonic acid, L-1-tosylamido-2-phenylethylchloromethyl ketone, Cu++, Ca++, and Zn++.	Zinc	243-247	prolyl endopeptidase	Homo sapiens	11-15
3544718-7	1986	Similar to PPCE characterized from other sites, vascular PPCE was stabilized and activated by dithiothreitol and EDTA, and inhibited by DFP, p-chloromercuriphenyl sulfonic acid, L-1-tosylamido-2-phenylethylchloromethyl ketone, Cu++, Ca++, and Zn++.	Zinc	243-247	prolyl endopeptidase	Homo sapiens	57-61
6433837-7	1984	Therefore, the inotropic effect of PEP imposes a high metabolic demand and is associated with increased myocardial noradrenaline secretion.	Norepinephrine	115-128	prolyl endopeptidase	Homo sapiens	35-38
6662115-5	1983	When the two hypertensive groups were compared with each other the HP group showed a shortened LVET and a prolonged PEP (P less than 0.01), and also a slower heart rate (HP 74 +/- 3 b min-1.	histidylproline	67-69	prolyl endopeptidase	Homo sapiens	116-119
7201494-8	1981	In patients with HCM, ET and delta ET were unchanged, but PEP and delta PEP prolonged at 10 and 15 min after verapamil administration.	Verapamil	109-118	prolyl endopeptidase	Homo sapiens	72-75
7028730-1	1981	A post-proline cleaving enzyme [post-proline endopeptidase: EC 3.4.21.26] was purified from lamb brain by a series of column chromatographies on DEAE-Sephadex, hydroxyapatite and Sephadex G-150.	DEAE-Dextran	145-158	prolyl endopeptidase	Homo sapiens	2-30
7028730-1	1981	A post-proline cleaving enzyme [post-proline endopeptidase: EC 3.4.21.26] was purified from lamb brain by a series of column chromatographies on DEAE-Sephadex, hydroxyapatite and Sephadex G-150.	Durapatite	160-174	prolyl endopeptidase	Homo sapiens	2-30
7028730-1	1981	A post-proline cleaving enzyme [post-proline endopeptidase: EC 3.4.21.26] was purified from lamb brain by a series of column chromatographies on DEAE-Sephadex, hydroxyapatite and Sephadex G-150.	sephadex	179-193	prolyl endopeptidase	Homo sapiens	2-30
943990-5	1976	However, halothane caused significantly more myocardial depression than enflurane, as indicated by a larger preejection period (PEP) and preejection period/left ventricular ejection time (PEP/LVET) and a smaller 1/PEP2 and ejection fraction.	Halothane	9-18	prolyl endopeptidase	Homo sapiens	188-191
7009773-5	1981	Prolyl endopeptidase was determined with N-benzyloxycarbonyl-glycyl-L-prolyl-sulfamethoxazole as the substrate.	-l-prolyl-sulfamethoxazole	67-93	prolyl endopeptidase	Homo sapiens	0-20
476124-2	1979	Synthesis and application of the first fluorogenic substrate, N-carbobenzoxyglycylprolyl-4-methylcoumarinyl amide (Z-Gly-Pro-MeCouNH) for the determination of the post-proline cleaving enzyme (EC 3.4.21.-) were reported.	N-carbobenzoxyglycyl-prolyl-4-methylcoumarinyl amide	62-113	prolyl endopeptidase	Homo sapiens	163-191
476124-2	1979	Synthesis and application of the first fluorogenic substrate, N-carbobenzoxyglycylprolyl-4-methylcoumarinyl amide (Z-Gly-Pro-MeCouNH) for the determination of the post-proline cleaving enzyme (EC 3.4.21.-) were reported.	z-gly-pro-mecounh	115-132	prolyl endopeptidase	Homo sapiens	163-191
476124-4	1979	This substrate showed a higher affinity (Km = 0.02 mM) for the enzyme than the proline containing substrates studied previously and allowed the detection of 10-50 ng post-proline cleaving enzyme activity per ml sample after a 1 min incubation period.	Proline	79-86	prolyl endopeptidase	Homo sapiens	166-194
476124-5	1979	Distribution of post-proline cleaving enzyme and other proline specific peptidases in rat tissues was studied using Z-Gly-Pro-MeCouNH and other proline-containing substrates.	z-gly-pro-mecounh	116-133	prolyl endopeptidase	Homo sapiens	16-44
476124-7	1979	Inhibition experiments indicated that post-proline cleaving enzyme activity was completely inactivated by 0.1 mM diisopropylphosphofluoridate and Z-Gly-Pro-chloromethylketone, as had been found in the case of the enzyme isolated from lamb kidney.	Isoflurophate	113-141	prolyl endopeptidase	Homo sapiens	38-66
476124-7	1979	Inhibition experiments indicated that post-proline cleaving enzyme activity was completely inactivated by 0.1 mM diisopropylphosphofluoridate and Z-Gly-Pro-chloromethylketone, as had been found in the case of the enzyme isolated from lamb kidney.	z-gly-pro-chloromethylketone	146-174	prolyl endopeptidase	Homo sapiens	38-66
476124-8	1979	Activity in human body fluids was also tested for levels of post-proline cleaving enzyme activity using Z-Gly-Pro-MeCouNH and semen was found to show the highest cleaving activity.	z-gly-pro-mecounh	104-121	prolyl endopeptidase	Homo sapiens	60-88
943990-5	1976	However, halothane caused significantly more myocardial depression than enflurane, as indicated by a larger preejection period (PEP) and preejection period/left ventricular ejection time (PEP/LVET) and a smaller 1/PEP2 and ejection fraction.	Halothane	9-18	prolyl endopeptidase	Homo sapiens	128-131
12173-7	1976	Dipeptides with the structure Z-Pro-LD-X competitively inhibit post-proline cleaving enzyme.	Dipeptides	0-10	prolyl endopeptidase	Homo sapiens	63-91
943990-6	1976	When N2O was discontinued, both agents increased PEP and PEP/LVET and decreased 1/PEP2 and the ejection fraction.	Nitrous Oxide	5-8	prolyl endopeptidase	Homo sapiens	49-52
943990-6	1976	When N2O was discontinued, both agents increased PEP and PEP/LVET and decreased 1/PEP2 and the ejection fraction.	Nitrous Oxide	5-8	prolyl endopeptidase	Homo sapiens	57-81
33878557-4	2021	Characterisation of the peptides in treated beer showed that prolyl-endopeptidase activity was not complete with many peptides containing (multiple) internal proline-residues.	Peptides	24-32	prolyl endopeptidase	Homo sapiens	61-81
2300-4	1976	The enzyme releasing glycinamide from oxytocin and the "Post-Proline Cleaving Enzyme", which releases C-terminal dipeptide from oxytocin and arginine vasopressin, were partially purified from lamb kidney by ammonium sulfate fractionation and column chromatography.	Dipeptides	113-122	prolyl endopeptidase	Homo sapiens	56-85
2300-4	1976	The enzyme releasing glycinamide from oxytocin and the "Post-Proline Cleaving Enzyme", which releases C-terminal dipeptide from oxytocin and arginine vasopressin, were partially purified from lamb kidney by ammonium sulfate fractionation and column chromatography.	Ammonium Sulfate	207-223	prolyl endopeptidase	Homo sapiens	56-85
33878557-4	2021	Characterisation of the peptides in treated beer showed that prolyl-endopeptidase activity was not complete with many peptides containing (multiple) internal proline-residues.	Proline	158-165	prolyl endopeptidase	Homo sapiens	61-81
34006161-5	2021	Sixty-nine (n = 69) MSM with increased risk for HIV received PrEP with oral tenofovir disproxil fumarate /emtricitabine and acquisition were followed for a mean of 566.6 days.	tenofovir disproxil fumarate	76-104	prolyl endopeptidase	Homo sapiens	61-65
33838285-3	2021	Prolyl oligopeptidase (PREP) is a serine protease that is linked to neurodegeneration, as endogenous PREP inhibits autophagy and induces the accumulation of detrimental protein aggregates.	Serine	34-40	prolyl endopeptidase	Homo sapiens	0-21
33838285-3	2021	Prolyl oligopeptidase (PREP) is a serine protease that is linked to neurodegeneration, as endogenous PREP inhibits autophagy and induces the accumulation of detrimental protein aggregates.	Serine	34-40	prolyl endopeptidase	Homo sapiens	23-27
33838285-3	2021	Prolyl oligopeptidase (PREP) is a serine protease that is linked to neurodegeneration, as endogenous PREP inhibits autophagy and induces the accumulation of detrimental protein aggregates.	Serine	34-40	prolyl endopeptidase	Homo sapiens	101-105
33838285-5	2021	In addition, PREP inhibition has been shown to reduce production of reactive oxygen species (ROS) and the absence of PREP blocks stress-induced ROS production.	Reactive Oxygen Species	68-91	prolyl endopeptidase	Homo sapiens	13-17
33838285-5	2021	In addition, PREP inhibition has been shown to reduce production of reactive oxygen species (ROS) and the absence of PREP blocks stress-induced ROS production.	Reactive Oxygen Species	93-96	prolyl endopeptidase	Homo sapiens	13-17
33838285-5	2021	In addition, PREP inhibition has been shown to reduce production of reactive oxygen species (ROS) and the absence of PREP blocks stress-induced ROS production.	Reactive Oxygen Species	144-147	prolyl endopeptidase	Homo sapiens	117-121
33838285-6	2021	However, the mechanism behind PREP-related ROS regulation is not known.	Reactive Oxygen Species	43-46	prolyl endopeptidase	Homo sapiens	30-34
33838285-8	2021	We studied the impact of a PREP inhibitor, KYP-2047, on hydrogen peroxide and ferrous chloride induced ROS production and on cellular antioxidant response in HEK-293 and SH-SY5Y cells.	3-hydroxy-2-({4-[4-(pyrimidin-2-yl)piperazine-1-carbonyl]phenyl}methyl)-1-benzofuran-7-carboxamide	43-46	prolyl endopeptidase	Homo sapiens	27-31
33838285-8	2021	We studied the impact of a PREP inhibitor, KYP-2047, on hydrogen peroxide and ferrous chloride induced ROS production and on cellular antioxidant response in HEK-293 and SH-SY5Y cells.	Hydrogen Peroxide	56-73	prolyl endopeptidase	Homo sapiens	27-31
33838285-8	2021	We studied the impact of a PREP inhibitor, KYP-2047, on hydrogen peroxide and ferrous chloride induced ROS production and on cellular antioxidant response in HEK-293 and SH-SY5Y cells.	ferrous chloride	78-94	prolyl endopeptidase	Homo sapiens	27-31
33838285-9	2021	In addition, we used HEK-293 and SH-SY5Y PREP knock-out cells to validate the role of PREP on stress-induced ROS production.	Reactive Oxygen Species	109-112	prolyl endopeptidase	Homo sapiens	86-90
33838285-10	2021	We were able to show that absence of PREP almost entirely blocks the stress-induced ROS production in both cell lines.	Reactive Oxygen Species	84-87	prolyl endopeptidase	Homo sapiens	37-41
33838285-11	2021	Reduced ROS production and smaller antioxidant response was also seen in both cell lines after PREP inhibition by 10 muM KYP-2047.	4-phenylbutanoyl-prolylcyanopyrrolidine	121-129	prolyl endopeptidase	Homo sapiens	95-99
33838285-12	2021	Our results also revealed that the OS reducing mechanism of PREP inhibition is related to reduced activation of ROS producing NADPH oxidase through enhanced PP2A activation.	Reactive Oxygen Species	112-115	prolyl endopeptidase	Homo sapiens	60-64
32713065-4	2021	We aimed to investigate whether statins and chronic ASA intake are associated with lower risk of PEP.	Aspirin	52-55	prolyl endopeptidase	Homo sapiens	97-100
32729019-0	2021	Marketing of Tenofovir Disoproxil Fumarate (TDF) Lawsuits and Social Media Misinformation Campaigns" Impact on PrEP Uptake Among Gender and Sexual Minority Individuals.	Tenofovir	13-42	prolyl endopeptidase	Homo sapiens	111-115
32729019-0	2021	Marketing of Tenofovir Disoproxil Fumarate (TDF) Lawsuits and Social Media Misinformation Campaigns" Impact on PrEP Uptake Among Gender and Sexual Minority Individuals.	Tenofovir	44-47	prolyl endopeptidase	Homo sapiens	111-115
32729019-1	2021	There has been an influx of ads on social media seeking plaintiffs in lawsuits for harms/side-effects caused by tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC, Truvada) for PrEP.	Tenofovir	112-141	prolyl endopeptidase	Homo sapiens	179-183
32729019-1	2021	There has been an influx of ads on social media seeking plaintiffs in lawsuits for harms/side-effects caused by tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC, Truvada) for PrEP.	Emtricitabine	142-155	prolyl endopeptidase	Homo sapiens	179-183
32729019-1	2021	There has been an influx of ads on social media seeking plaintiffs in lawsuits for harms/side-effects caused by tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC, Truvada) for PrEP.	tdf/ftc	157-164	prolyl endopeptidase	Homo sapiens	179-183
32729019-1	2021	There has been an influx of ads on social media seeking plaintiffs in lawsuits for harms/side-effects caused by tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC, Truvada) for PrEP.	Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination	166-173	prolyl endopeptidase	Homo sapiens	179-183
33842153-5	2021	PEP medications, in particular raltegravir, are known to have a common side effect of insomnia.	Raltegravir Potassium	31-42	prolyl endopeptidase	Homo sapiens	0-3
33476807-9	2021	All five completed RCTs focused on the use of HCQ as either PrEP or PEP and these and the cross-sectional studies reported no prophylactic effect.	Hydroxychloroquine	46-49	prolyl endopeptidase	Homo sapiens	60-64
33783339-9	2021	The availability of CBDP improved quality of PEP prescription and allowed for better data collection and reduction of PEP prescription.	2-(2-cresyl)-4H-1-3-2-benzodioxaphosphorin-2-oxide	20-24	prolyl endopeptidase	Homo sapiens	45-48
33783339-9	2021	The availability of CBDP improved quality of PEP prescription and allowed for better data collection and reduction of PEP prescription.	2-(2-cresyl)-4H-1-3-2-benzodioxaphosphorin-2-oxide	20-24	prolyl endopeptidase	Homo sapiens	118-121
33752741-2	2021	The primary objective of the COVID-19 Ring-based Prevention Trial with lopinavir/ritonavir (CORIPREV-LR) is to evaluate the efficacy of a 14-day course of oral lopinavir/ritonavir as PEP against COVID-19 among individuals with a high-risk exposure to a confirmed case.	lopinavir-ritonavir drug combination	71-90	prolyl endopeptidase	Homo sapiens	183-186
33752741-2	2021	The primary objective of the COVID-19 Ring-based Prevention Trial with lopinavir/ritonavir (CORIPREV-LR) is to evaluate the efficacy of a 14-day course of oral lopinavir/ritonavir as PEP against COVID-19 among individuals with a high-risk exposure to a confirmed case.	coriprev-lr	92-103	prolyl endopeptidase	Homo sapiens	183-186
33752741-2	2021	The primary objective of the COVID-19 Ring-based Prevention Trial with lopinavir/ritonavir (CORIPREV-LR) is to evaluate the efficacy of a 14-day course of oral lopinavir/ritonavir as PEP against COVID-19 among individuals with a high-risk exposure to a confirmed case.	lopinavir-ritonavir drug combination	160-179	prolyl endopeptidase	Homo sapiens	183-186
33752741-13	2021	DISCUSSION: Harnessing safe, existing drugs such as LPV/r as PEP could provide an important tool for control of the COVID-19 pandemic.	lopinavir-ritonavir drug combination	52-57	prolyl endopeptidase	Homo sapiens	61-64
33897801-8	2021	Next, molecular docking was performed to learn about the affinity of the filtered alkaloids with the POP.	Alkaloids	82-91	prolyl endopeptidase	Homo sapiens	101-104
33897801-10	2021	Our study identified metergoline, pipercallosine, celacinnine, lobeline, cystodytin G, lycoperine A, hookerianamide J, and martefragin A as putative lead compounds against POP.	Metergoline	21-32	prolyl endopeptidase	Homo sapiens	172-175
33897801-10	2021	Our study identified metergoline, pipercallosine, celacinnine, lobeline, cystodytin G, lycoperine A, hookerianamide J, and martefragin A as putative lead compounds against POP.	PIPERCALLOSINE	34-48	prolyl endopeptidase	Homo sapiens	172-175
33897801-10	2021	Our study identified metergoline, pipercallosine, celacinnine, lobeline, cystodytin G, lycoperine A, hookerianamide J, and martefragin A as putative lead compounds against POP.	celacinnine	50-61	prolyl endopeptidase	Homo sapiens	172-175
33897801-10	2021	Our study identified metergoline, pipercallosine, celacinnine, lobeline, cystodytin G, lycoperine A, hookerianamide J, and martefragin A as putative lead compounds against POP.	Lobeline	63-71	prolyl endopeptidase	Homo sapiens	172-175
33897801-10	2021	Our study identified metergoline, pipercallosine, celacinnine, lobeline, cystodytin G, lycoperine A, hookerianamide J, and martefragin A as putative lead compounds against POP.	cystodytin G	73-85	prolyl endopeptidase	Homo sapiens	172-175
33897801-10	2021	Our study identified metergoline, pipercallosine, celacinnine, lobeline, cystodytin G, lycoperine A, hookerianamide J, and martefragin A as putative lead compounds against POP.	lycoperine A	87-99	prolyl endopeptidase	Homo sapiens	172-175
33897801-10	2021	Our study identified metergoline, pipercallosine, celacinnine, lobeline, cystodytin G, lycoperine A, hookerianamide J, and martefragin A as putative lead compounds against POP.	HOOKERIANAMIDE J	101-117	prolyl endopeptidase	Homo sapiens	172-175
33897801-10	2021	Our study identified metergoline, pipercallosine, celacinnine, lobeline, cystodytin G, lycoperine A, hookerianamide J, and martefragin A as putative lead compounds against POP.	Martefragin A	123-136	prolyl endopeptidase	Homo sapiens	172-175
33842153-7	2021	The knowledge of these side effects of PEP medications, understanding its interactions with mood stabilizers like lithium and valproic acid is important when caring for these individuals.	Lithium	114-121	prolyl endopeptidase	Homo sapiens	39-42
33842153-7	2021	The knowledge of these side effects of PEP medications, understanding its interactions with mood stabilizers like lithium and valproic acid is important when caring for these individuals.	Valproic Acid	126-139	prolyl endopeptidase	Homo sapiens	39-42
33507010-0	2021	Differences in tenofovir trough concentrations between branded and generic formulations in people taking PrEP.	Tenofovir	15-24	prolyl endopeptidase	Homo sapiens	105-109
33108035-8	2021	In addition, the rankogram showed that EVG/c had the highest probability of being the best treatment for the lowest rates in PEP non-completion at day 28, switching, lost to follow-up or adverse events and MVC for PEP discontinuations due to adverse events.	elvitegravir	39-42	prolyl endopeptidase	Homo sapiens	125-128
33108035-8	2021	In addition, the rankogram showed that EVG/c had the highest probability of being the best treatment for the lowest rates in PEP non-completion at day 28, switching, lost to follow-up or adverse events and MVC for PEP discontinuations due to adverse events.	elvitegravir	39-42	prolyl endopeptidase	Homo sapiens	214-217
33148996-0	2021	Is long-acting injectable cabotegravir likely to expand PrEP coverage among MSM in the District of Columbia?	cabotegravir	26-38	prolyl endopeptidase	Homo sapiens	56-60
32653730-7	2020	A second enzyme OphP, a prolyl oligopeptidase cleaves the core peptide from OphMA and cyclizes it into omphalotin.	Peptides	63-70	prolyl endopeptidase	Homo sapiens	24-45
33563372-15	2021	EFA may be preferable for weaker patients and/or with airway leakages in whom PEP has limited indications.	efa	0-3	prolyl endopeptidase	Homo sapiens	78-81
33579026-1	2021	Prolyl oligopeptidase (PREP) is a serine protease that binds to alpha-synuclein (aSyn) and induces its aggregation.	Serine	34-40	prolyl endopeptidase	Homo sapiens	0-21
33579026-1	2021	Prolyl oligopeptidase (PREP) is a serine protease that binds to alpha-synuclein (aSyn) and induces its aggregation.	Serine	34-40	prolyl endopeptidase	Homo sapiens	23-27
33579026-2	2021	PREP inhibitors have been shown to have beneficial effects in Parkinson"s disease models by enhancing the clearance of aSyn aggregates and modulating striatal dopamine.	Dopamine	159-167	prolyl endopeptidase	Homo sapiens	0-4
33579026-6	2021	Our results confirmed our previous findings that a lack of PREP can increase phosphorylation and internalization of DAT and decrease uptake of dopamine.	Dopamine	143-151	prolyl endopeptidase	Homo sapiens	59-63
33560092-2	2021	We conducted a survey-based study to evaluate how community members and healthcare providers in Southern California would perceive doxycycline pre-exposure/post-exposure prophylaxis (PrEP/PEP) to predict its acceptability and identify potential areas of concern.	Doxycycline	131-142	prolyl endopeptidase	Homo sapiens	183-187
33560092-5	2021	RESULTS: Among 212 enrolled community member participants, 67.5% indicated they would take doxycycline PrEP/PEP if offered by their provider.	Doxycycline	91-102	prolyl endopeptidase	Homo sapiens	103-107
33560092-7	2021	For healthcare providers, 89.5% of 76 enrolled participants expressed willingness to prescribe doxycycline PrEP/PEP to their patients if recommended by the Centers for Disease Control and Prevention, but only 43.4% were willing if not.	Doxycycline	95-106	prolyl endopeptidase	Homo sapiens	107-111
33560092-9	2021	CONCLUSION: Doxycycline PrEP/PEP as a preventive strategy against chlamydial infections and syphilis would likely be accepted among community members and healthcare providers.	Doxycycline	12-23	prolyl endopeptidase	Homo sapiens	24-28
33171209-9	2021	In conclusion, LegH Prep from this P. pastoris production process is unlikely to pose a risk of food allergenicity.	legh	15-19	prolyl endopeptidase	Homo sapiens	20-24
33040554-2	2021	Several randomized controlled trials and meta-analyses have demonstrated the effectiveness of nonsteroidal anti-inflammatories (NSAIDs) such as diclofenac and indomethacin as a post-ERC pancreatitis (PEP) prophylaxis.	Diclofenac	144-154	prolyl endopeptidase	Homo sapiens	200-203
33040554-2	2021	Several randomized controlled trials and meta-analyses have demonstrated the effectiveness of nonsteroidal anti-inflammatories (NSAIDs) such as diclofenac and indomethacin as a post-ERC pancreatitis (PEP) prophylaxis.	Indomethacin	159-171	prolyl endopeptidase	Homo sapiens	200-203
33040554-3	2021	The aim is to determine if the rectal diclofenac use reduces the PEP rate.	Diclofenac	38-48	prolyl endopeptidase	Homo sapiens	65-68
33040554-6	2021	Two groups were analyzed: group A (without diclofenac use) and group B (with use of diclofenac as PEP prophylaxis).	Diclofenac	84-94	prolyl endopeptidase	Homo sapiens	98-101
33427376-1	2021	Acylpeptide hydrolase is a serine protease which, together with prolyl oligopeptidase, dipeptidyl peptidase IV and oligopeptidase B belongs to the prolyl oligopeptidase family.	Serine	27-33	prolyl endopeptidase	Homo sapiens	64-85
33427376-1	2021	Acylpeptide hydrolase is a serine protease which, together with prolyl oligopeptidase, dipeptidyl peptidase IV and oligopeptidase B belongs to the prolyl oligopeptidase family.	Serine	27-33	prolyl endopeptidase	Homo sapiens	147-168
33444486-1	2021	BACKGROUND AND AIMS: Rectal indomethacin and pancreatic duct (PD) stenting (PDS) are recommended for the prevention of post-ERCP pancreatitis (PEP).	Indomethacin	28-40	prolyl endopeptidase	Homo sapiens	143-146
33444486-13	2021	CONCLUSIONS: The current study indicated that the combined prevention of PEP with indomethacin plus PDS was useful in PEP prevention in patients undergoing DGT.	Indomethacin	82-94	prolyl endopeptidase	Homo sapiens	118-121
33413241-8	2021	MSM (adjusted odds: 2.88; 95% CI: 1.59-5.3) and those who used alcohol during sexual intercourse (adjusted odds: 1.7; 95% CI: 1.0-2.8) were more likely to know about the PEP.	Alcohols	63-70	prolyl endopeptidase	Homo sapiens	170-173
32666773-9	2021	After adjusting for age, sex, total bilirubin levels, and any stent placement, patients with a positive IOC had a significantly increased risk of PEP (odds ratio, 4.79; 95% confidence interval, 1.05-21.89; p<0.05).	Bilirubin	36-45	prolyl endopeptidase	Homo sapiens	146-149
32711365-3	2020	The nanocomposite polypeptide doped PEDOT (PEDOT/PEP), with a 3D microporous network structure, large surface area and excellent antifouling ability, was utilized for the attachment of BRCA1 complementary oligonucleotides to construct a DNA biosensor.	Oligonucleotides	205-221	prolyl endopeptidase	Homo sapiens	43-52
32653730-7	2020	A second enzyme OphP, a prolyl oligopeptidase cleaves the core peptide from OphMA and cyclizes it into omphalotin.	OMPHALOTIN A	103-113	prolyl endopeptidase	Homo sapiens	24-45
33152946-0	2020	Prolyl oligopeptidase inhibition by KYP-2407 increases alpha-synuclein fibril degradation in neuron-like cells.	kyp-2407	36-44	prolyl endopeptidase	Homo sapiens	0-21
33188441-4	2020	Sublingual nitrate may provide additional benefit to rectal NSAIDs in preventing PEP.	Nitrates	11-18	prolyl endopeptidase	Homo sapiens	81-84
33188441-5	2020	A tacrolimus trough > 2.5 ng/mL was recently shown to be associated with a lower risk of PEP in liver transplant patients undergoing ERCP.	Tacrolimus	2-12	prolyl endopeptidase	Homo sapiens	89-92
33188441-6	2020	Routine usage of rectal indomethacin in all patients undergoing ERCP reduces the risk of PEP.	Indomethacin	24-36	prolyl endopeptidase	Homo sapiens	89-92
33188441-8	2020	There is emerging data that aggressive hydration with lactated Ringer"s and nitrates may further reduce PEP.	Nitrates	76-84	prolyl endopeptidase	Homo sapiens	104-107
33188441-9	2020	Tacrolimus is a promising potential agent to prevent PEP but needs further clinical study.	Tacrolimus	0-10	prolyl endopeptidase	Homo sapiens	53-56
33166694-4	2020	Hydroxychloroquine (HCQ) has been tried against COVID-19 owing to its in vitro virucidal action against SARS-CoV-2, but the role of HCQ as post-exposure prophylaxis (PEP) remains inconclusive.	Hydroxychloroquine	20-23	prolyl endopeptidase	Homo sapiens	166-169
33166694-6	2020	The PEP group received HCQ 800 mg on Day 1 followed by 400 mg once weekly for 3 weeks.	Hydroxychloroquine	23-26	prolyl endopeptidase	Homo sapiens	4-7
33166694-14	2020	PEP with HCQ has the potential for the prevention of COVID-19 in at-risk individuals.	Hydroxychloroquine	9-12	prolyl endopeptidase	Homo sapiens	0-3
32787892-5	2020	METHODS: The PREP-IT program comprises two ongoing pragmatic cluster randomized crossover trials (Aqueous-PREP and PREPARE) which compare the effect of iodophor versus chlorhexidine solutions on surgical site infection and unplanned fracture-related reoperations in patients undergoing operative fracture management.	Iodophors	152-160	prolyl endopeptidase	Homo sapiens	13-17
32688201-0	2020	Discovery of novel berberine derivatives with balanced cholinesterase and prolyl oligopeptidase inhibition profile.	Berberine	19-28	prolyl endopeptidase	Homo sapiens	74-95
32830824-6	2020	METHODS: In this retrospective study, we targeted 282 patients without past history of abdominal surgery and who underwent initial ERCP and insertion of prophylactic PS to prevent PEP between January 2007 and April 2019.	ps	166-168	prolyl endopeptidase	Homo sapiens	180-183
32854751-3	2020	This provided a unique opportunity to study the effectiveness of hydroxychloroquine (HCQ) for post-exposure prophylaxis (PEP), while taking stringent, non-pharmacologic, public health measures to prevent spread.	Hydroxychloroquine	65-83	prolyl endopeptidase	Homo sapiens	121-124
32854751-3	2020	This provided a unique opportunity to study the effectiveness of hydroxychloroquine (HCQ) for post-exposure prophylaxis (PEP), while taking stringent, non-pharmacologic, public health measures to prevent spread.	Hydroxychloroquine	85-88	prolyl endopeptidase	Homo sapiens	121-124
32854751-4	2020	Our aim is to study the effectiveness and safety of HCQ for PEP among naval personnel with exposure to COVID-19-positive patients.	Hydroxychloroquine	52-55	prolyl endopeptidase	Homo sapiens	60-63
32854751-7	2020	DISCUSSION: This trial will provide high-quality evidence of the effectiveness and safety of HCQ as PEP for COVID-19.	Hydroxychloroquine	93-96	prolyl endopeptidase	Homo sapiens	100-103
32766890-1	2021	BACKGROUND: Pilot studies showed lower tenofovir plasma concentrations during PrEP use among transgender women (TGW) using feminizing hormones compared with cisgender men (CGM).	Tenofovir	39-48	prolyl endopeptidase	Homo sapiens	78-82
32766890-2	2021	Tenofovir diphosphate (TFV-DP) concentrations in TGW and transgender men (TGM) using gender affirming hormones and on directly observed dosing of PrEP have not been studied.	tenofovir diphosphate	0-21	prolyl endopeptidase	Homo sapiens	146-150
32447211-2	2020	Our earlier results have revealed that the potent small molecular PREP inhibitor KYP-2047 is able to increase autophagy and decrease dimerization of alphaSyn but other PREP inhibitors have not been systematically studied for these two protein-protein interaction mediated biological functions of PREP.	3-hydroxy-2-({4-[4-(pyrimidin-2-yl)piperazine-1-carbonyl]phenyl}methyl)-1-benzofuran-7-carboxamide	81-84	prolyl endopeptidase	Homo sapiens	66-70
32707451-7	2020	The biological efficacy of a single dose of FTC/TAF/EVG as PrEP or PEP was investigated using a repeat-challenge macaque model of rectal HIV infection.	elvitegravir	52-55	prolyl endopeptidase	Homo sapiens	59-63
32743060-13	2020	In subgroup analysis, topical epinephrine appeared to decrease risk of PEP in the absence of rectal indomethacin, and could be considered when rectal indomethacin is unavailable or if there is a contraindication to its use.	Epinephrine	30-41	prolyl endopeptidase	Homo sapiens	71-74
32707451-7	2020	The biological efficacy of a single dose of FTC/TAF/EVG as PrEP or PEP was investigated using a repeat-challenge macaque model of rectal HIV infection.	ftc/taf	44-51	prolyl endopeptidase	Homo sapiens	59-63
32707451-7	2020	The biological efficacy of a single dose of FTC/TAF/EVG as PrEP or PEP was investigated using a repeat-challenge macaque model of rectal HIV infection.	ftc/taf	44-51	prolyl endopeptidase	Homo sapiens	67-70
32743060-3	2020	Topical epinephrine has shown mixed results and is still not widely accepted as an alternative for prevention of PEP.	Epinephrine	8-19	prolyl endopeptidase	Homo sapiens	113-116
32743060-4	2020	We performed a systematic review and meta-analysis to evaluate the efficacy of topical epinephrine in preventing PEP.	Epinephrine	87-98	prolyl endopeptidase	Homo sapiens	113-116
32743060-5	2020	Methods  A comprehensive literature review was conducted by searching Cochrane library database, Embase and PubMed up to August 2019, to identify all studies that evaluated use of topical epinephrine alone or in conjunction with other agents for prevention of PEP.	Epinephrine	188-199	prolyl endopeptidase	Homo sapiens	260-263
32743060-6	2020	Outcomes included prevention of PEP with use of topical epinephrine and evaluation of whether addiing epinephrine provides any additional benefit in preventing PEP.	Epinephrine	102-113	prolyl endopeptidase	Homo sapiens	160-163
32743060-10	2020	However, on a subgroup analysis, topical epinephrine significantly decreases the risk of PEP when compared to placebo alone (means no intervention was done including no rectal indomethacin)., RR = 0.32 (0.18-0.57).	Epinephrine	41-52	prolyl endopeptidase	Homo sapiens	89-92
32728930-2	2020	In 2014, a most potent FAP-inhibitor (referred to as UAMC1110) with low nanomolar FAP-affinity and high selectivity toward related enzymes such as prolyl oligopeptidase (PREP) and the dipeptidyl-peptidases (DPPs): DPP4, DPP8/9 and DPP2 were developed.	uamc1110	53-61	prolyl endopeptidase	Homo sapiens	147-168
32728930-2	2020	In 2014, a most potent FAP-inhibitor (referred to as UAMC1110) with low nanomolar FAP-affinity and high selectivity toward related enzymes such as prolyl oligopeptidase (PREP) and the dipeptidyl-peptidases (DPPs): DPP4, DPP8/9 and DPP2 were developed.	uamc1110	53-61	prolyl endopeptidase	Homo sapiens	170-174
32787892-5	2020	METHODS: The PREP-IT program comprises two ongoing pragmatic cluster randomized crossover trials (Aqueous-PREP and PREPARE) which compare the effect of iodophor versus chlorhexidine solutions on surgical site infection and unplanned fracture-related reoperations in patients undergoing operative fracture management.	Chlorhexidine	168-181	prolyl endopeptidase	Homo sapiens	13-17
32592669-0	2020	Cabotegravir, a new option for PrEP.	cabotegravir	0-12	prolyl endopeptidase	Homo sapiens	31-35
32624662-1	2020	Background: Evidence shows that rectal indomethacin (RI) reduces the risk of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) in high-risk patients.	Indomethacin	39-51	prolyl endopeptidase	Homo sapiens	150-153
32624662-1	2020	Background: Evidence shows that rectal indomethacin (RI) reduces the risk of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) in high-risk patients.	placental ribonuclease inhibitor	53-55	prolyl endopeptidase	Homo sapiens	150-153
32624663-3	2020	This study investigated the difference in the incidence of PEP between intramuscular and rectal prophylactic administration of diclofenac before ERCP.	Diclofenac	127-137	prolyl endopeptidase	Homo sapiens	59-62
32539288-1	2020	BACKGROUND: Tenofovir alafenamide (TAF), in combination with FTC, was recently approved for PrEP in the United States.	tenofovir alafenamide	12-33	prolyl endopeptidase	Homo sapiens	92-96
32539288-1	2020	BACKGROUND: Tenofovir alafenamide (TAF), in combination with FTC, was recently approved for PrEP in the United States.	tenofovir alafenamide	35-38	prolyl endopeptidase	Homo sapiens	92-96
32496740-1	2020	INTRODUCTION: The benefit of indomethacin suppositories for prophylaxis against post-ERCP pancreatitis (PEP) in high-risk patients was established in a landmark trial published in 2012.	Indomethacin	29-41	prolyl endopeptidase	Homo sapiens	104-107
32630529-0	2020	Prolyl Endopeptidase-Like Facilitates the alpha-Synuclein Aggregation Seeding, and This Effect Is Reverted by Serine Peptidase Inhibitor PMSF.	Serine	110-116	prolyl endopeptidase	Homo sapiens	0-20
32630529-0	2020	Prolyl Endopeptidase-Like Facilitates the alpha-Synuclein Aggregation Seeding, and This Effect Is Reverted by Serine Peptidase Inhibitor PMSF.	Phenylmethylsulfonyl Fluoride	137-141	prolyl endopeptidase	Homo sapiens	0-20
32630529-2	2020	alpha-Syn oligomerization/aggregation is accelerated by the serine peptidase, prolyl oligopeptidase (POP).	Serine	60-66	prolyl endopeptidase	Homo sapiens	78-99
32630529-2	2020	alpha-Syn oligomerization/aggregation is accelerated by the serine peptidase, prolyl oligopeptidase (POP).	Serine	60-66	prolyl endopeptidase	Homo sapiens	101-104
32630529-5	2020	Prolyl endopeptidase-like (PREPL) protein is structurally related to the serine peptidases belonging to the POP family.	Serine	73-79	prolyl endopeptidase	Homo sapiens	108-111
32474860-2	2020	On the basis of clinical practice and in-vitro studies, we postulated that post-exposure prophylaxis (PEP) using Arbidol is associated with decreased infection among individuals exposed to confirmed cases of COVID-19 infection.	umifenovir	113-120	prolyl endopeptidase	Homo sapiens	102-105
32474860-8	2020	The Cox regression based on the data of the family members and health care workers with Arbidol or not showed that Arbidol PEP was a protective factor against the development of COVID-19 (HR 0.025, 95% CI 0.003-0.209, P=0.0006 for family members and HR 0.056, 95% CI 0.005-0.662, P=0.0221 for health care workers).	umifenovir	88-95	prolyl endopeptidase	Homo sapiens	123-126
32474860-8	2020	The Cox regression based on the data of the family members and health care workers with Arbidol or not showed that Arbidol PEP was a protective factor against the development of COVID-19 (HR 0.025, 95% CI 0.003-0.209, P=0.0006 for family members and HR 0.056, 95% CI 0.005-0.662, P=0.0221 for health care workers).	umifenovir	115-122	prolyl endopeptidase	Homo sapiens	123-126
32305587-4	2020	After a large COVID-19 exposure event in an LTCH in Korea, PEP using hydroxychloroquine (HCQ) was administered to 211 individuals, including 189 patients and 22 careworkers, whose baseline polymerase chain reaction (PCR) tests for COVID-19 were negative.	Hydroxychloroquine	69-87	prolyl endopeptidase	Homo sapiens	59-62
32305587-4	2020	After a large COVID-19 exposure event in an LTCH in Korea, PEP using hydroxychloroquine (HCQ) was administered to 211 individuals, including 189 patients and 22 careworkers, whose baseline polymerase chain reaction (PCR) tests for COVID-19 were negative.	Hydroxychloroquine	89-92	prolyl endopeptidase	Homo sapiens	59-62
32267374-1	2020	The aim was to analyze the acceptability of chemoprophylaxis with single-dose rifampicin (PEP) in contacts, index leprosy cases, and health professionals and related factors that can influence adherence.	Rifampin	78-88	prolyl endopeptidase	Homo sapiens	90-93
32347667-5	2020	As a result, RIDOH provided PEP to those involved in the event.	ridoh	13-18	prolyl endopeptidase	Homo sapiens	28-31
32528527-10	2020	In the absence of metabolic disturbances, 4-week PEP containing PI plus AZT + 3TC led to higher mitochondrial toxicity (-17.9 +- 25.8 decrease in mtDNA/nDNA levels) than PI plus TDF + FTC (which increased by 43.2 +- 24.3 units mtDNA/nDNA; p < 0.05 between groups).	Zidovudine	72-75	prolyl endopeptidase	Homo sapiens	49-52
32528527-10	2020	In the absence of metabolic disturbances, 4-week PEP containing PI plus AZT + 3TC led to higher mitochondrial toxicity (-17.9 +- 25.8 decrease in mtDNA/nDNA levels) than PI plus TDF + FTC (which increased by 43.2 +- 24.3 units mtDNA/nDNA; p < 0.05 between groups).	Lamivudine	78-81	prolyl endopeptidase	Homo sapiens	49-52
32528527-12	2020	Conclusions: In absence of HIV infection, preventive short antiretroviral treatment can cause secondary effects responsible for treatment discontinuation and subclinical mitochondrial damage, especially pyrimidine analogs such as AZT, which still rank as the alternative option and first choice in certain cohorts for PEP.	Zidovudine	230-233	prolyl endopeptidase	Homo sapiens	318-321
32297517-5	2020	We redesigned Sphaerobacter thermophiles PEP with high-temperature activity/stability, a wide range of pH stabilities, and high proline specificity.	Proline	128-135	prolyl endopeptidase	Homo sapiens	41-44
32315321-1	2020	The proline-specific enzymes dipeptidyl peptidase 4 (DPP4), prolylcarboxypeptidase (PRCP), fibroblast activation protein alpha (FAP) and prolyl oligopeptidase (PREP) are known for their involvement in the immune system and blood pressure regulation.	Proline	4-11	prolyl endopeptidase	Homo sapiens	137-158
32315321-1	2020	The proline-specific enzymes dipeptidyl peptidase 4 (DPP4), prolylcarboxypeptidase (PRCP), fibroblast activation protein alpha (FAP) and prolyl oligopeptidase (PREP) are known for their involvement in the immune system and blood pressure regulation.	Proline	4-11	prolyl endopeptidase	Homo sapiens	160-164
32292447-1	2020	Objective: To determine efficacy of diclofenac suppository in reducing post-ERCP pancreatitis (PEP) and identify risk factors for PEP.	Diclofenac	36-46	prolyl endopeptidase	Homo sapiens	95-98
32196495-7	2020	We demonstrate a computational approach to the discovery of Substrate Selective Inhibitors for one enzyme, Prolyl Oligopeptidase (POP) (E.C 3.4.21.26), a serine protease which cleaves small peptides between Pro and other amino acids.	Serine	154-160	prolyl endopeptidase	Homo sapiens	107-128
32292447-6	2020	Among 82 (49.7%) patients in diclofenac group, 8 (9.7%) developed pancreatitis while 19(22.9%) of 83(50.3%) in placebo group had PEP (p value 0.02).	Diclofenac	29-39	prolyl endopeptidase	Homo sapiens	129-132
31732257-0	2020	Discovery of covalent prolyl oligopeptidase boronic ester inhibitors.	Boronic Acids	44-57	prolyl endopeptidase	Homo sapiens	22-43
32077867-1	2020	BACKGROUND: We conducted a systematic review and meta-analysis (CRD#42017070552) to quantify the impact of oral TDF/FTC on bone mineral density (BMD), and the risk of osteoporosis, low bone mass, and fractures, among people taking it as PrEP, HIV treatment and hepatitis B (HBV) treatment.	(trifluoromethyl)phenyldiazirinylfenpyroximate	112-115	prolyl endopeptidase	Homo sapiens	237-241
32077867-5	2020	TDF was associated with greater BMD decline when taken as PrEP (lumbar spine: mean difference, MD=-0.82%, 95%CI=-1.28,-0.37%, I2=38%; total hip: MD=-0.81%, 95%CI=-1.22,-0.40%, I2=48%) and HIV treatment (lumbar spine: MD=-1.62%, 95%CI=-2.30,-0.95%, I2=93%; total hip: MD=-1.75%, 95%CI=-2.08,-1.42%, I2=83%; femoral neck: MD=-1.26%, 95%CI=-2.15,-0.38%, I2=43%) in comparison to those not taking TDF.	(trifluoromethyl)phenyldiazirinylfenpyroximate	0-3	prolyl endopeptidase	Homo sapiens	58-62
32077867-10	2020	The clinically-significant BMD decline caused by TDF and current expansion of PrEP use suggest attention to the adverse bone effects of TDF will increase in importance.	(trifluoromethyl)phenyldiazirinylfenpyroximate	136-139	prolyl endopeptidase	Homo sapiens	78-82
31732257-1	2020	Over the past decade, many drug discovery endeavors have been invested in targeting the serine proteases prolyl oligopeptidase (POP) for the treatment of Alzheimer"s and Parkinson"s disease and, more recently, epithelial cancers.	cholecystokinin C-terminal flanking peptide	88-94	prolyl endopeptidase	Homo sapiens	105-126
31732257-1	2020	Over the past decade, many drug discovery endeavors have been invested in targeting the serine proteases prolyl oligopeptidase (POP) for the treatment of Alzheimer"s and Parkinson"s disease and, more recently, epithelial cancers.	cholecystokinin C-terminal flanking peptide	88-94	prolyl endopeptidase	Homo sapiens	128-131
31732257-4	2020	Herein we report a series of computationally-designed POP boronic ester pro-drug inhibitors exhibiting nanomolar-potencies in vitro as their active boronic acid species.	Boronic Acids	58-71	prolyl endopeptidase	Homo sapiens	54-57
31732257-4	2020	Herein we report a series of computationally-designed POP boronic ester pro-drug inhibitors exhibiting nanomolar-potencies in vitro as their active boronic acid species.	Boronic Acids	148-160	prolyl endopeptidase	Homo sapiens	54-57
31565846-0	2019	Prolyl oligopeptidase inhibition reduces PolyQ aggregation and improves cell viability in cellular model of Huntington"s disease.	polyglutamine	41-46	prolyl endopeptidase	Homo sapiens	0-21
31759088-1	2020	Prolyl oligopeptidase (PREP) is a serine protease that has been studied particularly in the context of neurodegenerative diseases for decades but its physiological function has remained unclear.	cholecystokinin C-terminal flanking peptide	34-40	prolyl endopeptidase	Homo sapiens	0-21
31759088-1	2020	Prolyl oligopeptidase (PREP) is a serine protease that has been studied particularly in the context of neurodegenerative diseases for decades but its physiological function has remained unclear.	cholecystokinin C-terminal flanking peptide	34-40	prolyl endopeptidase	Homo sapiens	23-27
31627809-1	2019	In this paper, a novel and sensitive ratiometric fluorescence strategy for the detection of epinephrine (EP) and ascorbic acid (AA) was established based on the fluorescence resonance energy transfer (FRET) between the molybdenum disulfide quantum dots (MQDs) and the fluorescent oxidative polymerization product (PEP-PEI) of EP in polyethyleneimine (PEI) aqueous solution.	Epinephrine	92-103	prolyl endopeptidase	Homo sapiens	314-317
31627809-1	2019	In this paper, a novel and sensitive ratiometric fluorescence strategy for the detection of epinephrine (EP) and ascorbic acid (AA) was established based on the fluorescence resonance energy transfer (FRET) between the molybdenum disulfide quantum dots (MQDs) and the fluorescent oxidative polymerization product (PEP-PEI) of EP in polyethyleneimine (PEI) aqueous solution.	Ascorbic Acid	113-126	prolyl endopeptidase	Homo sapiens	314-317
31805862-3	2019	Post-exposure prophylaxis (PEP) with a single dose of Rifampicin (SDR) has conditionally been recommended by the World Health Organization (WHO), based on a randomized-controlled-trial in Bangladesh.	Rifampin	54-64	prolyl endopeptidase	Homo sapiens	27-30
31855323-4	2019	We hypothesize that providing long-acting PrEP to women using injectable contraceptives, the most frequently used contraceptive method in South Africa, could improve adherence to PrEP, result in a reduction of new HIV infections, and be a relatively easy-to-reach target population.	Contraceptive Agents	73-87	prolyl endopeptidase	Homo sapiens	42-46
31855323-4	2019	We hypothesize that providing long-acting PrEP to women using injectable contraceptives, the most frequently used contraceptive method in South Africa, could improve adherence to PrEP, result in a reduction of new HIV infections, and be a relatively easy-to-reach target population.	Contraceptive Agents	73-87	prolyl endopeptidase	Homo sapiens	179-183
31398714-6	2019	We found that D-Asp upregulated the expression of prolyl endopeptidase (PREP), a serine protease having a pivotal role in the regulation of mammalian spermatogenesis and spermiogenesis.	D-Aspartic Acid	14-19	prolyl endopeptidase	Homo sapiens	50-70
31400851-3	2019	Benzyloxycarbonyl-proline-prolinal (ZPP) is known to suppress the PGP pathway via inhibition of prolyl endopeptidase (PE), the terminal enzyme in the generation of PGP from collagen.	benzyloxycarbonyl-proline-prolinal	0-34	prolyl endopeptidase	Homo sapiens	96-116
31400851-3	2019	Benzyloxycarbonyl-proline-prolinal (ZPP) is known to suppress the PGP pathway via inhibition of prolyl endopeptidase (PE), the terminal enzyme in the generation of PGP from collagen.	benzyloxycarbonyl-proline-prolinal	0-34	prolyl endopeptidase	Homo sapiens	118-120
31400851-3	2019	Benzyloxycarbonyl-proline-prolinal (ZPP) is known to suppress the PGP pathway via inhibition of prolyl endopeptidase (PE), the terminal enzyme in the generation of PGP from collagen.	zinc protoporphyrin	36-39	prolyl endopeptidase	Homo sapiens	96-116
31400851-3	2019	Benzyloxycarbonyl-proline-prolinal (ZPP) is known to suppress the PGP pathway via inhibition of prolyl endopeptidase (PE), the terminal enzyme in the generation of PGP from collagen.	zinc protoporphyrin	36-39	prolyl endopeptidase	Homo sapiens	118-120
31400851-5	2019	In this investigation, we confirm that ZPP inhibits PE in vitro, demonstrate that ZPP inhibits both ELR + CXC and PGP-mediated chemotaxis in human and murine neutrophils, abrogates neutrophil influx induced by murine intratracheal challenge with LPS, and attenuates human neutrophil chemotaxis to sputum samples of human subjects with cystic fibrosis.	zinc protoporphyrin	39-42	prolyl endopeptidase	Homo sapiens	52-54
31876520-4	2019	In the presence of PEP, dopamine (DP) and serotonin (Srt) are cleaved from the synthesized preparations.	Dopamine	24-32	prolyl endopeptidase	Homo sapiens	19-22
31876520-4	2019	In the presence of PEP, dopamine (DP) and serotonin (Srt) are cleaved from the synthesized preparations.	Dopamine	34-36	prolyl endopeptidase	Homo sapiens	19-22
31876520-4	2019	In the presence of PEP, dopamine (DP) and serotonin (Srt) are cleaved from the synthesized preparations.	Serotonin	42-51	prolyl endopeptidase	Homo sapiens	19-22
31876520-4	2019	In the presence of PEP, dopamine (DP) and serotonin (Srt) are cleaved from the synthesized preparations.	Serotonin	53-56	prolyl endopeptidase	Homo sapiens	19-22
31302884-15	2019	The percentage of patients with uncontrolled phosphate level was reduced from 59.3 to 35.6% and 42.1% after the PEP (p = 0.003).	Phosphates	45-54	prolyl endopeptidase	Homo sapiens	112-115
31302884-17	2019	The adherence to phosphate binder also improved from 17.2 to 41.4% after PEP (p = 0.007).	Phosphates	17-26	prolyl endopeptidase	Homo sapiens	73-76
31398714-6	2019	We found that D-Asp upregulated the expression of prolyl endopeptidase (PREP), a serine protease having a pivotal role in the regulation of mammalian spermatogenesis and spermiogenesis.	D-Aspartic Acid	14-19	prolyl endopeptidase	Homo sapiens	72-76
31398714-6	2019	We found that D-Asp upregulated the expression of prolyl endopeptidase (PREP), a serine protease having a pivotal role in the regulation of mammalian spermatogenesis and spermiogenesis.	Serine	81-87	prolyl endopeptidase	Homo sapiens	50-70
31398714-6	2019	We found that D-Asp upregulated the expression of prolyl endopeptidase (PREP), a serine protease having a pivotal role in the regulation of mammalian spermatogenesis and spermiogenesis.	Serine	81-87	prolyl endopeptidase	Homo sapiens	72-76
31398714-8	2019	Moreover, PREP was found to co-localize with GluA2/3, an AMPA receptor subunit, whose protein expression also increased after D-Asp treatments.	D-Aspartic Acid	126-131	prolyl endopeptidase	Homo sapiens	10-14
31393718-5	2019	This computational method was also successfully applied to FAP, as an overview of known FAP inhibitors confirmed our computational predictions that more reactive warheads (e.g., boronic acids) must be employed to inhibit FAP than for POP.	Boronic Acids	178-191	prolyl endopeptidase	Homo sapiens	234-237
30914213-6	2019	CONCLUSIONS: Because of a high level of macrolide resistance, a systematic search for M. genitalium macrolide resistance associated-mutations may be recommended in PrEP users before initiating the antibiotic therapy.	Macrolides	40-49	prolyl endopeptidase	Homo sapiens	164-168
31430318-1	2019	INTRODUCTION: Efficacy of daily emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) for PrEP is strongly dependent on the adherence.	Emtricitabine	32-45	prolyl endopeptidase	Homo sapiens	90-94
31430318-1	2019	INTRODUCTION: Efficacy of daily emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) for PrEP is strongly dependent on the adherence.	Tenofovir	46-75	prolyl endopeptidase	Homo sapiens	90-94
31612188-3	2019	Rectal nonsteroidal anti-inflammatory drugs (specifically, 100 mg of diclofenac) have shown promising prophylactic activity in PEP.	Diclofenac	69-79	prolyl endopeptidase	Homo sapiens	127-130
31612188-9	2019	RESULT: Data were prospectively collected and to demonstrate the preventive effect of rectal diclofenac on PEP, a two-by-two table and chi-square test with Yates correction were used: the incidence of PEP was significantly lower (p &lt; 0.001) in the rectal diclofenac group respect to other groups and, in the same way, the incidence of post-ERCP pain was significantly lower in the rectal diclofenac group than in the other groups (p = 0.001) and patients discharge was consequently earlier (p &lt; 0.01).	Diclofenac	93-103	prolyl endopeptidase	Homo sapiens	107-110
31612188-9	2019	RESULT: Data were prospectively collected and to demonstrate the preventive effect of rectal diclofenac on PEP, a two-by-two table and chi-square test with Yates correction were used: the incidence of PEP was significantly lower (p &lt; 0.001) in the rectal diclofenac group respect to other groups and, in the same way, the incidence of post-ERCP pain was significantly lower in the rectal diclofenac group than in the other groups (p = 0.001) and patients discharge was consequently earlier (p &lt; 0.01).	Diclofenac	93-103	prolyl endopeptidase	Homo sapiens	201-204
31612188-10	2019	CONCLUSION: 100 mg dose rectal diclofenac administered 30-60 minutes before ERCP can effectively prevent PEP.	Diclofenac	31-41	prolyl endopeptidase	Homo sapiens	105-108
30981844-4	2019	METHODS: FAP and PREP activities were measured in human EDTA-plasma in presence of well characterized PREP and FAP inhibitors.	Edetic Acid	56-60	prolyl endopeptidase	Homo sapiens	17-21
30981844-5	2019	RESULTS: A combined kinetic assay was developed in conditions to optimally measure FAP as well as PREP activity with Z-Gly-Pro-AMC as substrate.	N-carbobenzoxyglycyl-prolyl-4-methylcoumarinyl amide	117-130	prolyl endopeptidase	Homo sapiens	98-102
30914213-6	2019	CONCLUSIONS: Because of a high level of macrolide resistance, a systematic search for M. genitalium macrolide resistance associated-mutations may be recommended in PrEP users before initiating the antibiotic therapy.	Macrolides	100-109	prolyl endopeptidase	Homo sapiens	164-168
30758752-6	2019	The two photosynthesis models, differing in whether ATP could freely transport between RuBP and PEP regeneration processes yielded consistent results under high light, but they may diverge under low light intensities.	Adenosine Triphosphate	52-55	prolyl endopeptidase	Homo sapiens	96-99
31291899-7	2019	PrEP therapy was then initiated with fixed association of emtricitabine-tenofovir disoproxil.	emtricitabine-tenofovir disoproxil	58-92	prolyl endopeptidase	Homo sapiens	0-4
31291899-10	2019	Genotyping and treatment sensitivity performed on sample after one month of PrEP showed a virus resistance to lamivudine and emtricitabine.	Lamivudine	110-120	prolyl endopeptidase	Homo sapiens	76-80
31291899-10	2019	Genotyping and treatment sensitivity performed on sample after one month of PrEP showed a virus resistance to lamivudine and emtricitabine.	Emtricitabine	125-138	prolyl endopeptidase	Homo sapiens	76-80
31234389-4	2019	Due to the membrane lytic ability of the D-(KLAKLAK)2 peptide and the membrane disruptive effect of the singlet oxygen generated from chlorin e6, Lipo (Pep, Ce6) accelerated the disruption of the endosomal compartment, and exhibited strong synergistic anticancer activity in vitro.	Singlet Oxygen	104-118	prolyl endopeptidase	Homo sapiens	152-155
30212672-2	2018	The operational parameters of photoelectro-peroxone/zero valent iron (PEP/ZVI) process were studied and the complete decoloration was found at pH = 3.0, 100 mg/L ZVI, 33.2 mg/L ozone, 300 mA applied current and 25 min reaction time.	-peroxone	42-51	prolyl endopeptidase	Homo sapiens	70-73
31192286-3	2019	Our aim was to assess the potential risk factors associated with PEP occurrence in patients undergoing ERCP with indomethacin prophylaxis.	Indomethacin	113-125	prolyl endopeptidase	Homo sapiens	65-68
31192286-8	2019	PEP prophylaxis consisted of indomethacin in all cases (100%) and PD stenting in 7.4%.	Indomethacin	29-41	prolyl endopeptidase	Homo sapiens	0-3
30665156-10	2019	The hit compounds interacted with POP effectively via hydrogen bonds with important active site residues along with hydrophobic interactions.	Hydrogen	54-62	prolyl endopeptidase	Homo sapiens	34-37
30665156-12	2019	A potential new hydrogen bond interaction was discovered between Hit 2 with the Arg252 residue of POP.	Hydrogen	16-24	prolyl endopeptidase	Homo sapiens	98-101
31043606-1	2019	A long-acting injectable formulation of the HIV integrase inhibitor cabotegravir (CAB-LA) is currently in clinical development for PrEP.	cabotegravir	68-80	prolyl endopeptidase	Homo sapiens	131-135
30918485-14	2019	As reduced dose EFV has a lower toxicity profile, we predicted the reduction in HIV infection when 400 mg EFV-PrEP was poorly adhered to, when it was taken "on demand" and as post-exposure prophylaxis (PEP).	efavirenz	16-19	prolyl endopeptidase	Homo sapiens	202-205
29971734-2	2019	Tenofovir-based PrEP is effective in preventing HIV transmission in MSM.	Tenofovir	0-9	prolyl endopeptidase	Homo sapiens	16-20
29971734-8	2019	At Truvada"s current price in China, daily oral PrEP costs $46,813-52,008 per DALY averted and is not cost-effective; on-demand Truvada reduces ICER to $25,057-27,838 per DALY averted, marginally cost-effective; daily generic tenofovir-based regimens further reduce ICER to $3675-8963, wholly cost-effective.	Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination	3-10	prolyl endopeptidase	Homo sapiens	48-52
29971734-9	2019	The cost of daily oral Truvada PrEP regimen would need to be reduced by half to achieve cost-effectiveness and realize the public health good of preventing hundreds of thousands of HIV infections among MSM in China.	Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination	23-30	prolyl endopeptidase	Homo sapiens	31-35
30694548-0	2019	Ensuring the Safe Use of High Alcohol-Based Skin Prep Solutions.	Alcohols	30-37	prolyl endopeptidase	Homo sapiens	49-53
31353647-3	2019	The results indicated zeta potential of CS/PEP-NPs increased with the increase in molecular weight of CS (10-50 kDa).	Chitosan	40-42	prolyl endopeptidase	Homo sapiens	43-46
31353647-6	2019	CS/PEP-NPs could reduce the tight junction integrity of Caco-2 cells and enhance the intracellular fluorescence intensities of fluorescein isothiocyanate-labeled peptide.	Chitosan	0-2	prolyl endopeptidase	Homo sapiens	3-6
31353647-6	2019	CS/PEP-NPs could reduce the tight junction integrity of Caco-2 cells and enhance the intracellular fluorescence intensities of fluorescein isothiocyanate-labeled peptide.	fluorescein isothiocyanate	127-153	prolyl endopeptidase	Homo sapiens	3-6
31353647-10	2019	CS/PEP-NPs could reduce the tight junction integrity of Caco-2 cells and enhance the peptide uptake by paracellular pathway.	Chitosan	0-2	prolyl endopeptidase	Homo sapiens	3-6
30723412-0	2018	Enhanced Anti-tumor of Pep-1 Modified Superparamagnetic Iron Oxide/PTX Loaded Polymer Nanoparticles.	ferric oxide	56-66	prolyl endopeptidase	Homo sapiens	23-26
30723412-0	2018	Enhanced Anti-tumor of Pep-1 Modified Superparamagnetic Iron Oxide/PTX Loaded Polymer Nanoparticles.	Paclitaxel	67-70	prolyl endopeptidase	Homo sapiens	23-26
30723412-5	2018	The resulting Pep-NP-SPION/PTX showed a spherical morphology and an average size of 100 nm.	Paclitaxel	27-30	prolyl endopeptidase	Homo sapiens	14-17
30723412-7	2018	The IC50 value of Pep-NP-SPION/PTX and NP-SPION/PTX was determined to be 10.2 and 19.4 mug/mL, respectively.	Paclitaxel	31-34	prolyl endopeptidase	Homo sapiens	18-21
30723412-10	2018	Furthermore, Pep-NP-SPION/PTX presented desirable in vivo anti-tumor effects based on active targeting and magnetic targeting characteristics.	Paclitaxel	26-29	prolyl endopeptidase	Homo sapiens	13-16
30723412-11	2018	Altogether, Pep-NP-SPION/PTX can offer magnetic targeting and receptor mediated targeting to enhance the anti-tumor outcome.	Paclitaxel	25-28	prolyl endopeptidase	Homo sapiens	12-15
30654370-8	2019	Although there were no significant differences, the severe grade of PEP was more frequent in the HOCM group than in the IOCM group (p = 0.08).	hocm	97-101	prolyl endopeptidase	Homo sapiens	68-71
30654370-8	2019	Although there were no significant differences, the severe grade of PEP was more frequent in the HOCM group than in the IOCM group (p = 0.08).	iocm	120-124	prolyl endopeptidase	Homo sapiens	68-71
31133658-6	2019	Based on colony forming unit analysis, motif Pep-H led to killing of more than 90% M. tb in vitro at 10 mug/ml, whereas, similar activity against intracellularly growing M. tb was observed at 5 mug/ml only.	Terbium	86-88	prolyl endopeptidase	Homo sapiens	45-48
31133658-6	2019	Based on colony forming unit analysis, motif Pep-H led to killing of more than 90% M. tb in vitro at 10 mug/ml, whereas, similar activity against intracellularly growing M. tb was observed at 5 mug/ml only.	Terbium	173-175	prolyl endopeptidase	Homo sapiens	45-48
30212672-2	2018	The operational parameters of photoelectro-peroxone/zero valent iron (PEP/ZVI) process were studied and the complete decoloration was found at pH = 3.0, 100 mg/L ZVI, 33.2 mg/L ozone, 300 mA applied current and 25 min reaction time.	Iron	64-68	prolyl endopeptidase	Homo sapiens	70-73
30212672-2	2018	The operational parameters of photoelectro-peroxone/zero valent iron (PEP/ZVI) process were studied and the complete decoloration was found at pH = 3.0, 100 mg/L ZVI, 33.2 mg/L ozone, 300 mA applied current and 25 min reaction time.	Iron	162-165	prolyl endopeptidase	Homo sapiens	70-73
30212672-4	2018	ZVI showed high reusability in PEP/ZVI process.	Iron	0-3	prolyl endopeptidase	Homo sapiens	31-34
30212672-7	2018	PEP/ZVI process was tested for several emerging pollutants (benzotriazole, 4-chlorophenol, carmoisine and tetracycline); the results presented the effectiveness of the process for the degradation of pollutants in a way that complete degradation occurred at only 30 min.	benzotriazole	60-73	prolyl endopeptidase	Homo sapiens	0-3
30212672-7	2018	PEP/ZVI process was tested for several emerging pollutants (benzotriazole, 4-chlorophenol, carmoisine and tetracycline); the results presented the effectiveness of the process for the degradation of pollutants in a way that complete degradation occurred at only 30 min.	4-chlorophenol	75-89	prolyl endopeptidase	Homo sapiens	0-3
30212672-7	2018	PEP/ZVI process was tested for several emerging pollutants (benzotriazole, 4-chlorophenol, carmoisine and tetracycline); the results presented the effectiveness of the process for the degradation of pollutants in a way that complete degradation occurred at only 30 min.	azo rubin S	91-101	prolyl endopeptidase	Homo sapiens	0-3
30212672-7	2018	PEP/ZVI process was tested for several emerging pollutants (benzotriazole, 4-chlorophenol, carmoisine and tetracycline); the results presented the effectiveness of the process for the degradation of pollutants in a way that complete degradation occurred at only 30 min.	Tetracycline	106-118	prolyl endopeptidase	Homo sapiens	0-3
29290075-0	2018	Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States.	cabotegravir	109-121	prolyl endopeptidase	Homo sapiens	125-129
29980976-2	2018	Rectal indomethacin has been widely administered to decrease the incidence of PEP in high-risk patients.	Indomethacin	7-19	prolyl endopeptidase	Homo sapiens	78-81
29980976-4	2018	The purpose of the study was to evaluate the risk factors for PEP in high-risk patients receiving post-ERCP indomethacin.	Indomethacin	108-120	prolyl endopeptidase	Homo sapiens	62-65
29980976-9	2018	RESULTS: Seven hundred ninety patients at high risk for PEP received post-ERCP indomethacin.	Indomethacin	79-91	prolyl endopeptidase	Homo sapiens	56-59
30044845-2	2018	Non-adherence to daily use limiting the effectiveness of oral PrEP (Truvada) has led to current trials with adult MSM testing Cabotegravir, a long-term injectable medication.	Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination	68-75	prolyl endopeptidase	Homo sapiens	62-66
30308051-1	2018	BACKGROUND: Plasmalogens are either phosphatidylcholine (PC P) or phosphatidylethanolamine (PE P) glycerophospholipids containing a vinyl ether moiety in sn-1-position and an esterified fatty acid in sn-2 position.	phosphatidylethanolamine	66-90	prolyl endopeptidase	Homo sapiens	92-96
30308051-1	2018	BACKGROUND: Plasmalogens are either phosphatidylcholine (PC P) or phosphatidylethanolamine (PE P) glycerophospholipids containing a vinyl ether moiety in sn-1-position and an esterified fatty acid in sn-2 position.	Glycerophospholipids	98-118	prolyl endopeptidase	Homo sapiens	92-96
30308051-1	2018	BACKGROUND: Plasmalogens are either phosphatidylcholine (PC P) or phosphatidylethanolamine (PE P) glycerophospholipids containing a vinyl ether moiety in sn-1-position and an esterified fatty acid in sn-2 position.	Fatty Acids	186-196	prolyl endopeptidase	Homo sapiens	92-96
30308051-11	2018	On the other hand treatment with oxLDL led to a significant increase in PC P. Analysis of individual lipid species showed lipoprotein and saturation specific effects for LPC, PC P and PE P species.	oxldl	33-38	prolyl endopeptidase	Homo sapiens	184-188
30308051-13	2018	In contrast the observed changes in the saturated to mono-unsaturated fatty acid (SFA to MUFA) and saturated to poly-unsaturated fatty acid (SFA to PUFA) ratios in PE P could represent a cellular reaction to counteract this effect by producing more fluid membranes.	Fatty Acids, Monounsaturated	53-80	prolyl endopeptidase	Homo sapiens	164-168
30308051-13	2018	In contrast the observed changes in the saturated to mono-unsaturated fatty acid (SFA to MUFA) and saturated to poly-unsaturated fatty acid (SFA to PUFA) ratios in PE P could represent a cellular reaction to counteract this effect by producing more fluid membranes.	suppressive factor of allergy	82-85	prolyl endopeptidase	Homo sapiens	164-168
30308051-13	2018	In contrast the observed changes in the saturated to mono-unsaturated fatty acid (SFA to MUFA) and saturated to poly-unsaturated fatty acid (SFA to PUFA) ratios in PE P could represent a cellular reaction to counteract this effect by producing more fluid membranes.	Fatty Acids, Unsaturated	112-139	prolyl endopeptidase	Homo sapiens	164-168
30308051-13	2018	In contrast the observed changes in the saturated to mono-unsaturated fatty acid (SFA to MUFA) and saturated to poly-unsaturated fatty acid (SFA to PUFA) ratios in PE P could represent a cellular reaction to counteract this effect by producing more fluid membranes.	suppressive factor of allergy	141-144	prolyl endopeptidase	Homo sapiens	164-168
30308051-20	2018	This is consistent with the consumption of arachidonic acid containing PE P species in oxLDL treated cells, presumably for the synthesis of inflammatory mediators.	Arachidonic Acid	43-59	prolyl endopeptidase	Homo sapiens	71-75
29744767-0	2018	Poppers and PrEP: Use of Pre-exposure Prophylaxis Among Men Who Have Sex with Men Who Use Inhaled Nitrites.	Nitrites	98-106	prolyl endopeptidase	Homo sapiens	12-16
30044845-2	2018	Non-adherence to daily use limiting the effectiveness of oral PrEP (Truvada) has led to current trials with adult MSM testing Cabotegravir, a long-term injectable medication.	cabotegravir	126-138	prolyl endopeptidase	Homo sapiens	62-66
29202450-1	2017	The neutrophil chemoattractant proline-glycine-proline (PGP) is generated from collagen by matrix metalloproteinase-8/9 (MMP-8/9) and prolyl endopeptidase (PE), and it is concomitantly degraded by extracellular leukotriene A4 hydrolase (LTA4H) to limit neutrophilia.	proline-glycine-proline	31-54	prolyl endopeptidase	Homo sapiens	134-154
32254280-1	2018	Alginate dialdehyde (ADA), a biocompatible polymer, was used as an intermediate layer on a nylon membrane to readily fabricate cation exchange (CEX), metal-affinity (Me-affinity), histidine-affinity (His-affinity) and peptide-affinity (Pep-affinity) membrane adsorbers without any organic solvent usage.	alginate dialdehyde	0-19	prolyl endopeptidase	Homo sapiens	236-239
32254280-1	2018	Alginate dialdehyde (ADA), a biocompatible polymer, was used as an intermediate layer on a nylon membrane to readily fabricate cation exchange (CEX), metal-affinity (Me-affinity), histidine-affinity (His-affinity) and peptide-affinity (Pep-affinity) membrane adsorbers without any organic solvent usage.	N-(2-acetamido)iminodiacetic acid	21-24	prolyl endopeptidase	Homo sapiens	236-239
32254280-5	2018	The carboxylic groups along with the peptides on the Pep-affinity adsorber captured IgG synergistically with a higher recovery and purity (99% and 98.6%).	carboxylic	4-14	prolyl endopeptidase	Homo sapiens	53-56
29435160-4	2018	The results indicated that triglycerides and phosphatidylcholines contributed significantly to altered hepatic lipids, whereas triglycerides and phosphatidylethanolamine-based plasmalogens (PEp) contributed most to altered serum lipids.	phosphatidylethanolamine	145-169	prolyl endopeptidase	Homo sapiens	190-193
29202450-1	2017	The neutrophil chemoattractant proline-glycine-proline (PGP) is generated from collagen by matrix metalloproteinase-8/9 (MMP-8/9) and prolyl endopeptidase (PE), and it is concomitantly degraded by extracellular leukotriene A4 hydrolase (LTA4H) to limit neutrophilia.	proline-glycine-proline	31-54	prolyl endopeptidase	Homo sapiens	156-158
29202450-1	2017	The neutrophil chemoattractant proline-glycine-proline (PGP) is generated from collagen by matrix metalloproteinase-8/9 (MMP-8/9) and prolyl endopeptidase (PE), and it is concomitantly degraded by extracellular leukotriene A4 hydrolase (LTA4H) to limit neutrophilia.	pgp	56-59	prolyl endopeptidase	Homo sapiens	134-154
29202450-1	2017	The neutrophil chemoattractant proline-glycine-proline (PGP) is generated from collagen by matrix metalloproteinase-8/9 (MMP-8/9) and prolyl endopeptidase (PE), and it is concomitantly degraded by extracellular leukotriene A4 hydrolase (LTA4H) to limit neutrophilia.	pgp	56-59	prolyl endopeptidase	Homo sapiens	156-158
28708094-0	2017	Cholinesterase and Prolyl Oligopeptidase Inhibitory Activities of Alkaloids from Argemone platyceras (Papaveraceae).	Alkaloids	66-75	prolyl endopeptidase	Homo sapiens	19-40
29047268-3	2017	Barley-based beers crafted to remove gluten using proprietary precipitation and/or application of enzymes, e.g. prolyl endopeptidases (PEP) that degrade the proline-rich gluten molecules, are available commercially.	Proline	157-164	prolyl endopeptidase	Homo sapiens	135-138
30155226-3	2017	In this study, Fl incorporated into a short peptide, flavopeptide (Fl-Pep), was designed by a rational top-down approach using a computational method, which could stabilize the corresponding 4a-hydroperoxy adduct (FlOOH-Pep) through intramolecular hydrogen bonds.	Hydrogen	248-256	prolyl endopeptidase	Homo sapiens	70-73
30155226-3	2017	In this study, Fl incorporated into a short peptide, flavopeptide (Fl-Pep), was designed by a rational top-down approach using a computational method, which could stabilize the corresponding 4a-hydroperoxy adduct (FlOOH-Pep) through intramolecular hydrogen bonds.	Hydrogen	248-256	prolyl endopeptidase	Homo sapiens	220-223
30155226-4	2017	We report catalytic chemoselective sulfoxidation as well as Baeyer-Villiger oxidation by means of Fl-Pep under light-shielding and aerobic conditions, which are the first Fl-Enz-mimetic aerobic oxygenation reactions catalyzed by Fl under non-enzymatic conditions.	fl-enz	171-177	prolyl endopeptidase	Homo sapiens	101-104
30155226-4	2017	We report catalytic chemoselective sulfoxidation as well as Baeyer-Villiger oxidation by means of Fl-Pep under light-shielding and aerobic conditions, which are the first Fl-Enz-mimetic aerobic oxygenation reactions catalyzed by Fl under non-enzymatic conditions.	Flavins	98-100	prolyl endopeptidase	Homo sapiens	101-104
28070831-0	2017	The prolyl oligopeptidase inhibitor SUAM-14746 attenuates the proliferation of human breast cancer cell lines in vitro.	3-((4-(2-styrylphenoxy)butanoyl)-4-hydroxyprolyl)thiazolidine	36-46	prolyl endopeptidase	Homo sapiens	4-25
28070831-1	2017	BACKGROUND: Prolyl oligopeptidase (POP, EC 3.4.1.26) is a serine peptidase that hydrolyzes post-proline peptide bonds in peptides that are &lt;30 amino acids in length.	Proline	96-103	prolyl endopeptidase	Homo sapiens	12-33
28070831-1	2017	BACKGROUND: Prolyl oligopeptidase (POP, EC 3.4.1.26) is a serine peptidase that hydrolyzes post-proline peptide bonds in peptides that are &lt;30 amino acids in length.	Proline	96-103	prolyl endopeptidase	Homo sapiens	35-38
28070831-6	2017	RESULTS: POP-specific inhibitors 3-({4-[2-(E)-styrylphenoxy]butanoyl}-L-4-hydroxyprolyl)-thiazolidine (SUAM-14746) and benzyloxycarbonyl-thiopropyl-thioprolinal and RNAi-mediated POP knockdown inhibited the proliferation of MCF7 cells without inducing cell death.	3-((4-(2-styrylphenoxy)butanoyl)-4-hydroxyprolyl)thiazolidine	33-101	prolyl endopeptidase	Homo sapiens	9-12
28070831-6	2017	RESULTS: POP-specific inhibitors 3-({4-[2-(E)-styrylphenoxy]butanoyl}-L-4-hydroxyprolyl)-thiazolidine (SUAM-14746) and benzyloxycarbonyl-thiopropyl-thioprolinal and RNAi-mediated POP knockdown inhibited the proliferation of MCF7 cells without inducing cell death.	suam	103-107	prolyl endopeptidase	Homo sapiens	9-12
28070831-6	2017	RESULTS: POP-specific inhibitors 3-({4-[2-(E)-styrylphenoxy]butanoyl}-L-4-hydroxyprolyl)-thiazolidine (SUAM-14746) and benzyloxycarbonyl-thiopropyl-thioprolinal and RNAi-mediated POP knockdown inhibited the proliferation of MCF7 cells without inducing cell death.	suam	103-107	prolyl endopeptidase	Homo sapiens	179-182
28070831-6	2017	RESULTS: POP-specific inhibitors 3-({4-[2-(E)-styrylphenoxy]butanoyl}-L-4-hydroxyprolyl)-thiazolidine (SUAM-14746) and benzyloxycarbonyl-thiopropyl-thioprolinal and RNAi-mediated POP knockdown inhibited the proliferation of MCF7 cells without inducing cell death.	benzyloxycarbonyl-thiopropyl-thioprolinal	119-160	prolyl endopeptidase	Homo sapiens	9-12
28708094-11	2017	The most active compound (-)-munitagine, a pavine alkaloid, inhibited both acetylcholinesterase and prolyl oligopeptidase with IC50 values of 62.3 +- 5.8 microM and 277.0 +- 31.3 microM, respectively.	munitagine	29-39	prolyl endopeptidase	Homo sapiens	100-121
28293755-2	2017	Zn inhibited pyruvate kinase uncompetitively with respect to the substrate PEP, and competitively with respect to ADP.	Zinc	0-2	prolyl endopeptidase	Homo sapiens	75-78
28293755-3	2017	Quotient velocity plot calculated from the Zn-inhibition curves showed that Zn2+ as a ZnADP complex acted as competitive and uncompetitive inhibitors of the enzyme with respect to the substrate ADP and PEP, respectively: Zn2+ forms a ZnADP complex, which may bind to the ADP-binding site of the free enzyme with the Ki value of 1.4 muM causing competitive inhibition, or to the ADP-site of the enzyme-PEP complex with 2.6 muM resulting in uncompetitive inhibition.	Zinc	43-45	prolyl endopeptidase	Homo sapiens	202-205
28293755-3	2017	Quotient velocity plot calculated from the Zn-inhibition curves showed that Zn2+ as a ZnADP complex acted as competitive and uncompetitive inhibitors of the enzyme with respect to the substrate ADP and PEP, respectively: Zn2+ forms a ZnADP complex, which may bind to the ADP-binding site of the free enzyme with the Ki value of 1.4 muM causing competitive inhibition, or to the ADP-site of the enzyme-PEP complex with 2.6 muM resulting in uncompetitive inhibition.	Zinc	43-45	prolyl endopeptidase	Homo sapiens	401-404
28293755-3	2017	Quotient velocity plot calculated from the Zn-inhibition curves showed that Zn2+ as a ZnADP complex acted as competitive and uncompetitive inhibitors of the enzyme with respect to the substrate ADP and PEP, respectively: Zn2+ forms a ZnADP complex, which may bind to the ADP-binding site of the free enzyme with the Ki value of 1.4 muM causing competitive inhibition, or to the ADP-site of the enzyme-PEP complex with 2.6 muM resulting in uncompetitive inhibition.	Zinc	76-80	prolyl endopeptidase	Homo sapiens	202-205
28293755-3	2017	Quotient velocity plot calculated from the Zn-inhibition curves showed that Zn2+ as a ZnADP complex acted as competitive and uncompetitive inhibitors of the enzyme with respect to the substrate ADP and PEP, respectively: Zn2+ forms a ZnADP complex, which may bind to the ADP-binding site of the free enzyme with the Ki value of 1.4 muM causing competitive inhibition, or to the ADP-site of the enzyme-PEP complex with 2.6 muM resulting in uncompetitive inhibition.	Zinc	76-80	prolyl endopeptidase	Homo sapiens	401-404
28293755-3	2017	Quotient velocity plot calculated from the Zn-inhibition curves showed that Zn2+ as a ZnADP complex acted as competitive and uncompetitive inhibitors of the enzyme with respect to the substrate ADP and PEP, respectively: Zn2+ forms a ZnADP complex, which may bind to the ADP-binding site of the free enzyme with the Ki value of 1.4 muM causing competitive inhibition, or to the ADP-site of the enzyme-PEP complex with 2.6 muM resulting in uncompetitive inhibition.	znadp	86-91	prolyl endopeptidase	Homo sapiens	202-205
28293755-3	2017	Quotient velocity plot calculated from the Zn-inhibition curves showed that Zn2+ as a ZnADP complex acted as competitive and uncompetitive inhibitors of the enzyme with respect to the substrate ADP and PEP, respectively: Zn2+ forms a ZnADP complex, which may bind to the ADP-binding site of the free enzyme with the Ki value of 1.4 muM causing competitive inhibition, or to the ADP-site of the enzyme-PEP complex with 2.6 muM resulting in uncompetitive inhibition.	znadp	86-91	prolyl endopeptidase	Homo sapiens	401-404
28293755-3	2017	Quotient velocity plot calculated from the Zn-inhibition curves showed that Zn2+ as a ZnADP complex acted as competitive and uncompetitive inhibitors of the enzyme with respect to the substrate ADP and PEP, respectively: Zn2+ forms a ZnADP complex, which may bind to the ADP-binding site of the free enzyme with the Ki value of 1.4 muM causing competitive inhibition, or to the ADP-site of the enzyme-PEP complex with 2.6 muM resulting in uncompetitive inhibition.	Adenosine Diphosphate	88-91	prolyl endopeptidase	Homo sapiens	202-205
28293755-3	2017	Quotient velocity plot calculated from the Zn-inhibition curves showed that Zn2+ as a ZnADP complex acted as competitive and uncompetitive inhibitors of the enzyme with respect to the substrate ADP and PEP, respectively: Zn2+ forms a ZnADP complex, which may bind to the ADP-binding site of the free enzyme with the Ki value of 1.4 muM causing competitive inhibition, or to the ADP-site of the enzyme-PEP complex with 2.6 muM resulting in uncompetitive inhibition.	Adenosine Diphosphate	88-91	prolyl endopeptidase	Homo sapiens	401-404
28293755-3	2017	Quotient velocity plot calculated from the Zn-inhibition curves showed that Zn2+ as a ZnADP complex acted as competitive and uncompetitive inhibitors of the enzyme with respect to the substrate ADP and PEP, respectively: Zn2+ forms a ZnADP complex, which may bind to the ADP-binding site of the free enzyme with the Ki value of 1.4 muM causing competitive inhibition, or to the ADP-site of the enzyme-PEP complex with 2.6 muM resulting in uncompetitive inhibition.	Zinc	221-225	prolyl endopeptidase	Homo sapiens	202-205
28293755-3	2017	Quotient velocity plot calculated from the Zn-inhibition curves showed that Zn2+ as a ZnADP complex acted as competitive and uncompetitive inhibitors of the enzyme with respect to the substrate ADP and PEP, respectively: Zn2+ forms a ZnADP complex, which may bind to the ADP-binding site of the free enzyme with the Ki value of 1.4 muM causing competitive inhibition, or to the ADP-site of the enzyme-PEP complex with 2.6 muM resulting in uncompetitive inhibition.	Zinc	221-225	prolyl endopeptidase	Homo sapiens	401-404
28293755-3	2017	Quotient velocity plot calculated from the Zn-inhibition curves showed that Zn2+ as a ZnADP complex acted as competitive and uncompetitive inhibitors of the enzyme with respect to the substrate ADP and PEP, respectively: Zn2+ forms a ZnADP complex, which may bind to the ADP-binding site of the free enzyme with the Ki value of 1.4 muM causing competitive inhibition, or to the ADP-site of the enzyme-PEP complex with 2.6 muM resulting in uncompetitive inhibition.	znadp	234-239	prolyl endopeptidase	Homo sapiens	202-205
27503084-1	2017	Prolyl oligopeptidase (also named prolyl endopeptidase; PREP) hydrolyzes the Pro-Xaa bonds of biologically active oligopeptides on their carboxyl side.	Proline	0-3	prolyl endopeptidase	Homo sapiens	56-60
27503084-1	2017	Prolyl oligopeptidase (also named prolyl endopeptidase; PREP) hydrolyzes the Pro-Xaa bonds of biologically active oligopeptides on their carboxyl side.	xanthenone-4-acetic acid	81-84	prolyl endopeptidase	Homo sapiens	0-21
27503084-1	2017	Prolyl oligopeptidase (also named prolyl endopeptidase; PREP) hydrolyzes the Pro-Xaa bonds of biologically active oligopeptides on their carboxyl side.	xanthenone-4-acetic acid	81-84	prolyl endopeptidase	Homo sapiens	56-60
27503084-1	2017	Prolyl oligopeptidase (also named prolyl endopeptidase; PREP) hydrolyzes the Pro-Xaa bonds of biologically active oligopeptides on their carboxyl side.	Oligopeptides	114-127	prolyl endopeptidase	Homo sapiens	0-21
27503084-1	2017	Prolyl oligopeptidase (also named prolyl endopeptidase; PREP) hydrolyzes the Pro-Xaa bonds of biologically active oligopeptides on their carboxyl side.	Oligopeptides	114-127	prolyl endopeptidase	Homo sapiens	56-60
27503084-2	2017	In 1987, we detected PREP activity in human cerebrospinal fluid (CSF) using highly sensitive liquid chromatography-fluorometry with succinyl-Gly-Pro-4-methyl-coumarin amide as a new synthetic substrate, and found a marked decrease in its activity in the cerebrospinal fluid (CSF) from patients with Parkinson"s disease (PD) as compared with its level in control patients without neurological diseases.	succinyl-gly-pro-4-methyl-coumarin amide	132-172	prolyl endopeptidase	Homo sapiens	21-25
27503084-5	2017	Several recent studies also suggest that the level of PREP in the brain of PD patients may be related to dopamine (DA) cell death via promotion of alpha-synuclein oligomerization and that inhibitors of PREP may play a neuroprotective role in PD.	Dopamine	105-113	prolyl endopeptidase	Homo sapiens	54-58
27503084-5	2017	Several recent studies also suggest that the level of PREP in the brain of PD patients may be related to dopamine (DA) cell death via promotion of alpha-synuclein oligomerization and that inhibitors of PREP may play a neuroprotective role in PD.	Dopamine	115-117	prolyl endopeptidase	Homo sapiens	54-58
28550305-0	2017	Dynamics and ligand-induced conformational changes in human prolyl oligopeptidase analyzed by hydrogen/deuterium exchange mass spectrometry.	Hydrogen	94-102	prolyl endopeptidase	Homo sapiens	60-81
28550305-0	2017	Dynamics and ligand-induced conformational changes in human prolyl oligopeptidase analyzed by hydrogen/deuterium exchange mass spectrometry.	Deuterium	103-112	prolyl endopeptidase	Homo sapiens	60-81
28550305-5	2017	Here we used Hydrogen Deuterium eXchange Mass Spectrometry (HDX-MS) to derive the first near-residue resolution analysis of global PREP dynamics in the presence or absence of inhibitor bound in the active site.	Hydrogen	13-21	prolyl endopeptidase	Homo sapiens	131-135
28550305-5	2017	Here we used Hydrogen Deuterium eXchange Mass Spectrometry (HDX-MS) to derive the first near-residue resolution analysis of global PREP dynamics in the presence or absence of inhibitor bound in the active site.	Deuterium	22-31	prolyl endopeptidase	Homo sapiens	131-135
28293755-3	2017	Quotient velocity plot calculated from the Zn-inhibition curves showed that Zn2+ as a ZnADP complex acted as competitive and uncompetitive inhibitors of the enzyme with respect to the substrate ADP and PEP, respectively: Zn2+ forms a ZnADP complex, which may bind to the ADP-binding site of the free enzyme with the Ki value of 1.4 muM causing competitive inhibition, or to the ADP-site of the enzyme-PEP complex with 2.6 muM resulting in uncompetitive inhibition.	znadp	234-239	prolyl endopeptidase	Homo sapiens	401-404
26787118-13	2016	Thus, these findings may help in developing PEP layer-based biopolymers for protein-based nanodevices, nanoelectrodes and more stable biopesticides.	Biopolymers	60-71	prolyl endopeptidase	Homo sapiens	44-47
27818354-0	2017	Prolyl oligopeptidase inhibition attenuates the toxicity of a proteasomal inhibitor, lactacystin, in the alpha-synuclein overexpressing cell culture.	lactacystin	85-96	prolyl endopeptidase	Homo sapiens	0-21
27818354-3	2017	Our recent studies have shown that inhibitors of prolyl oligopeptidase (PREP) can prevent the aggregation and enhance the clearance of accumulated aSyn, and therefore, we wanted to study if PREP inhibition can overcome the aSyn aggregation and toxicity induced by lactacystin, a proteasomal inhibitor.	lactacystin	264-275	prolyl endopeptidase	Homo sapiens	72-76
27856484-3	2016	Large-scale clinical trials with single dose rifampicin (SDR) given as post-exposure prophylaxis (PEP) to contacts of newly diagnosed patients with leprosy have shown a 50-60% reduction of the risk of developing leprosy over the following 2 years.	Rifampin	45-55	prolyl endopeptidase	Homo sapiens	98-101
26781865-1	2016	Comparing Announced and Unannounced Tenofovir Levels in a PrEP Trial.	Tenofovir	36-45	prolyl endopeptidase	Homo sapiens	58-62
26781865-2	2016	Differences between unannounced and announced tenofovir levels as measures of PrEP adherence are not well understood.	Tenofovir	46-55	prolyl endopeptidase	Homo sapiens	78-82
26619267-0	2016	3-Oxo-hexahydro-1H-isoindole-4-carboxylic Acid as a Drug Chiral Bicyclic Scaffold: Structure-Based Design and Preparation of Conformationally Constrained Covalent and Noncovalent Prolyl Oligopeptidase Inhibitors.	3-oxo-hexahydro-1h-isoindole-4-carboxylic acid	0-46	prolyl endopeptidase	Homo sapiens	179-200
27849643-8	2017	The overall incidence of PEP was 8.6%, which occurred in five of the 124 (4%) patients who received diclofenac, seven of the 122 (5.8%) patients who received indomethacin, and 20 of the 126 (15.9%) patients who received naproxen.	Diclofenac	100-110	prolyl endopeptidase	Homo sapiens	25-28
27849643-8	2017	The overall incidence of PEP was 8.6%, which occurred in five of the 124 (4%) patients who received diclofenac, seven of the 122 (5.8%) patients who received indomethacin, and 20 of the 126 (15.9%) patients who received naproxen.	Indomethacin	158-170	prolyl endopeptidase	Homo sapiens	25-28
27849643-8	2017	The overall incidence of PEP was 8.6%, which occurred in five of the 124 (4%) patients who received diclofenac, seven of the 122 (5.8%) patients who received indomethacin, and 20 of the 126 (15.9%) patients who received naproxen.	Naproxen	220-228	prolyl endopeptidase	Homo sapiens	25-28
27849643-11	2017	CONCLUSION: Diclofenac and indomethacin patient groups had a lower incidence of PEP than the naproxen group.	Diclofenac	12-22	prolyl endopeptidase	Homo sapiens	80-83
27849643-11	2017	CONCLUSION: Diclofenac and indomethacin patient groups had a lower incidence of PEP than the naproxen group.	Indomethacin	27-39	prolyl endopeptidase	Homo sapiens	80-83
27846073-1	2016	The World Health Organization has issued an early release revision to its antiretroviral guidelines in which PrEP (pre-exposure prophylaxis in the form of daily oral, fixed dose combination tenofovir disoproxil fumarate/emtricitabine) is recommended as a prevention option to all people at substantial risk of acquiring HIV.	Tenofovir	190-219	prolyl endopeptidase	Homo sapiens	109-113
27846073-1	2016	The World Health Organization has issued an early release revision to its antiretroviral guidelines in which PrEP (pre-exposure prophylaxis in the form of daily oral, fixed dose combination tenofovir disoproxil fumarate/emtricitabine) is recommended as a prevention option to all people at substantial risk of acquiring HIV.	Emtricitabine	220-233	prolyl endopeptidase	Homo sapiens	109-113
25894999-5	2015	This study describes the bioactivity-guided isolation of a cyclotide from Psychotria solitudinum as an inhibitor of another serine-type protease, namely, the human prolyl oligopeptidase (POP).	Cyclotides	59-68	prolyl endopeptidase	Homo sapiens	164-185
26364263-1	2016	BACKGROUND: Randomised placebo-controlled trials have shown that daily oral pre-exposure prophylaxis (PrEP) with tenofovir-emtricitabine reduces the risk of HIV infection.	Tenofovir	113-122	prolyl endopeptidase	Homo sapiens	76-79
26364263-1	2016	BACKGROUND: Randomised placebo-controlled trials have shown that daily oral pre-exposure prophylaxis (PrEP) with tenofovir-emtricitabine reduces the risk of HIV infection.	Tenofovir	113-122	prolyl endopeptidase	Homo sapiens	102-106
26364263-1	2016	BACKGROUND: Randomised placebo-controlled trials have shown that daily oral pre-exposure prophylaxis (PrEP) with tenofovir-emtricitabine reduces the risk of HIV infection.	Emtricitabine	123-136	prolyl endopeptidase	Homo sapiens	76-79
26364263-1	2016	BACKGROUND: Randomised placebo-controlled trials have shown that daily oral pre-exposure prophylaxis (PrEP) with tenofovir-emtricitabine reduces the risk of HIV infection.	Emtricitabine	123-136	prolyl endopeptidase	Homo sapiens	102-106
26574880-0	2016	Isolation of prolyl endopeptidase inhibitory peptides from a sodium caseinate hydrolysate.	sodium caseinate hydrolysate	61-89	prolyl endopeptidase	Homo sapiens	13-33
27629944-7	2016	PEP occurred in 10% of the patients, with a significantly higher frequency in those with hilar/upper bile duct stricture (p=0.026) and a normal bilirubin level at admission (p=0.016).	Bilirubin	144-153	prolyl endopeptidase	Homo sapiens	0-3
27629944-12	2016	Conclusion Patients with upper/hilar bile duct stricture or a normal bilirubin level are at high risk of developing PEP after preoperative BD.	Bilirubin	69-78	prolyl endopeptidase	Homo sapiens	116-119
26559816-9	2015	Seventy-eight percent (n = 2772) of patients received a prescription for PEP, consisting of Tenofovir/Emtracitabine (TVD) + Lopinavir/Ritonavir (LPV) in 74% of cases, followed by Zidovudine/Lamivudine (CBV) + LPV (10%) and TVD + Raltegravir (RAL) (8%).	Tenofovir	92-101	prolyl endopeptidase	Homo sapiens	73-76
26559816-9	2015	Seventy-eight percent (n = 2772) of patients received a prescription for PEP, consisting of Tenofovir/Emtracitabine (TVD) + Lopinavir/Ritonavir (LPV) in 74% of cases, followed by Zidovudine/Lamivudine (CBV) + LPV (10%) and TVD + Raltegravir (RAL) (8%).	emtracitabine	102-115	prolyl endopeptidase	Homo sapiens	73-76
26559816-9	2015	Seventy-eight percent (n = 2772) of patients received a prescription for PEP, consisting of Tenofovir/Emtracitabine (TVD) + Lopinavir/Ritonavir (LPV) in 74% of cases, followed by Zidovudine/Lamivudine (CBV) + LPV (10%) and TVD + Raltegravir (RAL) (8%).	tvd	117-120	prolyl endopeptidase	Homo sapiens	73-76
26559816-9	2015	Seventy-eight percent (n = 2772) of patients received a prescription for PEP, consisting of Tenofovir/Emtracitabine (TVD) + Lopinavir/Ritonavir (LPV) in 74% of cases, followed by Zidovudine/Lamivudine (CBV) + LPV (10%) and TVD + Raltegravir (RAL) (8%).	Lopinavir	124-133	prolyl endopeptidase	Homo sapiens	73-76
26559816-9	2015	Seventy-eight percent (n = 2772) of patients received a prescription for PEP, consisting of Tenofovir/Emtracitabine (TVD) + Lopinavir/Ritonavir (LPV) in 74% of cases, followed by Zidovudine/Lamivudine (CBV) + LPV (10%) and TVD + Raltegravir (RAL) (8%).	Ritonavir	134-143	prolyl endopeptidase	Homo sapiens	73-76
26559816-9	2015	Seventy-eight percent (n = 2772) of patients received a prescription for PEP, consisting of Tenofovir/Emtracitabine (TVD) + Lopinavir/Ritonavir (LPV) in 74% of cases, followed by Zidovudine/Lamivudine (CBV) + LPV (10%) and TVD + Raltegravir (RAL) (8%).	lopinavir-ritonavir drug combination	145-148	prolyl endopeptidase	Homo sapiens	73-76
26559816-9	2015	Seventy-eight percent (n = 2772) of patients received a prescription for PEP, consisting of Tenofovir/Emtracitabine (TVD) + Lopinavir/Ritonavir (LPV) in 74% of cases, followed by Zidovudine/Lamivudine (CBV) + LPV (10%) and TVD + Raltegravir (RAL) (8%).	Zidovudine	179-189	prolyl endopeptidase	Homo sapiens	73-76
26559816-9	2015	Seventy-eight percent (n = 2772) of patients received a prescription for PEP, consisting of Tenofovir/Emtracitabine (TVD) + Lopinavir/Ritonavir (LPV) in 74% of cases, followed by Zidovudine/Lamivudine (CBV) + LPV (10%) and TVD + Raltegravir (RAL) (8%).	Lamivudine	190-200	prolyl endopeptidase	Homo sapiens	73-76
26559816-9	2015	Seventy-eight percent (n = 2772) of patients received a prescription for PEP, consisting of Tenofovir/Emtracitabine (TVD) + Lopinavir/Ritonavir (LPV) in 74% of cases, followed by Zidovudine/Lamivudine (CBV) + LPV (10%) and TVD + Raltegravir (RAL) (8%).	CBV protocol	202-205	prolyl endopeptidase	Homo sapiens	73-76
26559816-9	2015	Seventy-eight percent (n = 2772) of patients received a prescription for PEP, consisting of Tenofovir/Emtracitabine (TVD) + Lopinavir/Ritonavir (LPV) in 74% of cases, followed by Zidovudine/Lamivudine (CBV) + LPV (10%) and TVD + Raltegravir (RAL) (8%).	lopinavir-ritonavir drug combination	209-212	prolyl endopeptidase	Homo sapiens	73-76
26559816-9	2015	Seventy-eight percent (n = 2772) of patients received a prescription for PEP, consisting of Tenofovir/Emtracitabine (TVD) + Lopinavir/Ritonavir (LPV) in 74% of cases, followed by Zidovudine/Lamivudine (CBV) + LPV (10%) and TVD + Raltegravir (RAL) (8%).	tvd	223-226	prolyl endopeptidase	Homo sapiens	73-76
26559816-9	2015	Seventy-eight percent (n = 2772) of patients received a prescription for PEP, consisting of Tenofovir/Emtracitabine (TVD) + Lopinavir/Ritonavir (LPV) in 74% of cases, followed by Zidovudine/Lamivudine (CBV) + LPV (10%) and TVD + Raltegravir (RAL) (8%).	Raltegravir Potassium	229-240	prolyl endopeptidase	Homo sapiens	73-76
26559816-9	2015	Seventy-eight percent (n = 2772) of patients received a prescription for PEP, consisting of Tenofovir/Emtracitabine (TVD) + Lopinavir/Ritonavir (LPV) in 74% of cases, followed by Zidovudine/Lamivudine (CBV) + LPV (10%) and TVD + Raltegravir (RAL) (8%).	Raltegravir Potassium	242-245	prolyl endopeptidase	Homo sapiens	73-76
26018317-0	2015	Metabolic Instability of Cyanothiazolidine-Based Prolyl Oligopeptidase Inhibitors: a Structural Assignment Challenge and Potential Medicinal Chemistry Implications.	cyanothiazolidine	25-42	prolyl endopeptidase	Homo sapiens	49-70
26018317-1	2015	As part of the development of cyanothiazolidine-based prolyl oligopeptidase inhibitors, initial metabolism studies suggested multiple sites of oxidation by P450 enzymes.	cyanothiazolidine	30-47	prolyl endopeptidase	Homo sapiens	54-75
26405201-8	2016	Based on these findings, we propose a local acetyl-CoA production system in which PKM2 and PDC locally supply acetyl-CoA to p300 from abundant PEP for histone acetylation at the gene enhancer, and our data suggest that PKM2 sensitizes AhR-mediated detoxification in actively proliferating cells such as cancer and fetal cells.	Acetyl Coenzyme A	44-54	prolyl endopeptidase	Homo sapiens	143-146
26405201-8	2016	Based on these findings, we propose a local acetyl-CoA production system in which PKM2 and PDC locally supply acetyl-CoA to p300 from abundant PEP for histone acetylation at the gene enhancer, and our data suggest that PKM2 sensitizes AhR-mediated detoxification in actively proliferating cells such as cancer and fetal cells.	Acetyl Coenzyme A	110-120	prolyl endopeptidase	Homo sapiens	143-146
26716467-2	2016	A prolyl endopeptidase (PEP) inhibitory peptide with the amino acid sequence proline-proline-leucine (PPL) was chemically synthesized labeled with 5-FAM and assessed using a transcytosis assay for its ability to cross the BBB.	proline-proline-leucine	77-100	prolyl endopeptidase	Homo sapiens	2-22
26716467-2	2016	A prolyl endopeptidase (PEP) inhibitory peptide with the amino acid sequence proline-proline-leucine (PPL) was chemically synthesized labeled with 5-FAM and assessed using a transcytosis assay for its ability to cross the BBB.	proline-proline-leucine	77-100	prolyl endopeptidase	Homo sapiens	24-27
26716467-2	2016	A prolyl endopeptidase (PEP) inhibitory peptide with the amino acid sequence proline-proline-leucine (PPL) was chemically synthesized labeled with 5-FAM and assessed using a transcytosis assay for its ability to cross the BBB.	penicilloyl poly-L-lysine	102-105	prolyl endopeptidase	Homo sapiens	2-22
26716467-2	2016	A prolyl endopeptidase (PEP) inhibitory peptide with the amino acid sequence proline-proline-leucine (PPL) was chemically synthesized labeled with 5-FAM and assessed using a transcytosis assay for its ability to cross the BBB.	penicilloyl poly-L-lysine	102-105	prolyl endopeptidase	Homo sapiens	24-27
26716467-2	2016	A prolyl endopeptidase (PEP) inhibitory peptide with the amino acid sequence proline-proline-leucine (PPL) was chemically synthesized labeled with 5-FAM and assessed using a transcytosis assay for its ability to cross the BBB.	4-carboxyfluorescein	147-152	prolyl endopeptidase	Homo sapiens	2-22
26716467-2	2016	A prolyl endopeptidase (PEP) inhibitory peptide with the amino acid sequence proline-proline-leucine (PPL) was chemically synthesized labeled with 5-FAM and assessed using a transcytosis assay for its ability to cross the BBB.	4-carboxyfluorescein	147-152	prolyl endopeptidase	Homo sapiens	24-27
26669104-2	2015	The alkaloids were tested for their inhibition activity of human cholinesterases and prolyl oligopeptidase.	Alkaloids	4-13	prolyl endopeptidase	Homo sapiens	85-106
25863351-0	2015	Isoquinoline alkaloids as prolyl oligopeptidase inhibitors.	isoquinoline alkaloids	0-22	prolyl endopeptidase	Homo sapiens	26-47
25863351-1	2015	Prolyl oligopeptidase is a cytosolic serine peptidase that hydrolyses proline-containing peptides at the carboxy terminus of proline residues.	Proline	70-77	prolyl endopeptidase	Homo sapiens	0-21
25863351-1	2015	Prolyl oligopeptidase is a cytosolic serine peptidase that hydrolyses proline-containing peptides at the carboxy terminus of proline residues.	Proline	125-132	prolyl endopeptidase	Homo sapiens	0-21
25863351-3	2015	Thirty-one isoquinoline alkaloids of various structural types, previously isolated in our laboratory, were screened for their ability to inhibit prolyl oligopeptidase.	isoquinoline alkaloids	11-33	prolyl endopeptidase	Homo sapiens	145-166
25894999-5	2015	This study describes the bioactivity-guided isolation of a cyclotide from Psychotria solitudinum as an inhibitor of another serine-type protease, namely, the human prolyl oligopeptidase (POP).	Cyclotides	59-68	prolyl endopeptidase	Homo sapiens	187-190
25894999-7	2015	In addition the prototypical cyclotide kalata B1 inhibited POP activity with an IC50 of 5.6 muM.	Cyclotide Kalata B1	29-48	prolyl endopeptidase	Homo sapiens	59-62
25438071-9	2015	Although the risk of PEP in individuals with FPC can be reduced by using prophylactic self-expelling stents and diclofenac, it remains too high for routine screening.	Diclofenac	112-122	prolyl endopeptidase	Homo sapiens	21-24
25747269-13	2015	The costs of azithromycin PEP among infants, children and adults were $1,976, $132 and $90, respectively.	Azithromycin	13-25	prolyl endopeptidase	Homo sapiens	26-29
25577089-9	2015	A number of novel PEP inhibitory peptide sequences were identified in this study, including PPL, APPH, IPP and PPG with corresponding IC50 values of 2.86, 3.95, 4.02 and 2.70 mM, respectively.	indolepropanol phosphate	103-106	prolyl endopeptidase	Homo sapiens	18-21
26084651-0	2015	Alkaloids from hydrastidis canadensis and their cholinesterase and prolyl oligopeptidase inhibitory.	Alkaloids	0-9	prolyl endopeptidase	Homo sapiens	67-88
25240592-0	2014	Inhibition of prolyl oligopeptidase increases the survival of alpha-synuclein overexpressing cells after rotenone exposure by reducing alpha-synuclein oligomers.	Rotenone	105-113	prolyl endopeptidase	Homo sapiens	14-35
25564858-1	2015	Prolyl oligopeptidase (POP) is a large 80 kDa protease, which cleaves oligopeptides at the C-terminal side of proline residues and constitutes an important pharmaceutical target.	Proline	110-117	prolyl endopeptidase	Homo sapiens	0-21
25564858-1	2015	Prolyl oligopeptidase (POP) is a large 80 kDa protease, which cleaves oligopeptides at the C-terminal side of proline residues and constitutes an important pharmaceutical target.	Proline	110-117	prolyl endopeptidase	Homo sapiens	23-26
25564858-6	2015	Here, we present an exhaustive sampling of POP with a known inhibitor, Z-pro-prolinal.	N-benzyloxycarbonylprolylprolinal	71-85	prolyl endopeptidase	Homo sapiens	43-46
25236746-0	2014	Mechanism of oxidative inactivation of human presequence protease by hydrogen peroxide.	Hydrogen Peroxide	69-86	prolyl endopeptidase	Homo sapiens	45-65
25240592-3	2014	In this study, we investigated the effects of a specific PREP inhibitor, KYP-2047, on rotenone induced aSyn aggregation and increased the production of reactive oxygen species (ROS) in cells overexpressing A53T mutation of aSyn.	3-hydroxy-2-({4-[4-(pyrimidin-2-yl)piperazine-1-carbonyl]phenyl}methyl)-1-benzofuran-7-carboxamide	73-76	prolyl endopeptidase	Homo sapiens	57-61
25240592-3	2014	In this study, we investigated the effects of a specific PREP inhibitor, KYP-2047, on rotenone induced aSyn aggregation and increased the production of reactive oxygen species (ROS) in cells overexpressing A53T mutation of aSyn.	Rotenone	86-94	prolyl endopeptidase	Homo sapiens	57-61
25240592-6	2014	Inhibition of PREP also decreased the production of ROS in [A53T]aSyn overexpressing cells, leading to improved cell viability.	Reactive Oxygen Species	52-55	prolyl endopeptidase	Homo sapiens	14-18
32261776-1	2014	In this study, a modified dehydropeptide, Boc-FDeltaF-epsilonAhx-OH, was conjugated with an aminoglycoside antibiotic, neomycin, to construct a multifunctional conjugate, Pep-Neo.	dehydropeptide	26-40	prolyl endopeptidase	Homo sapiens	171-174
32261776-1	2014	In this study, a modified dehydropeptide, Boc-FDeltaF-epsilonAhx-OH, was conjugated with an aminoglycoside antibiotic, neomycin, to construct a multifunctional conjugate, Pep-Neo.	boc-fdeltaf-epsilonahx-oh	42-67	prolyl endopeptidase	Homo sapiens	171-174
32261776-1	2014	In this study, a modified dehydropeptide, Boc-FDeltaF-epsilonAhx-OH, was conjugated with an aminoglycoside antibiotic, neomycin, to construct a multifunctional conjugate, Pep-Neo.	Aminoglycosides	92-106	prolyl endopeptidase	Homo sapiens	171-174
32261776-1	2014	In this study, a modified dehydropeptide, Boc-FDeltaF-epsilonAhx-OH, was conjugated with an aminoglycoside antibiotic, neomycin, to construct a multifunctional conjugate, Pep-Neo.	Neomycin	119-127	prolyl endopeptidase	Homo sapiens	171-174
24650999-8	2014	MATERIALS AND METHODS: A novel bioactive protein (PEP) was extracted from Pleurotus eryngii fruiting bodies powder and purified on DEAE-52, CM-52 and Superdex 75 column chromatographies using an AKTA purifier.	2-diethylaminoethanol	131-135	prolyl endopeptidase	Homo sapiens	50-53
25024617-4	2014	We retrospectively compared the two groups to examine the need for pancreatic stenting to prevent post-ERCP pancreatitis (PEP) in patients undergoing EST after biliary cannulation by P-GW.	p-gw	183-187	prolyl endopeptidase	Homo sapiens	122-125
24650999-11	2014	RESULTS: Based on high performance gel permeation chromatography (HPGPC), Fourier transform infrared (FT-IR) and nuclear magnetic resonance (NMR) analyses, the isolated protein (PEP) had a molecular weight of 63 kDa, a secondary (alpha-helical) structure and was mainly composed of arginine, serine and glycine.	Arginine	282-290	prolyl endopeptidase	Homo sapiens	178-181
24650999-11	2014	RESULTS: Based on high performance gel permeation chromatography (HPGPC), Fourier transform infrared (FT-IR) and nuclear magnetic resonance (NMR) analyses, the isolated protein (PEP) had a molecular weight of 63 kDa, a secondary (alpha-helical) structure and was mainly composed of arginine, serine and glycine.	Serine	292-298	prolyl endopeptidase	Homo sapiens	178-181
24650999-11	2014	RESULTS: Based on high performance gel permeation chromatography (HPGPC), Fourier transform infrared (FT-IR) and nuclear magnetic resonance (NMR) analyses, the isolated protein (PEP) had a molecular weight of 63 kDa, a secondary (alpha-helical) structure and was mainly composed of arginine, serine and glycine.	Glycine	303-310	prolyl endopeptidase	Homo sapiens	178-181
24602793-7	2014	Compounds 3c &4c enhanced hPreP-mediated proteolysis of Abeta (1-42), pF1beta (2-54) and fluorogenic-substrate V. These results suggest that activation of hPreP by small benzimidazole derivatives provide a promising avenue for AD treatment.	benzimidazole	170-183	prolyl endopeptidase	Homo sapiens	26-31
24602793-7	2014	Compounds 3c &4c enhanced hPreP-mediated proteolysis of Abeta (1-42), pF1beta (2-54) and fluorogenic-substrate V. These results suggest that activation of hPreP by small benzimidazole derivatives provide a promising avenue for AD treatment.	benzimidazole	170-183	prolyl endopeptidase	Homo sapiens	155-160
24269815-1	2014	Prolyl oligopeptidase (POP) is a serine endopeptidase that hydrolyzes post-proline peptide bonds in peptides that are &lt;30 amino acids in length.	Proline	75-82	prolyl endopeptidase	Homo sapiens	0-21
24016298-2	2014	We tested the hypothesis that this T cell reactivity could be abolished by using prolyl-endopeptidase (PEP), an enzyme that cleaves peptide bonds after proline.	Proline	152-159	prolyl endopeptidase	Homo sapiens	103-106
24269815-1	2014	Prolyl oligopeptidase (POP) is a serine endopeptidase that hydrolyzes post-proline peptide bonds in peptides that are &lt;30 amino acids in length.	Proline	75-82	prolyl endopeptidase	Homo sapiens	23-26
24269815-5	2014	POP specific inhibitors, 3-({4-[2-(E)-styrylphenoxy]butanoyl}-l-4-hydroxyprolyl)-thiazolidine (SUAM-14746) and benzyloxycarbonyl-thioprolyl-thioprolinal, or RNAi-mediated POP knockdown inhibited the growth of KATO III cells irrespective of their p53 status.	suam	95-99	prolyl endopeptidase	Homo sapiens	0-3
23873833-6	2014	PREP and MEIS recognize slightly different consensus sequences: PREP prefers to bind to promoters and to have PBX as a DNA-binding partner; MEIS prefers HOX as partner, and both PREP and MEIS drive PBX to their own binding sites.	4-Bromobenzene-1,2,3-triol	110-113	prolyl endopeptidase	Homo sapiens	0-4
23873833-6	2014	PREP and MEIS recognize slightly different consensus sequences: PREP prefers to bind to promoters and to have PBX as a DNA-binding partner; MEIS prefers HOX as partner, and both PREP and MEIS drive PBX to their own binding sites.	4-Bromobenzene-1,2,3-triol	110-113	prolyl endopeptidase	Homo sapiens	64-68
23873833-6	2014	PREP and MEIS recognize slightly different consensus sequences: PREP prefers to bind to promoters and to have PBX as a DNA-binding partner; MEIS prefers HOX as partner, and both PREP and MEIS drive PBX to their own binding sites.	4-Bromobenzene-1,2,3-triol	110-113	prolyl endopeptidase	Homo sapiens	64-68
23873833-6	2014	PREP and MEIS recognize slightly different consensus sequences: PREP prefers to bind to promoters and to have PBX as a DNA-binding partner; MEIS prefers HOX as partner, and both PREP and MEIS drive PBX to their own binding sites.	4-Bromobenzene-1,2,3-triol	198-201	prolyl endopeptidase	Homo sapiens	0-4
23873833-6	2014	PREP and MEIS recognize slightly different consensus sequences: PREP prefers to bind to promoters and to have PBX as a DNA-binding partner; MEIS prefers HOX as partner, and both PREP and MEIS drive PBX to their own binding sites.	4-Bromobenzene-1,2,3-triol	198-201	prolyl endopeptidase	Homo sapiens	64-68
23873833-6	2014	PREP and MEIS recognize slightly different consensus sequences: PREP prefers to bind to promoters and to have PBX as a DNA-binding partner; MEIS prefers HOX as partner, and both PREP and MEIS drive PBX to their own binding sites.	4-Bromobenzene-1,2,3-triol	198-201	prolyl endopeptidase	Homo sapiens	64-68
24244481-1	2013	The natural tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) is generated from the N-terminus of thymosin-beta4 through enzymatic cleavage by prolyl oligopeptidase (POP).	goralatide	25-49	prolyl endopeptidase	Homo sapiens	140-161
24244481-1	2013	The natural tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) is generated from the N-terminus of thymosin-beta4 through enzymatic cleavage by prolyl oligopeptidase (POP).	goralatide	25-49	prolyl endopeptidase	Homo sapiens	163-166
23643808-4	2013	In this work, we measured the circulating levels of PREP in patients suffering of relapsing remitting (RR), secondary progressive (SP), primary progressive (PP) MS, and in subjects with clinically isolated syndrome (CIS).	sp	131-133	prolyl endopeptidase	Homo sapiens	52-56
23090004-3	2013	We assessed the effect of risperidone combined with ulinastatin for the prevention of PEP in high-risk patients.	Risperidone	26-37	prolyl endopeptidase	Homo sapiens	86-89
23090004-9	2013	The incidence of moderate/severe PEP was lower in the risperidone + ulinastatin group (1.8 %) than in the ulinastatin group (4.4 %), but this difference was not significant.	Risperidone	54-65	prolyl endopeptidase	Homo sapiens	33-36
23383243-3	2013	The generation of this tripeptide is mediated by a multistep pathway involving matrix metalloproteases (MMPs) 8 and 9 and prolyl endopeptidase (PE).	tripeptide K-26	23-33	prolyl endopeptidase	Homo sapiens	122-142
22940581-5	2013	Here we determined kinetic and structural properties of POP with mutations in loop A, loop B, and in two additional flexible loops (the catalytic His loop, propeller Asp/Glu loop).	Histidine	146-149	prolyl endopeptidase	Homo sapiens	56-59
22940581-5	2013	Here we determined kinetic and structural properties of POP with mutations in loop A, loop B, and in two additional flexible loops (the catalytic His loop, propeller Asp/Glu loop).	Aspartic Acid	166-169	prolyl endopeptidase	Homo sapiens	56-59
22940581-5	2013	Here we determined kinetic and structural properties of POP with mutations in loop A, loop B, and in two additional flexible loops (the catalytic His loop, propeller Asp/Glu loop).	Glutamic Acid	170-173	prolyl endopeptidase	Homo sapiens	56-59
23594271-5	2013	Here, we report the first potent FAP inhibitor with selectivity over both the DPPs and PREP, N-(pyridine-4-carbonyl)-d-Ala-boroPro (ARI-3099, 6).	n-(pyridine-4-carbonyl)-d-ala-boropro	93-130	prolyl endopeptidase	Homo sapiens	87-91
23594271-5	2013	Here, we report the first potent FAP inhibitor with selectivity over both the DPPs and PREP, N-(pyridine-4-carbonyl)-d-Ala-boroPro (ARI-3099, 6).	Py(D)AlaboroPro	132-140	prolyl endopeptidase	Homo sapiens	87-91
23594271-6	2013	We also report a similarly potent and selective PREP inhibitor, N-(pyridine-3-carbonyl)-Val-boroPro (ARI-3531, 22).	n-(pyridine-3-carbonyl)-val-boropro	64-99	prolyl endopeptidase	Homo sapiens	48-52
23594271-6	2013	We also report a similarly potent and selective PREP inhibitor, N-(pyridine-3-carbonyl)-Val-boroPro (ARI-3531, 22).	ARI-3531	101-109	prolyl endopeptidase	Homo sapiens	48-52
23348613-1	2013	Prolyl oligopeptidase is a serine protease that cleaves peptides shorter 30-mer at carboxyl side of an internal proline.	Proline	112-119	prolyl endopeptidase	Homo sapiens	0-21
23348613-7	2013	To study the functional relevance of prolyl oligopeptidase-glyceraldehyde-3-phosphate dehydrogenase interactions, we investigated whether this interaction was involved in cytosine arabinoside-induced glyceraldehyde-3-phosphate dehydrogenase nuclear translocation and cell death.	Cytarabine	171-191	prolyl endopeptidase	Homo sapiens	37-58
23348613-8	2013	Prolyl oligopeptidase inhibitor, SUAM-14746, and prolyl oligopeptidase knockdown successfully inhibited glyceraldehyde-3-phosphate dehydrogenase translocation and promoted the survival of cytosine arabinoside-treated NB-1 cells.	Cytarabine	188-208	prolyl endopeptidase	Homo sapiens	0-21
23348613-8	2013	Prolyl oligopeptidase inhibitor, SUAM-14746, and prolyl oligopeptidase knockdown successfully inhibited glyceraldehyde-3-phosphate dehydrogenase translocation and promoted the survival of cytosine arabinoside-treated NB-1 cells.	Cytarabine	188-208	prolyl endopeptidase	Homo sapiens	49-70
23348613-10	2013	These results indicate that the interaction between prolyl oligopeptidase and glyceraldehyde-3-phosphate dehydrogenase is required for cytosine arabinoside-induced glyceraldehyde-3-phosphate dehydrogenase nuclear translocation and cell death.	Cytarabine	135-155	prolyl endopeptidase	Homo sapiens	52-73
23383243-3	2013	The generation of this tripeptide is mediated by a multistep pathway involving matrix metalloproteases (MMPs) 8 and 9 and prolyl endopeptidase (PE).	tripeptide K-26	23-33	prolyl endopeptidase	Homo sapiens	144-146
22750443-0	2012	Comparative analysis of the substrate preferences of two post-proline cleaving endopeptidases, prolyl oligopeptidase and fibroblast activation protein alpha.	Proline	62-69	prolyl endopeptidase	Homo sapiens	95-116
23572190-1	2013	Solving the crystal structure of Cbl(TKB) in complex with a pentapeptide, pYTPEP, revealed that the PEP region adopted a poly-L-proline type II (PPII) helix.	polyproline	121-135	prolyl endopeptidase	Homo sapiens	77-80
23041349-2	2012	Recent studies showed that PreP activity is reduced in Alzheimer disease (AD) patients and AD mouse models compared to controls, which correlated with an enhanced reactive oxygen species production in mitochondria.	Reactive Oxygen Species	163-186	prolyl endopeptidase	Homo sapiens	27-31
23041349-3	2012	In this study, we have investigated the effects of a biologically relevant oxidant, hydrogen peroxide (H(2)O(2)), on the activity of recombinant human PreP (hPreP).	Hydrogen Peroxide	84-101	prolyl endopeptidase	Homo sapiens	151-155
23041349-3	2012	In this study, we have investigated the effects of a biologically relevant oxidant, hydrogen peroxide (H(2)O(2)), on the activity of recombinant human PreP (hPreP).	Hydrogen Peroxide	84-101	prolyl endopeptidase	Homo sapiens	157-162
23041349-4	2012	H(2)O(2) inhibited hPreP activity in a concentration-dependent manner, resulting in oxidation of amino acid residues (detected by carbonylation) and lowered protein stability.	Hydrogen Peroxide	0-8	prolyl endopeptidase	Homo sapiens	19-24
23041349-6	2012	The activity of hPreP oxidized at low concentrations of H(2)O(2) could be restored by methionine sulfoxide reductase A (MsrA), an enzyme that localizes to the mitochondrial matrix, suggesting that hPreP constitutes a substrate for MsrA.	Hydrogen Peroxide	56-64	prolyl endopeptidase	Homo sapiens	16-21
23041349-6	2012	The activity of hPreP oxidized at low concentrations of H(2)O(2) could be restored by methionine sulfoxide reductase A (MsrA), an enzyme that localizes to the mitochondrial matrix, suggesting that hPreP constitutes a substrate for MsrA.	Hydrogen Peroxide	56-64	prolyl endopeptidase	Homo sapiens	197-202
26204593-0	2012	Tenofovir/FTC approved for PrEP...but issues remain regarding implementation.	Tenofovir	0-9	prolyl endopeptidase	Homo sapiens	27-31
21538948-1	2012	The aim of this study is to define the diagnostic role of Liqui-Prep (LP) technique for the diagnosis of thyroid lesions and to assess interobserver variabilities.	leucylproline	70-72	prolyl endopeptidase	Homo sapiens	64-68
22484394-5	2012	The results from enzyme kinetics of PREP variants also support this hypothesis: When loop A is (1) locked to loop B through a disulphide bridge, all enzyme activity is halted, (2) nicked, enzyme activity is increased, and (3) removed, enzyme activity is only reduced.	disulphide	126-136	prolyl endopeptidase	Homo sapiens	36-40
22233220-2	2012	The aim of this study was to investigate the effects of a PREP inhibitor, KYP-2047, on alpha-synuclein aggregation in cell lines overexpressing wild-type or A30P/A53T mutant human alpha-syn and in the brains of two A30P alpha-synuclein transgenic mouse strains.	3-hydroxy-2-({4-[4-(pyrimidin-2-yl)piperazine-1-carbonyl]phenyl}methyl)-1-benzofuran-7-carboxamide	74-77	prolyl endopeptidase	Homo sapiens	58-62
21133893-1	2011	BACKGROUND AND PURPOSE A serine protease, prolyl oligopeptidase (POP) has been reported to be involved in the release of the pro-angiogenic tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Ac-SDKP) from its precursor, 43-mer thymosin beta4 (Tbeta4).	goralatide	153-177	prolyl endopeptidase	Homo sapiens	42-63
22069228-0	2011	15N relaxation NMR studies of prolyl oligopeptidase, an 80 kDa enzyme, reveal a pre-existing equilibrium between different conformational states.	15n	0-3	prolyl endopeptidase	Homo sapiens	30-51
21968909-2	2011	We found prolonged total and right segmental CTT despite high doses of oral polyethylene glycol 4000 and repeated treatment with polyethylene glycol-electrolyte solution (Klean-Prep ) by nasogastric tube.	polyethylene glycol-electrolyte	129-160	prolyl endopeptidase	Homo sapiens	177-181
21133893-1	2011	BACKGROUND AND PURPOSE A serine protease, prolyl oligopeptidase (POP) has been reported to be involved in the release of the pro-angiogenic tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Ac-SDKP) from its precursor, 43-mer thymosin beta4 (Tbeta4).	goralatide	153-177	prolyl endopeptidase	Homo sapiens	65-68
21133893-3	2011	The aim of this study was to clarify the release of Ac-SDKP, and test if POP and a POP inhibitor, 4-phenyl-butanoyl-L-prolyl-2(S)-cyanopyrrolidine (KYP-2047), can affect angiogenesis.	4-phenyl-butanoyl-l-prolyl-2(s)-cyanopyrrolidine	98-146	prolyl endopeptidase	Homo sapiens	83-86
21222622-1	2011	Prolyl oligopeptidase (POP) is a serine protease that cleaves peptides shorter than 30-mer at the carboxyl side of an internal proline.	Proline	127-134	prolyl endopeptidase	Homo sapiens	0-21
21539473-1	2011	INTRODUCTION: Prolyl Oligopeptidase (POP) is a serine peptidase that cleaves post-proline bonds in short peptides.	Serine	47-53	prolyl endopeptidase	Homo sapiens	14-35
21539473-1	2011	INTRODUCTION: Prolyl Oligopeptidase (POP) is a serine peptidase that cleaves post-proline bonds in short peptides.	Serine	47-53	prolyl endopeptidase	Homo sapiens	37-40
21539473-1	2011	INTRODUCTION: Prolyl Oligopeptidase (POP) is a serine peptidase that cleaves post-proline bonds in short peptides.	Proline	82-89	prolyl endopeptidase	Homo sapiens	14-35
21539473-1	2011	INTRODUCTION: Prolyl Oligopeptidase (POP) is a serine peptidase that cleaves post-proline bonds in short peptides.	Proline	82-89	prolyl endopeptidase	Homo sapiens	37-40
21539473-2	2011	Besides the direct hydrolytic regulation function over peptides, neuropeptides and peptide hormones, POP is probably involved in the regulation of the inositol pathway and participates in protein-protein interactions.	Inositol	151-159	prolyl endopeptidase	Homo sapiens	101-104
21539473-6	2011	AREAS COVERED: This review comprises patents and patent applications involving POP inhibitors patented between 2003 and 2010, classified as peptidomimetics, heteroaryl ketones and alkaloids.	heteroaryl ketones	157-175	prolyl endopeptidase	Homo sapiens	79-82
21539473-6	2011	AREAS COVERED: This review comprises patents and patent applications involving POP inhibitors patented between 2003 and 2010, classified as peptidomimetics, heteroaryl ketones and alkaloids.	Alkaloids	180-189	prolyl endopeptidase	Homo sapiens	79-82
21539473-8	2011	EXPERT OPINION: The major part of the repertory of POP inhibitors derived from systematical modification of the canonical compound benzyloxycarbonyl-prolyl-prolinal (ZPP).	benzyloxycarbonyl-prolyl-prolinal	131-164	prolyl endopeptidase	Homo sapiens	51-54
21539473-8	2011	EXPERT OPINION: The major part of the repertory of POP inhibitors derived from systematical modification of the canonical compound benzyloxycarbonyl-prolyl-prolinal (ZPP).	zinc protoporphyrin	166-169	prolyl endopeptidase	Homo sapiens	51-54
21620802-1	2011	Prolyl oligopeptidase (POP) is a post-proline cleaving enzyme, which is widely distributed in various organs, with high levels in the brain.	Proline	38-45	prolyl endopeptidase	Homo sapiens	0-21
21620802-1	2011	Prolyl oligopeptidase (POP) is a post-proline cleaving enzyme, which is widely distributed in various organs, with high levels in the brain.	Proline	38-45	prolyl endopeptidase	Homo sapiens	23-26
21620802-2	2011	In this study, we investigated the effects of a selective POP inhibitor, 3-({4-[2-(E)-styrylphenoxy]butanoyl}-l-4-hydroxyprolyl)-thiazolidine (SUAM-14746), on the growth of NB-1 human neuroblastoma cells.	3-((4-(2-styrylphenoxy)butanoyl)-4-hydroxyprolyl)thiazolidine	73-141	prolyl endopeptidase	Homo sapiens	58-61
21620802-4	2011	Similar suppressive effects were observed with another POP inhibitor benzyloxycarbonyl-thioprolyl-thioprolinal.	benzyloxycarbonyl-thioprolyl-thioprolinal	69-110	prolyl endopeptidase	Homo sapiens	55-58
26596426-0	2011	Use of Umbrella Sampling to Calculate the Entrance/Exit Pathway for Z-Pro-Prolinal Inhibitor in Prolyl Oligopeptidase.	N-benzyloxycarbonylprolylprolinal	68-82	prolyl endopeptidase	Homo sapiens	96-117
26596426-4	2011	We examined three possible binding pathways using Steered Molecular Dynamics (SMD) and Umbrella Sampling (US) on a crystal structure of porcine POP with bound Z-pro-prolinal (ZPP).	N-benzyloxycarbonylprolylprolinal	159-173	prolyl endopeptidase	Homo sapiens	144-147
26596426-4	2011	We examined three possible binding pathways using Steered Molecular Dynamics (SMD) and Umbrella Sampling (US) on a crystal structure of porcine POP with bound Z-pro-prolinal (ZPP).	N-benzyloxycarbonylprolylprolinal	175-178	prolyl endopeptidase	Homo sapiens	144-147
21222622-1	2011	Prolyl oligopeptidase (POP) is a serine protease that cleaves peptides shorter than 30-mer at the carboxyl side of an internal proline.	Proline	127-134	prolyl endopeptidase	Homo sapiens	23-26
21222624-1	2011	Prolyl oligopeptidase (PO) interacts with alpha-syncline in vitro.	alpha-syncline	42-56	prolyl endopeptidase	Homo sapiens	0-21
21222624-1	2011	Prolyl oligopeptidase (PO) interacts with alpha-syncline in vitro.	alpha-syncline	42-56	prolyl endopeptidase	Homo sapiens	23-25
21222625-1	2011	Inhibition of prolyl oligopeptidase (PO) elevates inositol phosphate (IP) signalling and reduces cell sensitivity to lithium (Li+).	Inositol Phosphates	50-68	prolyl endopeptidase	Homo sapiens	14-35
21222625-1	2011	Inhibition of prolyl oligopeptidase (PO) elevates inositol phosphate (IP) signalling and reduces cell sensitivity to lithium (Li+).	Inositol Phosphates	50-68	prolyl endopeptidase	Homo sapiens	37-39
21222625-1	2011	Inhibition of prolyl oligopeptidase (PO) elevates inositol phosphate (IP) signalling and reduces cell sensitivity to lithium (Li+).	Inositol Phosphates	70-72	prolyl endopeptidase	Homo sapiens	14-35
21222625-1	2011	Inhibition of prolyl oligopeptidase (PO) elevates inositol phosphate (IP) signalling and reduces cell sensitivity to lithium (Li+).	Inositol Phosphates	70-72	prolyl endopeptidase	Homo sapiens	37-39
21222625-1	2011	Inhibition of prolyl oligopeptidase (PO) elevates inositol phosphate (IP) signalling and reduces cell sensitivity to lithium (Li+).	Lithium	117-124	prolyl endopeptidase	Homo sapiens	14-35
21222625-1	2011	Inhibition of prolyl oligopeptidase (PO) elevates inositol phosphate (IP) signalling and reduces cell sensitivity to lithium (Li+).	Lithium	117-124	prolyl endopeptidase	Homo sapiens	37-39
21222626-1	2011	Prolyl oligopeptidase or prolyl endopeptidase (PREP; EC 3.4.21.26) is an atypical serine protease that hydrolyses peptides and peptide hormones after proline in peptides up to around 30 residues long.	Proline	150-157	prolyl endopeptidase	Homo sapiens	0-21
21222626-1	2011	Prolyl oligopeptidase or prolyl endopeptidase (PREP; EC 3.4.21.26) is an atypical serine protease that hydrolyses peptides and peptide hormones after proline in peptides up to around 30 residues long.	Proline	150-157	prolyl endopeptidase	Homo sapiens	25-45
21222626-1	2011	Prolyl oligopeptidase or prolyl endopeptidase (PREP; EC 3.4.21.26) is an atypical serine protease that hydrolyses peptides and peptide hormones after proline in peptides up to around 30 residues long.	Proline	150-157	prolyl endopeptidase	Homo sapiens	47-51
21222628-2	2011	3.4.21.26, PREP) also known as prolyl oligopeptidase is an enzyme which cleaves several peptides at the carboxyl side of proline residues.	Proline	121-128	prolyl endopeptidase	Homo sapiens	11-15
21222628-2	2011	3.4.21.26, PREP) also known as prolyl oligopeptidase is an enzyme which cleaves several peptides at the carboxyl side of proline residues.	Proline	121-128	prolyl endopeptidase	Homo sapiens	31-52
21222629-1	2011	Prolyl oligopeptidase (POP), is an 80-kDa serine protease that hydrolyzes peptides smaller than 30-mer at the carboxyl side of an internal proline-residue.	Proline	139-146	prolyl endopeptidase	Homo sapiens	0-21
21222629-1	2011	Prolyl oligopeptidase (POP), is an 80-kDa serine protease that hydrolyzes peptides smaller than 30-mer at the carboxyl side of an internal proline-residue.	Proline	139-146	prolyl endopeptidase	Homo sapiens	23-26
20869470-7	2010	In native polyacrylamide gel electrophoresis, GAP43 interacted with one of the three forms of a polyhistidine-tagged prolyl oligopeptidase.	polyacrylamide	10-24	prolyl endopeptidase	Homo sapiens	117-138
20230877-0	2010	Subchronic administration of rosmarinic acid, a natural prolyl oligopeptidase inhibitor, enhances cognitive performances.	rosmarinic acid	29-44	prolyl endopeptidase	Homo sapiens	56-77
20230877-2	2010	In this study, we observed that rosmarinic acid (RA) inhibits POP activity with an IC(50) of 63.7 microM.	rosmarinic acid	32-47	prolyl endopeptidase	Homo sapiens	62-65
20230877-2	2010	In this study, we observed that rosmarinic acid (RA) inhibits POP activity with an IC(50) of 63.7 microM.	rosmarinic acid	49-51	prolyl endopeptidase	Homo sapiens	62-65
20230877-4	2010	The results demonstrated that RA is non-competitive POP inhibitor and that acute and subchronic RA treatments showed an inverted U-shaped dose-response curve in the platform crossings.	rosmarinic acid	30-32	prolyl endopeptidase	Homo sapiens	52-55
20230877-4	2010	The results demonstrated that RA is non-competitive POP inhibitor and that acute and subchronic RA treatments showed an inverted U-shaped dose-response curve in the platform crossings.	rosmarinic acid	96-98	prolyl endopeptidase	Homo sapiens	52-55
20230877-6	2010	These results suggest that RA has a cognitive-enhancing effect which may be mediated by inhibition of POP.	rosmarinic acid	27-29	prolyl endopeptidase	Homo sapiens	102-105
27616839-0	2010	Cleanliness in the Root Canal System: An Scanning Electron Microscopic Evaluation of Manual and Automated Instrumentation using 4% Sodium Hypochlorite and EDTA (Glyde File Prep)-An in vitro Study.	Edetic Acid	155-159	prolyl endopeptidase	Homo sapiens	172-176
20978968-7	2011	POP is a ubiquitous post-proline cleaving enzyme with particularly high expression levels in the mammalian brain, where it participates in the metabolism of neuroactive peptides and peptide-like hormones (e.g. thyroliberin, gonadotropin-releasing hormone).	Proline	25-32	prolyl endopeptidase	Homo sapiens	0-3
21487212-1	2011	Prolyl endopeptidase (PREP), probably acting through the inositol cycle, has been implicated in memory and learning.	Inositol	57-65	prolyl endopeptidase	Homo sapiens	0-20
21487212-1	2011	Prolyl endopeptidase (PREP), probably acting through the inositol cycle, has been implicated in memory and learning.	Inositol	57-65	prolyl endopeptidase	Homo sapiens	22-26
21487212-4	2011	Here, we report the levels and subcellular distribution of PREP in human neuroblastoma SH-SY5Y cells in proliferating conditions and under differentiation induced by retinoic acid (RA).	Tretinoin	166-179	prolyl endopeptidase	Homo sapiens	59-63
21487212-4	2011	Here, we report the levels and subcellular distribution of PREP in human neuroblastoma SH-SY5Y cells in proliferating conditions and under differentiation induced by retinoic acid (RA).	Tretinoin	181-183	prolyl endopeptidase	Homo sapiens	59-63